|
G |
Tgfb1 |
transforming growth factor, beta 1 |
decreases activity |
ISO |
ferbam results in decreased activity of TGFB1 protein |
CTD |
PMID:31652400 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
|
G |
Aco1 |
aconitase 1 |
increases activity decreases activity |
ISO |
ferric ammonium citrate results in increased activity of ACO1 protein ferric ammonium citrate results in decreased activity of ACO1 protein |
CTD |
PMID:11054110 PMID:18073202 |
|
NCBI chr 5:56,425,076...56,481,218
Ensembl chr 5:56,425,024...56,481,218
|
|
G |
Aco2 |
aconitase 2 |
multiple interactions increases activity |
ISO |
ferric ammonium citrate inhibits the reaction [manganese chloride results in decreased activity of ACO2 protein]; ferric ammonium citrate inhibits the reaction [Manganese results in decreased activity of ACO2 protein] ferric ammonium citrate results in increased activity of ACO2 protein |
CTD |
PMID:16625280 |
|
NCBI chr 7:123,102,493...123,145,608
Ensembl chr 7:123,102,468...123,145,635
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
ferric ammonium citrate inhibits the reaction [Palmitic Acid inhibits the reaction [INS protein results in increased phosphorylation of AKT1 protein]] |
CTD |
PMID:32283200 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
ferric ammonium citrate inhibits the reaction [Ozone results in increased expression of ALB protein] |
CTD |
PMID:24862973 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Anxa3 |
annexin A3 |
multiple interactions |
ISO |
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of ANXA3 protein] |
CTD |
PMID:19515424 |
|
NCBI chr14:14,371,921...14,426,503
Ensembl chr14:14,364,008...14,426,437
|
|
G |
Arhgdia |
Rho GDP dissociation inhibitor alpha |
multiple interactions |
ISO |
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of ARHGDIA protein] |
CTD |
PMID:19515424 |
|
NCBI chr10:109,754,012...109,757,506
Ensembl chr10:109,754,004...109,757,550
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
multiple interactions |
ISO |
ferric ammonium citrate affects the reaction [Deferoxamine inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]]; ferric ammonium citrate inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA] |
CTD |
PMID:25633564 |
|
NCBI chr17:26,955,142...27,112,820
Ensembl chr17:26,955,142...27,112,820
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions |
ISO |
ferric ammonium citrate results in increased cleavage of CASP3 protein 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [ferric ammonium citrate results in increased cleavage of CASP3 protein]; acetylleucyl-leucyl-norleucinal inhibits the reaction [ferric ammonium citrate results in increased cleavage of CASP3 protein]; Deferoxamine inhibits the reaction [ferric ammonium citrate results in increased cleavage of CASP3 protein]; DNM1L protein mutant form inhibits the reaction [ferric ammonium citrate results in increased cleavage of CASP3 protein]; N-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide inhibits the reaction [ferric ammonium citrate results in increased cleavage of CASP3 protein] |
CTD |
PMID:17191120 PMID:26318285 PMID:27481217 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
ferric ammonium citrate inhibits the reaction [2-hydroxy-1-naphthylaldehyde isonicotinoyl hydrazone results in decreased expression of CDKN1A protein] |
CTD |
PMID:12807743 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
decreases expression |
ISO |
ferric ammonium citrate results in decreased expression of COL1A1 mRNA |
CTD |
PMID:19735707 |
|
NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
|
|
G |
Dnm1l |
dynamin 1-like |
multiple interactions decreases phosphorylation |
ISO |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [ferric ammonium citrate results in decreased phosphorylation of DNM1L protein]; acetylleucyl-leucyl-norleucinal inhibits the reaction [ferric ammonium citrate results in decreased phosphorylation of DNM1L protein]; Cyclosporine inhibits the reaction [ferric ammonium citrate results in decreased phosphorylation of DNM1L protein]; Deferoxamine inhibits the reaction [ferric ammonium citrate results in decreased phosphorylation of DNM1L protein]; DNM1L protein mutant form inhibits the reaction [ferric ammonium citrate results in increased cleavage of CASP3 protein]; ferric ammonium citrate results in decreased phosphorylation of and affects the localization of DNM1L protein; N-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide inhibits the reaction [ferric ammonium citrate results in decreased phosphorylation of DNM1L protein]; Tacrolimus inhibits the reaction [ferric ammonium citrate results in decreased phosphorylation of DNM1L protein] |
CTD |
PMID:26318285 PMID:27481217 |
|
NCBI chr11:88,830,968...88,882,271
Ensembl chr11:88,830,957...88,880,198
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions |
ISO |
ferric ammonium citrate inhibits the reaction [Palmitic Acid results in increased phosphorylation of ERN1 protein] |
CTD |
PMID:32283200 |
|
NCBI chr10:94,588,555...94,682,072
Ensembl chr10:94,588,555...94,681,914
|
|
G |
Erp29 |
endoplasmic reticulum protein 29 |
multiple interactions |
ISO |
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of ERP29 protein] |
CTD |
PMID:19515424 |
|
NCBI chr12:40,619,377...40,625,884
Ensembl chr12:40,619,377...40,625,883
|
|
G |
F3 |
coagulation factor III, tissue factor |
increases expression multiple interactions |
ISO |
ferric ammonium citrate results in increased expression of F3 mRNA Deferoxamine inhibits the reaction [ferric ammonium citrate results in increased expression of F3 mRNA] |
CTD |
PMID:25858758 |
|
NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
|
|
G |
Fth1 |
ferritin heavy chain 1 |
multiple interactions |
ISO |
ferric ammonium citrate promotes the reaction [Palmitic Acid results in increased expression of FTH1 protein] |
CTD |
PMID:32283200 |
|
NCBI chr 1:226,030,940...226,033,228
Ensembl chr 1:226,030,938...226,033,228
|
|
G |
Ftl1 |
ferritin light chain 1 |
multiple interactions increases expression |
ISO |
[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of FTL mRNA ferric ammonium citrate results in increased expression of FTL1 mRNA SLC40A1 protein inhibits the reaction [ferric ammonium citrate results in increased expression of FTL1 mRNA] |
CTD |
PMID:12393473 PMID:19913091 |
|
NCBI chr 1:101,448,190...101,450,034
Ensembl chr 1:101,448,346...101,449,829
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
multiple interactions |
ISO |
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of GAPDH protein] |
CTD |
PMID:19515424 |
|
NCBI chr 4:157,676,336...157,680,322
Ensembl chr 4:157,676,595...157,679,962
|
|
G |
Glo1 |
glyoxalase 1 |
multiple interactions |
ISO |
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of GLO1 protein] |
CTD |
PMID:19515424 |
|
NCBI chr20:9,273,589...9,291,608
Ensembl chr20:9,273,594...9,291,610
|
|
G |
Hamp |
hepcidin antimicrobial peptide |
multiple interactions decreases expression |
ISO |
Deferoxamine promotes the reaction [ferric ammonium citrate results in decreased expression of HAMP mRNA]; ferric ammonium citrate affects the reaction [Deferoxamine inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]]; ferric ammonium citrate inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA] |
CTD |
PMID:25633564 |
|
NCBI chr 1:89,368,021...89,369,960
Ensembl chr 1:89,368,021...89,369,960
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
EXP ISO |
ferric ammonium citrate results in increased expression of HMOX1 protein [ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of HMOX1 mRNA N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [ferric ammonium citrate results in increased expression of HMOX1 protein] |
CTD |
PMID:12393473 PMID:16439612 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
multiple interactions |
ISO |
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of HSPA1A protein] |
CTD |
PMID:19515424 |
|
NCBI chr20:4,875,834...4,881,751
Ensembl chr20:4,877,324...4,879,779
|
|
G |
Hspa1l |
heat shock protein family A (Hsp70) member 1 like |
multiple interactions |
ISO |
[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of HSPA1L mRNA |
CTD |
PMID:12393473 |
|
NCBI chr20:4,879,998...4,965,191
Ensembl chr20:4,959,294...4,964,963
|
|
G |
Hspa9 |
heat shock protein family A (Hsp70) member 9 |
multiple interactions |
ISO |
[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of HSPA9 mRNA |
CTD |
PMID:12393473 |
|
NCBI chr18:27,731,072...27,749,235
Ensembl chr18:27,731,072...27,749,235
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
multiple interactions |
ISO |
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of HSPD1 protein] |
CTD |
PMID:19515424 |
|
NCBI chr 9:61,680,529...61,691,202
Ensembl chr 9:61,680,530...61,690,956
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
ferric ammonium citrate inhibits the reaction [Ozone results in increased expression of IL1B protein] |
CTD |
PMID:24862973 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
ferric ammonium citrate inhibits the reaction [Ozone results in increased expression of IL6 mRNA]; ferric ammonium citrate inhibits the reaction [Ozone results in increased secretion of IL6 protein] |
CTD |
PMID:24862973 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
ferric ammonium citrate inhibits the reaction [Palmitic Acid inhibits the reaction [INS protein results in increased phosphorylation of AKT1 protein]]; ferric ammonium citrate inhibits the reaction [Palmitic Acid inhibits the reaction [INS1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose]]; Thapsigargin inhibits the reaction [ferric ammonium citrate inhibits the reaction [Palmitic Acid inhibits the reaction [INS1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose]]] |
CTD |
PMID:32283200 |
|
NCBI chr 1:215,856,967...215,858,034
Ensembl chr 1:215,856,971...215,858,034
|
|
G |
Ireb2 |
iron responsive element binding protein 2 |
decreases expression decreases activity |
EXP ISO |
ferric ammonium citrate results in decreased expression of IREB2 protein ferric ammonium citrate results in decreased activity of IREB2 protein |
CTD |
PMID:11054110 PMID:17469137 PMID:18073202 |
|
NCBI chr 8:59,450,974...59,503,634
Ensembl chr 8:59,420,123...59,501,118
|
|
G |
Lcn2 |
lipocalin 2 |
multiple interactions |
ISO |
ferric ammonium citrate inhibits the reaction [bathophenanthroline disulfonic acid results in decreased expression of LCN2 protein] |
CTD |
PMID:17350462 |
|
NCBI chr 3:11,414,189...11,417,534
Ensembl chr 3:11,414,186...11,417,546
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO |
[ferric ammonium citrate co-treated with Buthionine Sulfoximine] results in decreased phosphorylation of MAPK1 protein ferric ammonium citrate results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:17191120 PMID:25858758 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
increases phosphorylation |
ISO |
ferric ammonium citrate results in increased phosphorylation of MAPK14 protein |
CTD |
PMID:17191120 |
|
NCBI chr20:5,933,290...5,995,137
Ensembl chr20:5,933,303...5,995,137
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
[ferric ammonium citrate co-treated with Buthionine Sulfoximine] results in decreased phosphorylation of MAPK3 protein ferric ammonium citrate results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:17191120 PMID:25858758 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mrps9 |
mitochondrial ribosomal protein S9 |
multiple interactions |
ISO |
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of MRPS9 protein] |
CTD |
PMID:19515424 |
|
NCBI chr 9:49,647,257...49,704,828
Ensembl chr 9:49,647,257...49,704,828
|
|
G |
Mt2A |
metallothionein 2A |
multiple interactions |
ISO |
[ferric ammonium citrate results in decreased abundance of Iron] which results in increased expression of MT2A mRNA |
CTD |
PMID:12393473 |
|
NCBI chr19:11,307,966...11,308,740
Ensembl chr19:11,307,967...11,308,740
|
|
G |
Ncoa4 |
nuclear receptor coactivator 4 |
multiple interactions |
ISO |
ferric ammonium citrate inhibits the reaction [Palmitic Acid results in increased expression of NCOA4 protein] |
CTD |
PMID:32283200 |
|
NCBI chr16:8,302,950...8,323,294
Ensembl chr16:8,302,950...8,323,293
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
[ferric ammonium citrate co-treated with Buthionine Sulfoximine] results in increased expression of NOS2 mRNA; Acetylcysteine inhibits the reaction [[ferric ammonium citrate co-treated with Buthionine Sulfoximine] results in increased expression of NOS2 mRNA] |
CTD |
PMID:9826428 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Oga |
O-GlcNAcase |
multiple interactions |
ISO |
ferric ammonium citrate inhibits the reaction [Ozone results in increased expression of OGA protein] |
CTD |
PMID:24862973 |
|
NCBI chr 1:265,506,752...265,542,452
Ensembl chr 1:265,507,451...265,542,276
|
|
G |
P4ha1 |
prolyl 4-hydroxylase subunit alpha 1 |
multiple interactions |
ISO |
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of P4HA1 protein] |
CTD |
PMID:19515424 |
|
NCBI chr20:28,920,616...28,972,576
Ensembl chr20:28,920,616...28,971,966
|
|
G |
Pdhb |
pyruvate dehydrogenase E1 subunit beta |
multiple interactions |
ISO |
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of PDHB protein] |
CTD |
PMID:19515424 |
|
NCBI chr15:18,540,826...18,546,855
Ensembl chr15:18,539,210...18,546,854
|
|
G |
Pgk1 |
phosphoglycerate kinase 1 |
multiple interactions |
ISO |
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of PGK1 protein] |
CTD |
PMID:19515424 |
|
NCBI chr X:77,263,399...77,279,373
Ensembl chr X:77,263,359...77,279,367
|
|
G |
Pmp22 |
peripheral myelin protein 22 |
multiple interactions |
ISO |
[ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of PMP22 mRNA |
CTD |
PMID:12393473 |
|
NCBI chr10:49,538,588...49,568,583
Ensembl chr10:49,538,588...49,568,583
|
|
G |
Ppia |
peptidylprolyl isomerase A |
multiple interactions |
ISO |
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of PPIA protein] |
CTD |
PMID:19515424 |
|
NCBI chr14:86,673,775...86,677,443
Ensembl chr14:86,673,775...86,677,443
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
ferric ammonium citrate inhibits the reaction [Ozone results in increased expression of PTGS2 mRNA] |
CTD |
PMID:24862973 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rack1 |
receptor for activated C kinase 1 |
multiple interactions |
ISO |
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of RACK1 protein] |
CTD |
PMID:19515424 |
|
NCBI chr10:34,149,717...34,155,198
Ensembl chr10:34,149,717...34,155,198 Ensembl chr12:34,149,717...34,155,198
|
|
G |
Slc11a1 |
solute carrier family 11 member 1 |
increases expression |
ISO |
ferric ammonium citrate results in increased expression of SLC11A1 mRNA |
CTD |
PMID:11054110 |
|
NCBI chr 9:81,655,590...81,666,697
Ensembl chr 9:81,655,629...81,666,706
|
|
G |
Slc11a2 |
solute carrier family 11 member 2 |
increases expression |
ISO |
ferric ammonium citrate results in increased expression of SLC11A2 mRNA |
CTD |
PMID:11054110 |
|
NCBI chr 7:142,025,812...142,062,892
Ensembl chr 7:142,025,815...142,063,212
|
|
G |
Slc40a1 |
solute carrier family 40 member 1 |
increases expression multiple interactions |
EXP ISO |
ferric ammonium citrate results in increased expression of SLC40A1 mRNA SLC40A1 protein inhibits the reaction [ferric ammonium citrate results in increased expression of FTL1 mRNA] |
CTD |
PMID:19913091 |
|
NCBI chr 9:52,819,451...52,830,461
Ensembl chr 9:52,894,365...52,912,293
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
ISO |
ferric ammonium citrate inhibits the reaction [Ozone results in increased expression of SOD1 mRNA] |
CTD |
PMID:24862973 |
|
NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
|
|
G |
Tf |
transferrin |
multiple interactions |
ISO |
ferric ammonium citrate inhibits the reaction [TF protein results in increased uptake of Iron] |
CTD |
PMID:11335103 |
|
NCBI chr 8:111,694,570...111,721,275
Ensembl chr 8:111,673,547...111,721,333
|
|
G |
Tfr2 |
transferrin receptor 2 |
decreases expression |
ISO |
ferric ammonium citrate results in decreased expression of TFR2 protein |
CTD |
PMID:25633564 |
|
NCBI chr12:22,177,382...22,194,330
Ensembl chr12:22,177,382...22,194,299
|
|
G |
Tfrc |
transferrin receptor |
decreases expression multiple interactions |
ISO |
ferric ammonium citrate results in decreased expression of TFRC mRNA; ferric ammonium citrate results in decreased expression of TFRC protein [ferric ammonium citrate results in decreased abundance of Iron] which results in increased expression of TFRC mRNA |
CTD |
PMID:11054110 PMID:12393473 PMID:16760464 PMID:18073202 PMID:25633564 |
|
NCBI chr11:71,397,423...71,419,263
Ensembl chr11:71,397,383...71,419,223
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
ferric ammonium citrate inhibits the reaction [Ozone results in increased expression of TNF protein] |
CTD |
PMID:24862973 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tpd52l1 |
TPD52 like 1 |
multiple interactions |
ISO |
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of TPD52L1 protein] |
CTD |
PMID:19515424 |
|
NCBI chr 1:28,454,949...28,578,736
Ensembl chr 1:28,454,966...28,576,553
|
|
G |
Vdac2 |
voltage-dependent anion channel 2 |
multiple interactions |
ISO |
ferric ammonium citrate inhibits the reaction [Deferoxamine results in increased expression of VDAC2 protein] |
CTD |
PMID:19515424 |
|
NCBI chr15:2,634,622...2,648,548
Ensembl chr15:2,634,624...2,648,551
|
|
G |
Xbp1 |
X-box binding protein 1 |
multiple interactions |
ISO |
ferric ammonium citrate inhibits the reaction [Palmitic Acid results in increased expression of XBP1 protein] |
CTD |
PMID:32283200 |
|
NCBI chr14:85,753,736...85,758,820
Ensembl chr14:85,753,760...85,758,145
|
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions |
ISO |
ABCC1 protein promotes the reaction [Nitric Oxide results in increased secretion of Iron] |
CTD |
PMID:16679408 |
|
NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
affects metabolic processing |
ISO |
ABCG2 protein affects the metabolism of Iron |
CTD |
PMID:17194590 |
|
NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
|
|
G |
Acbd3 |
acyl-CoA binding domain containing 3 |
multiple interactions |
EXP |
Nitric Oxide promotes the reaction [[RASD1 protein binds to ACBD3 protein binds to SLC11A2 protein] which results in increased uptake of Iron] |
CTD |
PMID:16908409 |
|
NCBI chr13:99,004,942...99,035,520
Ensembl chr13:99,004,942...99,035,519
|
|
G |
Aco1 |
aconitase 1 |
affects metabolic processing multiple interactions |
ISO EXP |
ACO1 protein affects the metabolism of Iron [Deferoxamine results in decreased abundance of Iron] which results in increased activity of ACO1 protein Iron inhibits the reaction [nickel chloride results in increased activity of ACO1 protein]; Iron inhibits the reaction [Nickel results in increased activity of ACO1 protein] |
CTD |
PMID:15893546 PMID:16039939 PMID:16877034 PMID:17194590 |
|
NCBI chr 5:56,425,076...56,481,218
Ensembl chr 5:56,425,024...56,481,218
|
|
G |
Aco2 |
aconitase 2 |
multiple interactions increases activity |
EXP |
[[[Superoxides results in decreased activity of ACO2 protein] which results in increased abundance of Iron] which co-treated with Hydrogen Peroxide] results in increased chemical synthesis of Hydroxyl Radical; [Superoxides results in decreased activity of ACO2 protein] which results in increased abundance of Iron; ACO2 protein affects the reaction [Paraquat results in increased abundance of Iron]; Iron deficiency promotes the reaction [Clofibrate results in increased expression of ACO2 protein]; Iron inhibits the reaction [manganese chloride results in decreased activity of ACO2 protein]; Iron inhibits the reaction [Manganese results in decreased activity of ACO2 protein] Iron results in increased activity of ACO2 protein |
CTD |
PMID:9675333 PMID:11969379 PMID:16162655 PMID:21517855 |
|
NCBI chr 7:123,102,493...123,145,608
Ensembl chr 7:123,102,468...123,145,635
|
|
G |
Acsf2 |
acyl-CoA synthetase family member 2 |
decreases expression |
EXP |
Iron deficiency results in decreased expression of ACSF2 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr10:82,284,719...82,326,771
Ensembl chr10:82,284,720...82,326,771
|
|
G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
decreases expression |
EXP |
Iron deficiency results in decreased expression of ACSL1 mRNA |
CTD |
PMID:19821111 |
|
NCBI chr16:48,937,456...49,003,898
Ensembl chr16:48,937,456...49,003,246
|
|
G |
Acsl3 |
acyl-CoA synthetase long-chain family member 3 |
decreases expression |
EXP |
Iron deficiency results in decreased expression of ACSL3 mRNA |
CTD |
PMID:19821111 |
|
NCBI chr 9:84,569,601...84,593,565
Ensembl chr 9:84,569,597...84,593,565
|
|
G |
Adgrg1 |
adhesion G protein-coupled receptor G1 |
decreases expression |
ISO |
Iron deficiency results in decreased expression of ADGRG1 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr19:10,423,534...10,460,674
Ensembl chr19:10,423,501...10,460,674
|
|
G |
Ahsp |
alpha hemoglobin stabilizing protein |
multiple interactions |
ISO |
AHSP protein binds to and affects the folding of and affects the stability of [HBA1 protein binds to Iron] |
CTD |
PMID:16901899 |
|
NCBI chr 1:199,720,038...199,721,010
Ensembl chr 1:199,720,038...199,721,010
|
|
G |
Akap13 |
A-kinase anchoring protein 13 |
decreases expression |
EXP |
Iron deficiency results in decreased expression of AKAP13 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr 1:137,089,558...137,315,272
Ensembl chr 1:137,014,272...137,315,272
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Iron results in increased phosphorylation of AKT1 protein]; Deferiprone inhibits the reaction [Iron results in increased phosphorylation of AKT1 protein]; Filipin inhibits the reaction [Iron results in increased phosphorylation of AKT1 protein]; HRAS protein affects the reaction [Iron results in increased phosphorylation of AKT1 protein]; MAP3K7 protein affects the reaction [Iron results in increased phosphorylation of AKT1 protein]; PIK3R1 protein affects the reaction [Iron results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:17172471 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Alas2 |
5'-aminolevulinate synthase 2 |
increases expression |
ISO |
Iron results in increased expression of ALAS2 mRNA |
CTD |
PMID:16424395 |
|
NCBI chr X:23,167,576...23,187,356
Ensembl chr X:23,167,696...23,187,341
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
ALB protein affects the reaction [[Iron co-treated with Bicarbonates] results in increased abundance of Malondialdehyde]; ALB protein inhibits the reaction [[Iron co-treated with Phosphates] results in increased abundance of Malondialdehyde] |
CTD |
PMID:16027354 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
decreases expression |
ISO |
Iron deficiency results in decreased expression of ALDOC mRNA |
CTD |
PMID:20368581 |
|
NCBI chr10:65,586,504...65,590,093
Ensembl chr10:65,586,504...65,590,126
|
|
G |
Ankrd22 |
ankyrin repeat domain 22 |
increases expression |
ISO |
Iron deficiency results in increased expression of ANKRD22 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 1:252,430,750...252,461,346
Ensembl chr 1:252,429,677...252,461,461
|
|
G |
Ankrd37 |
ankyrin repeat domain 37 |
increases expression |
EXP ISO |
Iron deficiency results in increased expression of ANKRD37 mRNA |
CTD |
PMID:16629162 PMID:23776592 |
|
NCBI chr16:49,463,016...49,465,905
Ensembl chr16:49,462,889...49,465,888
|
|
G |
Anxa1 |
annexin A1 |
decreases expression |
EXP |
Iron deficiency results in decreased expression of ANXA1 mRNA |
CTD |
PMID:19821111 |
|
NCBI chr 1:237,893,983...237,910,002
Ensembl chr 1:237,893,966...237,910,012
|
|
G |
Anxa2 |
annexin A2 |
increases expression |
ISO |
Iron deficiency results in increased expression of ANXA2 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 8:75,687,134...75,723,589
Ensembl chr 8:75,687,100...75,723,594
|
|
G |
Ap1s3 |
adaptor related protein complex 1 subunit sigma 3 |
decreases expression |
ISO |
Iron deficiency results in decreased expression of AP1S3 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 9:85,386,752...85,445,977
Ensembl chr 9:85,387,065...85,445,939
|
|
G |
Ap2a1 |
adaptor related protein complex 2 subunit alpha 1 |
multiple interactions |
EXP |
[Tungsten co-treated with Nickel co-treated with Iron] results in decreased expression of AP2A1 mRNA |
CTD |
PMID:24619124 |
|
NCBI chr 1:100,896,582...100,926,443
Ensembl chr 1:100,896,947...100,926,335
|
|
G |
Apoe |
apolipoprotein E |
increases response to substance |
ISO |
APOE gene polymorphism results in increased susceptibility to Iron |
CTD |
PMID:15993987 |
|
NCBI chr 1:80,612,894...80,616,820
Ensembl chr 1:80,612,895...80,617,057
|
|
G |
Apoh |
apolipoprotein H |
decreases expression |
EXP |
Iron deficiency results in decreased expression of APOH mRNA |
CTD |
PMID:19821111 |
|
NCBI chr10:96,640,013...96,653,939
Ensembl chr10:96,639,924...96,653,938
|
|
G |
App |
amyloid beta precursor protein |
increases expression increases uptake |
ISO |
Iron results in increased expression of APP mRNA Iron results in increased uptake of APP protein |
CTD |
PMID:15993987 PMID:16308480 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Aqp4 |
aquaporin 4 |
increases expression multiple interactions |
EXP ISO |
Iron deficiency results in increased expression of AQP4 mRNA [ferrous chloride results in increased abundance of Iron] which results in increased expression of AQP4 mRNA; [ferrous chloride results in increased abundance of Iron] which results in increased expression of AQP4 protein; SB 203580 inhibits the reaction [[ferrous chloride results in increased abundance of Iron] which results in increased expression of AQP4 protein]; U 0126 inhibits the reaction [[ferrous chloride results in increased abundance of Iron] which results in increased expression of AQP4 protein]; Vitamin E inhibits the reaction [[ferrous chloride results in increased abundance of Iron] which results in increased expression of AQP4 protein] |
CTD |
PMID:16629162 PMID:30914277 |
|
NCBI chr18:6,766,009...6,782,757
Ensembl chr18:6,765,945...6,782,996
|
|
G |
Arid3b |
AT-rich interaction domain 3B |
increases expression |
ISO |
Iron deficiency results in increased expression of ARID3B mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 8:62,569,601...62,616,837
Ensembl chr 8:62,569,528...62,616,828
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
multiple interactions |
ISO |
ARNT protein affects the reaction [Iron deficiency results in increased activity of CP promoter] |
CTD |
PMID:10777486 |
|
NCBI chr 2:196,594,178...196,651,486
Ensembl chr 2:196,594,303...196,651,179
|
|
G |
Arrdc3 |
arrestin domain containing 3 |
increases expression |
ISO |
Iron deficiency results in increased expression of ARRDC3 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 2:8,732,907...8,745,445
Ensembl chr 2:8,732,932...8,743,069
|
|
G |
Atm |
ATM serine/threonine kinase |
affects response to substance multiple interactions affects abundance |
ISO |
ATM protein affects the susceptibility to Iron Iron results in increased phosphorylation of and results in increased activity of ATM protein ATM protein affects the abundance of Iron |
CTD |
PMID:15336622 PMID:16959548 |
|
NCBI chr 8:58,015,938...58,119,973
Ensembl chr 8:58,015,940...58,120,045
|
|
G |
Atp7a |
ATPase copper transporting alpha |
affects metabolic processing increases expression multiple interactions affects transport decreases oxidation increases response to substance |
ISO EXP |
ATP7A protein mutant form affects the metabolism of Iron Iron deficiency results in increased expression of ATP7A; Iron deficiency results in increased expression of ATP7A mRNA; Iron deficiency results in increased expression of ATP7A protein [Iron deficiency results in increased expression of ATP7A] which results in increased abundance of Copper ATP7A mutant form affects the transport of Iron ATP7A gene mutant form results in decreased oxidation of Iron ATP7A gene mutant form results in increased susceptibility to Iron deficiency [ATP7A gene mutant form co-treated with Iron deficiency] results in increased uptake of Copper; [ATP7A gene mutant form co-treated with Iron deficiency] results in increased uptake of Iron; ATP7A gene mutant form promotes the reaction [Iron deficiency results in increased expression of MT1 mRNA]; Iron deficiency inhibits the reaction [ATP7A gene mutant form results in decreased oxidation of Iron] |
CTD |
PMID:16629162 PMID:21852364 PMID:23174565 PMID:23776592 PMID:23814049 PMID:24089420 PMID:24174620 PMID:25247420 |
|
NCBI chr X:77,076,085...77,193,644
Ensembl chr X:77,076,106...77,193,644
|
|
G |
Atp7b |
ATPase copper transporting beta |
increases abundance |
EXP |
ATP7B gene mutant form results in increased abundance of Iron |
CTD |
PMID:15911138 |
|
NCBI chr16:74,865,516...74,944,935
Ensembl chr16:74,865,516...74,945,286
|
|
G |
B2m |
beta-2 microglobulin |
multiple interactions affects metabolic processing |
ISO |
[HFE protein binds to B2M protein binds to SLC11A2 protein] which results in decreased uptake of Iron B2M protein affects the metabolism of Iron |
CTD |
PMID:16841247 PMID:17194590 |
|
NCBI chr 3:114,087,287...114,093,311
Ensembl chr 3:114,087,287...114,093,309
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions |
ISO |
[Arachidonic Acid co-treated with Iron] results in increased expression of BAD protein; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of BAD protein] |
CTD |
PMID:30626086 |
|
NCBI chr 1:222,198,516...222,207,459
Ensembl chr 1:222,198,534...222,207,453
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
[Arachidonic Acid co-treated with Iron] results in increased expression of BAX protein; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of BAX protein] |
CTD |
PMID:30626086 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2 protein; resveratrol inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2 protein] |
CTD |
PMID:19620254 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
ISO |
[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein; Drugs, Chinese Herbal inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein]; Resveratrol inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein] |
CTD |
PMID:19620254 PMID:27916511 PMID:30626086 |
|
NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
|
|
G |
Bcl3 |
BCL3, transcription coactivator |
increases expression |
ISO |
Iron deficiency results in increased expression of BCL3 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 1:80,730,758...80,745,273
Ensembl chr 1:80,730,499...80,744,831
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
increases abundance increases expression decreases abundance decreases expression |
ISO EXP |
BMP6 gene mutant form results in increased abundance of Iron Iron results in increased expression of BMP6 mRNA BMP6 protein results in decreased abundance of Iron Iron deficiency results in decreased expression of BMP6 mRNA |
CTD |
PMID:19252486 PMID:19252488 PMID:20164366 |
|
NCBI chr17:26,955,142...27,112,820
Ensembl chr17:26,955,142...27,112,820
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
increases expression |
ISO |
Iron deficiency results in increased expression of BNIP3 mRNA |
CTD |
PMID:23776592 |
|
NCBI chr 1:211,248,098...211,265,282
Ensembl chr 1:211,248,098...211,265,282
|
|
G |
Calr |
calreticulin |
increases expression |
ISO |
Iron results in increased expression of CALR mRNA; Iron results in increased expression of CALR protein |
CTD |
PMID:11500943 |
|
NCBI chr19:25,956,771...25,961,666
Ensembl chr19:25,956,771...25,961,666
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
[Acetaminophen co-treated with [ferric nitrate results in increased abundance of Iron]] results in increased cleavage of CASP3 protein; [Arachidonic Acid co-treated with Iron] results in decreased expression of CASP3 protein; [Arachidonic Acid co-treated with Iron] results in increased cleavage of CASP3 protein; [Arachidonic Acid co-treated with Iron] results in increased expression of CASP3 protein modified form; Drugs, Chinese Herbal inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased cleavage of CASP3 protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased cleavage of CASP3 protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of CASP3 protein modified form]; Resveratrol inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of CASP3 protein]; Rifampin inhibits the reaction [[Acetaminophen co-treated with [ferric nitrate results in increased abundance of Iron]] results in increased cleavage of CASP3 protein] |
CTD |
PMID:19620254 PMID:27916511 PMID:30626086 PMID:31678598 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Cat |
catalase |
multiple interactions decreases activity |
ISO EXP |
Iron deficiency inhibits the reaction [Benzoyl Peroxide results in decreased activity of CAT protein]; Iron promotes the reaction [Benzoyl Peroxide results in decreased activity of CAT protein]; Iron promotes the reaction [cumene hydroperoxide results in decreased activity of CAT protein]; Iron promotes the reaction [Hydrogen Peroxide results in decreased activity of CAT protein]; Iron promotes the reaction [mezerein results in decreased activity of CAT protein]; Iron promotes the reaction [Tetradecanoylphorbol Acetate results in decreased activity of CAT protein] Iron results in decreased activity of CAT protein [Arsenic co-treated with Cadmium co-treated with Lead co-treated with Mercury co-treated with Chromium co-treated with Nickel co-treated with Manganese co-treated with Iron] results in decreased activity of CAT protein; [Zinc co-treated with Iron co-treated with Calcium] inhibits the reaction [lead acetate results in decreased expression of CAT protein] |
CTD |
PMID:12065085 PMID:12067571 PMID:12504893 PMID:17176674 PMID:22534743 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Cav1 |
caveolin 1 |
affects localization |
EXP |
Iron affects the localization of CAV1 protein |
CTD |
PMID:17172471 |
|
NCBI chr 4:44,597,123...44,630,206
Ensembl chr 4:44,597,123...44,630,200
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression multiple interactions |
ISO EXP |
Iron deficiency results in increased expression of CCL2 mRNA [Iron co-treated with Diethylnitrosamine] results in increased expression of CCL2 mRNA; Iron promotes the reaction [[Copper co-treated with Diethylnitrosamine] results in increased expression of CCL2 mRNA] |
CTD |
PMID:20302851 PMID:20368581 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
EXP |
[Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of CCL3 mRNA |
CTD |
PMID:22198552 |
|
NCBI chr10:70,869,516...70,871,066
Ensembl chr10:70,869,513...70,871,066
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
increases expression |
ISO |
Iron deficiency results in increased expression of CCL5 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression |
ISO EXP |
Iron results in increased expression of CCND1 Iron deficiency results in increased expression of CCND1 mRNA; Iron results in increased expression of CCND1; Iron results in increased expression of CCND1 mRNA; Iron results in increased expression of CCND1 protein |
CTD |
PMID:16629162 PMID:16890145 PMID:22649188 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Ccng2 |
cyclin G2 |
increases expression |
ISO |
Iron deficiency results in increased expression of CCNG2 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr14:16,267,572...16,276,068
Ensembl chr14:16,267,573...16,276,068
|
|
G |
Ccpg1 |
cell cycle progression 1 |
increases expression |
ISO |
Iron deficiency results in increased expression of CCPG1 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 8:79,660,634...79,692,044
Ensembl chr 8:79,660,657...79,692,039
|
|
G |
Ccsap |
centriole, cilia and spindle-associated protein |
increases expression |
ISO |
Iron deficiency results in increased expression of CCSAP mRNA |
CTD |
PMID:20368581 |
|
NCBI chr19:56,615,326...56,634,031
Ensembl chr19:56,617,399...56,633,633
|
|
G |
Cd109 |
CD109 molecule |
increases expression |
ISO |
Iron deficiency results in increased expression of CD109 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 8:85,951,420...86,065,411
Ensembl chr 8:85,951,191...86,065,409
|
|
G |
Cd14 |
CD14 molecule |
multiple interactions increases expression |
ISO |
Acetylcysteine inhibits the reaction [Iron deficiency results in increased expression of CD14 protein]; pyrrolidine dithiocarbamic acid inhibits the reaction [Iron deficiency results in increased expression of CD14 protein]; Vitamin D promotes the reaction [Iron deficiency results in increased expression of CD14 protein] |
CTD |
PMID:20368581 |
|
NCBI chr18:29,560,341...29,562,290
Ensembl chr18:29,560,365...29,562,153
|
|
G |
Cd1d1 |
CD1d1 molecule |
decreases expression |
EXP |
Iron deficiency results in decreased expression of CD1D1 mRNA |
CTD |
PMID:19821111 |
|
NCBI chr 2:186,330,298...186,333,805
Ensembl chr 2:186,330,298...186,333,805
|
|
G |
Cd300a |
Cd300a molecule |
increases expression |
ISO |
Iron deficiency results in increased expression of CD300A mRNA |
CTD |
PMID:20368581 |
|
NCBI chr10:103,437,978...103,451,170
Ensembl chr10:103,438,303...103,450,947
|
|
G |
Cd36 |
CD36 molecule |
decreases expression |
EXP |
Iron deficiency results in decreased expression of CD36 mRNA |
CTD |
PMID:16629162 PMID:19821111 |
|
NCBI chr 4:14,150,309...14,191,498
Ensembl chr 4:14,001,761...14,249,749
|
|
G |
Cd70 |
Cd70 molecule |
increases expression |
ISO |
Iron deficiency results in increased expression of CD70 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 9:9,842,585...9,845,728
Ensembl chr 9:9,842,585...9,845,728
|
|
G |
Cd74 |
CD74 molecule |
decreases expression |
ISO |
Iron deficiency results in decreased expression of CD74 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr18:56,071,420...56,080,851
Ensembl chr18:56,071,478...56,080,849
|
|
G |
Cdipt |
CDP-diacylglycerol--inositol 3-phosphatidyltransferase |
decreases expression |
EXP |
Iron deficiency results in decreased expression of CDIPT mRNA |
CTD |
PMID:19821111 |
|
NCBI chr 1:198,409,186...198,413,497
Ensembl chr 1:198,409,360...198,413,497
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
EXP |
[Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of CDKN1A mRNA |
CTD |
PMID:22198552 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cdkn1c |
cyclin-dependent kinase inhibitor 1C |
decreases expression |
EXP |
Iron deficiency results in decreased expression of CDKN1C mRNA |
CTD |
PMID:16629162 |
|
NCBI chr 1:216,661,067...216,663,791
Ensembl chr 1:216,661,080...216,663,721
|
|
G |
Cdkn2d |
cyclin dependent kinase inhibitor 2D |
increases expression |
ISO |
Iron deficiency results in increased expression of CDKN2D mRNA |
CTD |
PMID:20368581 |
|
|
|
G |
Cdo1 |
cysteine dioxygenase type 1 |
multiple interactions |
EXP |
Iron binds to and results in increased activity of CDO1 protein |
CTD |
PMID:16611640 |
|
NCBI chr18:40,702,027...40,716,901
Ensembl chr18:40,701,984...40,716,686
|
|
G |
Cdrt4 |
CMT1A duplicated region transcript 4 |
increases expression |
ISO |
Iron deficiency results in increased expression of CDRT4 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr10:49,368,183...49,400,284
Ensembl chr10:49,368,314...49,400,193
|
|
G |
Cds1 |
CDP-diacylglycerol synthase 1 |
decreases expression |
EXP |
Iron deficiency results in decreased expression of CDS1 mRNA |
CTD |
PMID:19821111 |
|
NCBI chr14:9,396,511...9,456,964
Ensembl chr14:9,396,512...9,456,990
|
|
G |
Cel |
carboxyl ester lipase |
increases expression |
EXP |
Iron deficiency results in increased expression of CEL mRNA |
CTD |
PMID:19821111 |
|
NCBI chr 3:7,134,021...7,141,522
Ensembl chr 3:7,134,021...7,141,522
|
|
G |
Chek2 |
checkpoint kinase 2 |
multiple interactions |
EXP |
[Nickel co-treated with Iron co-treated with Tungsten] results in decreased expression of CHEK2 mRNA |
CTD |
PMID:22198552 |
|
NCBI chr12:51,845,574...51,878,098
Ensembl chr12:51,845,796...51,877,624
|
|
G |
Chi3l1 |
chitinase 3 like 1 |
decreases expression |
ISO |
Iron deficiency results in decreased expression of CHI3L1 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr13:51,022,844...51,030,797
Ensembl chr13:51,022,681...51,030,802
|
|
G |
Chrnd |
cholinergic receptor nicotinic delta subunit |
multiple interactions |
EXP |
[Tungsten co-treated with Nickel co-treated with Iron] results in decreased expression of CHRND mRNA |
CTD |
PMID:24619124 |
|
NCBI chr 9:94,286,550...94,294,968
Ensembl chr 9:94,286,550...94,294,968
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
EXP |
deferiprone inhibits the reaction [Iron results in increased activity of [CHUK protein binds to IKBKB protein]]; Filipin inhibits the reaction [Iron results in increased activity of [CHUK protein binds to IKBKB protein]]; Iron results in increased activity of [CHUK protein binds to IKBKB protein]; N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid inhibits the reaction [Iron results in increased activity of [CHUK protein binds to IKBKB protein]] |
CTD |
PMID:17172471 |
|
NCBI chr 1:263,848,829...263,884,354
Ensembl chr 1:263,848,884...263,885,169
|
|
G |
Cldn2 |
claudin 2 |
increases expression |
EXP |
Iron deficiency results in increased expression of CLDN2 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr X:111,122,552...111,133,188
Ensembl chr X:111,122,552...111,137,769
|
|
G |
Clps |
colipase |
increases expression |
EXP |
Iron deficiency results in increased expression of CLPS mRNA |
CTD |
PMID:19821111 |
|
NCBI chr20:5,803,447...5,806,107
Ensembl chr20:5,803,383...5,806,097
|
|
G |
Cnn3 |
calponin 3 |
increases expression |
EXP |
Iron deficiency results in increased expression of CNN3 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr 2:225,005,069...225,036,179
Ensembl chr 2:225,005,019...225,036,188
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
EXP |
Iron promotes the reaction [Asbestos, Amosite results in increased expression of COL1A1 mRNA] |
CTD |
PMID:11306436 |
|
NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
|
|
G |
Cp |
ceruloplasmin |
affects binding multiple interactions increases expression increases abundance increases activity increases oxidation decreases export |
ISO EXP |
CP protein binds to [TF protein binds to Iron] [Zinc co-treated with Iron co-treated with Calcium] inhibits the reaction [lead acetate results in decreased expression of CP protein] Iron deficiency results in increased expression of CP protein; Iron deficiency results in increased expression of CP protein modified form CP gene mutant form results in increased abundance of Iron Iron deficiency results in increased activity of CP promoter [CP gene mutant form results in increased abundance of Iron] which results in decreased expression of TFRC mRNA; [CP gene mutant form results in increased abundance of Iron] which results in increased expression of FTH1 mRNA; [CP gene mutant form results in increased abundance of Iron] which results in increased expression of FTL mRNA; [CP gene mutant form results in increased abundance of Iron] which results in increased expression of SLC11A1 mRNA; Iron inhibits the reaction [Diethylnitrosamine results in increased expression of CP protein] [CP protein results in increased oxidation of Iron] which results in increased stability of SLC40A1 protein; ARNT protein affects the reaction [Iron deficiency results in increased activity of CP promoter] CP gene mutant form results in decreased export of Iron |
CTD |
PMID:10777486 PMID:12572680 PMID:16988052 PMID:19061943 PMID:20655381 PMID:20801540 PMID:21049900 PMID:22457245 PMID:22534743 PMID:23814049 |
|
NCBI chr 2:104,744,249...104,803,034
Ensembl chr 2:104,744,461...104,799,853
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
EXP |
[Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of CSF2 mRNA |
CTD |
PMID:22198552 |
|
NCBI chr10:39,602,089...39,604,070
Ensembl chr10:39,602,089...39,604,070
|
|
G |
Cstf2t |
cleavage stimulation factor subunit 2, tau variant |
decreases expression |
ISO |
Iron deficiency results in decreased expression of CSTF2T mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 1:249,574,954...249,578,520
Ensembl chr 1:249,574,954...249,578,520
|
|
G |
Ctnnbip1 |
catenin, beta-interacting protein 1 |
decreases expression |
EXP |
Iron deficiency results in decreased expression of CTNNBIP1 mRNA |
CTD |
PMID:19821111 |
|
NCBI chr 5:166,464,170...166,513,030
Ensembl chr 5:166,464,252...166,513,027
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
multiple interactions |
EXP |
[Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of CXCL1 protein |
CTD |
PMID:22198552 |
|
NCBI chr14:18,743,678...18,745,457
Ensembl chr14:18,743,685...18,745,457
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
EXP |
[Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of CXCL2 protein |
CTD |
PMID:22198552 |
|
NCBI chr14:18,731,346...18,733,391
Ensembl chr14:18,731,378...18,733,391
|
|
G |
Cybrd1 |
cytochrome b reductase 1 |
decreases expression increases expression |
ISO EXP |
Iron results in decreased expression of CYBRD1 protein Iron deficiency results in increased expression of CYBRD1 mRNA Iron results in increased expression of CYBRD1 protein |
CTD |
PMID:16629162 PMID:18815723 PMID:19821111 PMID:21540277 PMID:23776592 PMID:23814049 |
|
NCBI chr 3:57,718,496...57,745,749
Ensembl chr 3:57,718,364...57,746,097
|
|
G |
Cyp2b15 |
cytochrome P450, family 2, subfamily b, polypeptide 15 |
decreases expression |
EXP |
Iron deficiency results in decreased expression of CYP2B15 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr 1:251,325,923...251,338,404
Ensembl chr 1:251,325,923...251,338,358
|
|
G |
Cytip |
cytohesin 1 interacting protein |
increases expression |
ISO |
Iron deficiency results in increased expression of CYTIP mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 3:44,150,494...44,225,723
Ensembl chr 3:44,150,992...44,177,689
|
|
G |
Dapl1 |
death associated protein-like 1 |
decreases expression |
EXP |
Iron deficiency results in decreased expression of DAPL1 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr 3:45,538,408...45,559,281
Ensembl chr 3:45,538,797...45,559,331
|
|
G |
Daxx |
death-domain associated protein |
increases expression |
ISO |
Iron results in increased expression of DAXX mRNA |
CTD |
PMID:16308480 |
|
NCBI chr20:5,480,103...5,485,962
Ensembl chr20:5,480,103...5,485,926
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions |
ISO EXP |
Iron deficiency results in increased expression of DDIT3 mRNA [Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of DDIT3 mRNA |
CTD |
PMID:20368581 PMID:22198552 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Defa6 |
defensin alpha 6 |
increases expression |
EXP |
Iron deficiency results in increased expression of DEFA6 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr16:75,400,781...75,401,655
Ensembl chr16:75,400,781...75,401,655
|
|
G |
Dgka |
diacylglycerol kinase, alpha |
increases expression |
EXP |
Iron deficiency results in increased expression of DGKA mRNA |
CTD |
PMID:19821111 |
|
NCBI chr 7:3,143,826...3,170,764
Ensembl chr 7:3,143,827...3,170,146
|
|
G |
Dlc1 |
DLC1 Rho GTPase activating protein |
increases expression |
EXP |
Iron deficiency results in increased expression of DLC1 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr16:58,776,489...59,247,752
Ensembl chr16:59,077,574...59,247,754
|
|
G |
Dock10 |
dedicator of cytokinesis 10 |
increases expression |
ISO |
Iron deficiency results in increased expression of DOCK10 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 9:86,424,638...86,571,854 NCBI chr 9:86,312,470...86,423,054
Ensembl chr 9:86,312,501...86,571,870
|
|
G |
Drd1 |
dopamine receptor D1 |
multiple interactions |
EXP |
[manganese chloride co-treated with Iron deficiency] results in decreased expression of DRD1 protein |
CTD |
PMID:22479410 |
|
NCBI chr17:11,099,736...11,104,352
Ensembl chr17:11,101,306...11,103,541
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions |
EXP |
[manganese chloride co-treated with Iron deficiency] results in increased expression of DRD2 protein |
CTD |
PMID:22479410 |
|
NCBI chr 8:53,678,777...53,743,643
Ensembl chr 8:53,678,777...53,743,642
|
|
G |
E2f1 |
E2F transcription factor 1 |
multiple interactions |
EXP |
[Nickel co-treated with Iron co-treated with Tungsten] results in decreased expression of E2F1 mRNA |
CTD |
PMID:22198552 |
|
NCBI chr 3:150,062,895...150,073,721
Ensembl chr 3:150,047,826...150,073,721
|
|
G |
E2f8 |
E2F transcription factor 8 |
increases expression |
ISO |
Iron deficiency results in increased expression of E2F8 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 1:104,185,436...104,203,683
Ensembl chr 1:104,187,100...104,202,591
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
EXP |
[Iron co-treated with Diethylnitrosamine] results in increased expression of EDN1 protein; Copper promotes the reaction [[Iron co-treated with Diethylnitrosamine] results in increased expression of EDN1 protein] |
CTD |
PMID:20302851 |
|
NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
|
|
G |
Eef2k |
eukaryotic elongation factor-2 kinase |
increases expression |
EXP |
Iron deficiency results in increased expression of EEF2K mRNA |
CTD |
PMID:16629162 |
|
NCBI chr 1:190,780,211...190,839,926
Ensembl chr 1:190,780,236...190,842,324
|
|
G |
Egln1 |
egl-9 family hypoxia-inducible factor 1 |
affects binding |
ISO |
Iron binds to EGLN1 protein |
CTD |
PMID:16649251 |
|
NCBI chr19:57,660,194...57,701,158
Ensembl chr19:57,662,278...57,699,113
|
|
G |
Egln3 |
egl-9 family hypoxia-inducible factor 3 |
increases expression |
EXP |
Iron deficiency results in increased expression of EGLN3 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr 6:75,050,329...75,075,795
Ensembl chr 6:75,050,329...75,075,795
|
|
G |
Egr1 |
early growth response 1 |
increases expression multiple interactions |
EXP |
Iron deficiency results in increased expression of EGR1 mRNA [Tungsten co-treated with Nickel co-treated with Iron] results in increased expression of EGR1 mRNA |
CTD |
PMID:16629162 PMID:24619124 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
Elane |
elastase, neutrophil expressed |
decreases expression |
ISO |
Iron deficiency results in decreased expression of ELANE mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 7:12,638,320...12,640,168
Ensembl chr 7:12,638,322...12,640,232
|
|
G |
Emp1 |
epithelial membrane protein 1 |
increases expression |
ISO |
Iron deficiency results in increased expression of EMP1 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 4:169,161,076...169,181,967
Ensembl chr 4:169,147,243...169,181,966
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
multiple interactions increases expression |
ISO EXP |
Iron inhibits the reaction [galangin results in increased expression of EPAS1 protein]; Iron inhibits the reaction [Quercetin results in increased expression of EPAS1 protein] Iron deficiency results in increased expression of EPAS1 protein |
CTD |
PMID:17973296 PMID:23814049 |
|
NCBI chr 6:10,306,508...10,385,239
Ensembl chr 6:10,306,405...10,387,265
|
|
G |
Epo |
erythropoietin |
affects response to substance |
ISO |
Iron affects the susceptibility to EPO protein |
CTD |
PMID:24806658 |
|
NCBI chr12:22,274,828...22,278,268
Ensembl chr12:22,274,828...22,278,266
|
|
G |
Exoc6 |
exocyst complex component 6 |
affects metabolic processing |
ISO |
EXOC6 protein affects the metabolism of Iron |
CTD |
PMID:17194590 |
|
NCBI chr 1:256,211,879...256,369,318
Ensembl chr 1:256,226,179...256,368,813
|
|
G |
F13a1 |
coagulation factor XIII A1 chain |
decreases expression |
ISO |
Iron deficiency results in decreased expression of F13A1 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr17:28,504,650...28,680,015
Ensembl chr17:28,504,623...28,680,362
|
|
G |
F2 |
coagulation factor II |
decreases activity |
ISO |
Iron results in decreased activity of F2 protein |
CTD |
PMID:6421970 |
|
NCBI chr 3:80,529,468...80,542,993
Ensembl chr 3:80,529,428...80,543,031
|
|
G |
Fabp2 |
fatty acid binding protein 2 |
increases expression |
EXP |
Iron deficiency results in increased expression of FABP2 mRNA |
CTD |
PMID:19821111 |
|
NCBI chr 2:227,080,912...227,083,654
Ensembl chr 2:227,080,924...227,083,501
|
|
G |
Fabp6 |
fatty acid binding protein 6 |
increases expression |
EXP |
Iron deficiency results in increased expression of FABP6 mRNA |
CTD |
PMID:19821111 |
|
NCBI chr10:29,191,621...29,196,593
Ensembl chr10:29,191,623...29,196,563
|
|
G |
Fam117b |
family with sequence similarity 117, member B |
increases expression |
EXP |
Iron deficiency results in increased expression of FAM117B mRNA |
CTD |
PMID:16629162 |
|
NCBI chr 9:66,716,969...66,784,487
Ensembl chr 9:66,716,969...66,784,487
|
|
G |
Fam20c |
FAM20C, golgi associated secretory pathway kinase |
decreases expression |
ISO |
Iron deficiency results in decreased expression of FAM20C mRNA |
CTD |
PMID:20368581 |
|
NCBI chr12:17,913,771...17,972,733
Ensembl chr12:17,913,767...17,972,737
|
|
G |
Fbxw5 |
F-box and WD repeat domain containing 5 |
multiple interactions |
EXP |
[Tungsten co-treated with Nickel co-treated with Iron] results in decreased expression of FBXW5 mRNA |
CTD |
PMID:24619124 |
|
NCBI chr 3:2,726,705...2,731,213
Ensembl chr 3:2,727,254...2,731,212
|
|
G |
Fech |
ferrochelatase |
multiple interactions |
ISO |
[Aminolevulinic Acid results in decreased activity of FECH protein] which results in increased abundance of Iron; [Griseofulvin results in decreased activity of FECH protein] which results in decreased uptake of Iron; [Porphobilinogen results in decreased activity of FECH protein] which results in increased abundance of Iron; heme arginate inhibits the reaction [[Griseofulvin results in decreased activity of FECH protein] which results in decreased uptake of Iron] [pyridoxal isonicotinoyl hydrazone results in decreased abundance of Iron] which results in decreased expression of FECH protein |
CTD |
PMID:15078340 PMID:30517741 |
|
NCBI chr18:59,941,992...59,975,192
Ensembl chr18:59,941,992...59,975,192
|
|
G |
Fen1 |
flap structure-specific endonuclease 1 |
multiple interactions |
ISO |
Iron binds to and inhibits the reaction [NEIL1 protein binds to FEN1 protein] |
CTD |
PMID:20622253 |
|
NCBI chr 1:226,251,516...226,256,160
Ensembl chr 1:226,251,518...226,255,886
|
|
G |
Flot1 |
flotillin 1 |
increases expression |
ISO |
Iron deficiency results in increased expression of FLOT1 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr20:3,427,890...3,438,418
Ensembl chr20:3,427,880...3,438,396
|
|
G |
Fn3k |
fructosamine 3 kinase |
multiple interactions |
EXP |
[Tungsten co-treated with Nickel co-treated with Iron] results in increased expression of FN3K mRNA |
CTD |
PMID:24619124 |
|
NCBI chr10:110,626,462...110,642,262
Ensembl chr10:110,631,494...110,642,260
|
|
G |
Fntb |
farnesyltransferase, CAAX box, beta |
increases expression |
EXP |
Iron deficiency results in increased expression of FNTB mRNA |
CTD |
PMID:16629162 |
|
NCBI chr 6:99,883,959...99,966,988
Ensembl chr 6:99,883,959...99,966,988
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
[Tungsten co-treated with Nickel co-treated with Iron] results in increased expression of FOS mRNA |
CTD |
PMID:24619124 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Fth1 |
ferritin heavy chain 1 |
affects abundance increases expression multiple interactions affects binding decreases expression affects metabolic processing |
ISO EXP |
FTH1 protein affects the abundance of Iron Iron results in increased expression of FTH1 mRNA [Deferoxamine results in decreased abundance of Iron] which results in decreased expression of FTH1 mRNA; Iron deficiency promotes the reaction [Vitamin A deficiency results in decreased expression of FTH1 protein] Iron binds to FTH1 protein [CP gene mutant form results in increased abundance of Iron] which results in increased expression of FTH1 mRNA; FTH1 protein inhibits the reaction [Iron results in increased abundance of Reactive Oxygen Species] [[NBD peptide, mouse results in decreased expression of FTH1 mRNA] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species Iron results in decreased expression of FTH1 mRNA FTH1 protein affects the metabolism of Iron |
CTD |
PMID:15893546 PMID:16424395 PMID:16448386 PMID:16988052 PMID:17070541 PMID:17194590 PMID:18931039 PMID:19258503 PMID:22154532 |
|
NCBI chr 1:226,030,940...226,033,228
Ensembl chr 1:226,030,938...226,033,228
|
|
G |
Ftl1 |
ferritin light chain 1 |
multiple interactions increases expression decreases expression affects binding decreases uptake |
ISO EXP |
2-pyridylcarboxaldehyde isonicotinoylhydrazone inhibits the reaction [Doxorubicin promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]]; 2-pyridylcarboxaldehyde isonicotinoylhydrazone inhibits the reaction [Iron binds to [FTL protein binds to FTMT protein]]; [Deferoxamine results in decreased abundance of Iron] which results in decreased expression of FTL mRNA; [ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of FTL mRNA; [Hemin results in increased abundance of Iron] which results in increased expression of FTL mRNA; Deferoxamine inhibits the reaction [Doxorubicin promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]]; Deferoxamine inhibits the reaction [Iron binds to [FTL protein binds to FTMT protein]]; Doxorubicin promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]; Paraquat promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]; Razoxane inhibits the reaction [Iron binds to [FTL protein binds to FTMT protein]]; Vitamin K 3 promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]] Iron results in increased expression of FTL1 mRNA Iron results in decreased expression of FTL1 mRNA [Deferoxamine results in decreased abundance of Iron] which results in decreased expression of FTL mRNA; [Iron co-treated with Diethylnitrosamine] results in increased expression of FTL mRNA; Copper promotes the reaction [[Iron co-treated with Diethylnitrosamine] results in increased expression of FTL mRNA] [CP gene mutant form results in increased abundance of Iron] which results in increased expression of FTL mRNA; [Iron co-treated with Ethanol] results in increased expression of FTL1 mRNA; Iron inhibits the reaction [Diethylnitrosamine results in decreased expression of FTL1 mRNA]; Quercetin inhibits the reaction [[Iron co-treated with Ethanol] results in increased expression of FTL1 mRNA]; Quercetin inhibits the reaction [Iron results in increased expression of FTL1 mRNA] FTL protein mutant form results in decreased uptake of Iron |
CTD |
PMID:12393473 PMID:12644586 PMID:15893546 PMID:16424395 PMID:16822677 PMID:16988052 PMID:19061943 PMID:20302851 PMID:24569067 |
|
NCBI chr 1:101,448,190...101,450,034
Ensembl chr 1:101,448,346...101,449,829
|
|
G |
Ftmt |
ferritin mitochondrial |
multiple interactions affects localization affects binding |
ISO |
2-pyridylcarboxaldehyde isonicotinoylhydrazone inhibits the reaction [Doxorubicin promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]]; 2-pyridylcarboxaldehyde isonicotinoylhydrazone inhibits the reaction [Iron binds to [FTL protein binds to FTMT protein]]; [diallyl trisulfide results in decreased expression of FTMT protein] which results in increased abundance of Iron; Deferoxamine inhibits the reaction [Doxorubicin promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]]; Deferoxamine inhibits the reaction [Iron binds to [FTL protein binds to FTMT protein]]; Doxorubicin promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]; Paraquat promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]]; Razoxane inhibits the reaction [Iron binds to [FTL protein binds to FTMT protein]]; Vitamin K 3 promotes the reaction [Iron binds to [FTL protein binds to FTMT protein]] FTMT protein affects the localization of Iron |
CTD |
PMID:12644586 PMID:16757684 PMID:21616139 |
|
NCBI chr18:47,294,292...47,295,541
Ensembl chr18:47,294,292...47,295,541
|
|
G |
Fxn |
frataxin |
increases abundance affects metabolic processing affects binding increases metabolic processing |
ISO |
FXN gene mutant form results in increased abundance of Iron FXN protein affects the metabolism of Iron Iron binds to FXN protein FXN protein results in increased metabolism of Iron |
CTD |
PMID:16120311 PMID:16911956 PMID:17101455 PMID:17194590 |
|
NCBI chr 1:242,123,975...242,152,834
Ensembl chr 1:242,123,975...242,152,834
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
decreases expression |
EXP |
Iron deficiency results in decreased expression of G6PC1 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr10:89,286,009...89,296,213
Ensembl chr10:89,285,855...89,296,213
|
|
G |
Gabbr2 |
gamma-aminobutyric acid type B receptor subunit 2 |
multiple interactions decreases expression |
EXP |
[Iron deficiency co-treated with manganese chloride] results in decreased expression of GABBR2 mRNA; [Iron deficiency co-treated with manganese chloride] results in decreased expression of GABBR2 protein Iron deficiency results in decreased expression of GABBR2 mRNA; Iron deficiency results in decreased expression of GABBR2 protein |
CTD |
PMID:18771689 |
|
NCBI chr 5:62,276,100...62,621,737
Ensembl chr 5:62,276,100...62,621,737
|
|
G |
Gabra1 |
gamma-aminobutyric acid type A receptor subunit alpha 1 |
multiple interactions decreases expression increases expression |
EXP |
[Iron deficiency co-treated with manganese chloride] results in increased expression of GABRA1 protein Iron deficiency results in decreased expression of GABRA1 mRNA Iron deficiency results in increased expression of GABRA1 protein |
CTD |
PMID:18771689 |
|
NCBI chr10:27,310,718...27,371,802
Ensembl chr10:27,310,725...27,366,665
|
|
G |
Gar1 |
GAR1 ribonucleoprotein |
increases expression |
EXP |
Iron deficiency results in increased expression of GAR1 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr 2:235,250,453...235,258,464
Ensembl chr 2:235,250,453...235,257,731
|
|
G |
Gas1 |
growth arrest-specific 1 |
multiple interactions |
ISO |
[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of GAS1 mRNA; [Hemin results in increased abundance of Iron] which results in increased expression of GAS1 mRNA |
CTD |
PMID:12393473 |
|
NCBI chr17:4,846,116...4,849,350
Ensembl chr17:4,846,789...4,847,940
|
|
G |
Gas7 |
growth arrest specific 7 |
increases expression |
ISO |
Iron deficiency results in increased expression of GAS7 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr10:54,010,723...54,240,805
Ensembl chr10:54,126,486...54,236,476
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions increases activity decreases expression |
ISO EXP |
Ursodeoxycholic Acid inhibits the reaction [Iron results in decreased expression of GCLC mRNA] Iron results in increased activity of GCLC protein |
CTD |
PMID:17189828 PMID:19073151 |
|
NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions decreases expression |
ISO |
Ursodeoxycholic Acid inhibits the reaction [Iron results in decreased expression of GCLM mRNA] |
CTD |
PMID:19073151 |
|
NCBI chr 2:225,827,504...225,847,876
Ensembl chr 2:225,827,504...225,847,874
|
|
G |
Gkn1 |
gastrokine 1 |
increases expression |
EXP |
Iron deficiency results in increased expression of GKN1 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr 4:119,143,070...119,148,358
Ensembl chr 4:119,143,070...119,148,358
|
|
G |
Gkn2 |
gastrokine 2 |
increases expression |
EXP |
Iron deficiency results in increased expression of GKN2 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr 4:119,131,255...119,177,329
Ensembl chr 4:119,171,245...119,177,329
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
multiple interactions increases activity |
EXP |
Capsaicin inhibits the reaction [Iron results in increased activity of GOT1 protein]; Curcumin inhibits the reaction [Iron results in increased activity of GOT1 protein] |
CTD |
PMID:16956363 |
|
NCBI chr 1:263,246,248...263,269,762
Ensembl chr 1:263,246,248...263,269,762
|
|
G |
Gpam |
glycerol-3-phosphate acyltransferase, mitochondrial |
increases expression |
EXP |
Iron deficiency results in increased expression of GPAM mRNA |
CTD |
PMID:16629162 |
|
NCBI chr 1:275,843,823...275,906,880
Ensembl chr 1:275,846,819...275,906,686
|
|
G |
Gpr34 |
G protein-coupled receptor 34 |
increases expression |
ISO |
Iron deficiency results in increased expression of GPR34 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr X:10,022,986...10,043,504
Ensembl chr X:10,023,489...10,031,167
|
|
G |
Gprc5a |
G protein-coupled receptor, class C, group 5, member A |
increases expression |
EXP |
Iron deficiency results in increased expression of GPRC5A mRNA |
CTD |
PMID:16629162 |
|
NCBI chr 4:168,832,937...168,851,650
Ensembl chr 4:168,832,910...168,851,652
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions increases activity |
EXP ISO |
Capsaicin inhibits the reaction [Iron results in increased activity of GPT protein]; Curcumin inhibits the reaction [Iron results in increased activity of GPT protein] Drugs, Chinese Herbal inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of ALT protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of ALT protein] |
CTD |
PMID:16956363 PMID:27916511 |
|
NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions decreases response to substance |
EXP ISO |
[Iron co-treated with Hydrogen Peroxide] results in decreased expression of and results in decreased activity of GPX1 protein GPX1 protein results in decreased susceptibility to Iron |
CTD |
PMID:16721761 PMID:17280487 |
|
NCBI chr 8:117,117,430...117,118,528
Ensembl chr 8:117,117,430...117,118,522
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
increases expression |
EXP |
Iron deficiency results in increased expression of GPX2 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr 6:99,839,960...99,843,245
Ensembl chr 6:99,839,960...99,843,245
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
ISO |
[SB 216763 results in decreased activity of GSK3B protein] results in decreased susceptibility to [Arachidonic Acid co-treated with Iron] |
CTD |
PMID:19620254 |
|
NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions decreases activity |
ISO EXP |
Iron deficiency inhibits the reaction [Benzoyl Peroxide results in decreased activity of GSR protein]; Iron promotes the reaction [Benzoyl Peroxide results in decreased activity of GSR protein]; Iron promotes the reaction [Tetradecanoylphorbol Acetate results in decreased activity of GSR protein] Iron results in decreased activity of GSR protein [Arsenic co-treated with Cadmium co-treated with Lead co-treated with Mercury co-treated with Chromium co-treated with Nickel co-treated with Manganese co-treated with Iron] results in decreased activity of GSR protein |
CTD |
PMID:12067571 PMID:12504893 PMID:17176674 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Gss |
glutathione synthetase |
multiple interactions decreases expression |
ISO |
Ursodeoxycholic Acid inhibits the reaction [Iron results in decreased expression of GSS mRNA] |
CTD |
PMID:19073151 |
|
NCBI chr 3:151,076,254...151,106,557
Ensembl chr 3:151,076,254...151,106,557
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
multiple interactions |
EXP |
[Copper co-treated with Diethylnitrosamine co-treated with Iron] results in decreased expression of GSTA2 mRNA |
CTD |
PMID:20302851 |
|
NCBI chr 8:85,640,081...85,645,621
|
|
G |
Gsta4 |
glutathione S-transferase alpha 4 |
multiple interactions |
EXP |
Iron results in increased expression of and results in increased activity of GSTA4 protein |
CTD |
PMID:7878679 |
|
NCBI chr 8:85,497,557...85,514,732
Ensembl chr 8:85,497,557...85,518,879
|
|
G |
Gsta5 |
glutathione S-transferase alpha 5 |
multiple interactions decreases expression increases expression |
EXP ISO |
[Copper co-treated with Diethylnitrosamine co-treated with Iron] results in increased expression of GSTA5 mRNA Iron results in decreased expression of GSTA1 protein Iron results in increased expression of GSTA1 mRNA; Iron results in increased expression of GSTA1 protein |
CTD |
PMID:11755321 PMID:20302851 |
|
NCBI chr 8:85,553,659...85,564,914
Ensembl chr 8:85,553,734...85,565,179
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
decreases expression increases expression |
ISO |
Iron results in decreased expression of GSTM1 protein Iron results in increased expression of GSTM1 mRNA; Iron results in increased expression of GSTM1 protein |
CTD |
PMID:11755321 |
|
NCBI chr 2:210,803,869...210,809,461
Ensembl chr 2:210,803,869...210,809,306
|
|
G |
Gstm5 |
glutathione S-transferase, mu 5 |
multiple interactions |
EXP |
[Copper co-treated with Diethylnitrosamine co-treated with Iron] results in increased expression of GSTM3 mRNA |
CTD |
PMID:20302851 |
|
NCBI chr 2:210,685,338...210,688,133
Ensembl chr 2:210,685,197...210,688,272
|
|
G |
H3f4 |
H3.4 histone |
multiple interactions increases methylation |
ISO |
[[Iron co-treated with Ketoglutaric Acids] results in increased activity of KDM3A protein] which results in decreased methylation of H3-4 protein Iron results in increased methylation of H3-4 protein |
CTD |
PMID:16603237 PMID:21385672 |
|
NCBI chr10:45,304,696...45,305,106
|
|
G |
Hamp |
hepcidin antimicrobial peptide |
decreases secretion increases expression affects expression decreases expression affects metabolic processing multiple interactions |
ISO EXP |
HAMP protein results in decreased secretion of Iron Iron results in increased expression of HAMP protein Iron affects the expression of HAMP mRNA Iron deficiency results in decreased expression of HAMP mRNA HAMP protein affects the metabolism of Iron [Acetaminophen results in decreased expression of HAMP mRNA] which results in increased abundance of Iron; Iron inhibits the reaction [Diethylnitrosamine results in decreased expression of HAMP mRNA] Iron results in increased expression of HAMP mRNA [IL6 protein results in increased expression of HAMP protein] which results in decreased secretion of Iron; Iron affects the reaction [HAMP protein results in increased uptake of SLC40A1 protein] |
CTD |
PMID:11113132 PMID:16460831 PMID:16574947 PMID:16648237 PMID:17116712 PMID:17194590 PMID:17255318 PMID:19061943 PMID:20655381 PMID:21540277 PMID:22457245 PMID:22610607 PMID:22659129 |
|
NCBI chr 1:89,368,021...89,369,960
Ensembl chr 1:89,368,021...89,369,960
|
|
G |
Hba-a2 |
hemoglobin alpha, adult chain 2 |
multiple interactions |
ISO |
AHSP protein binds to and affects the folding of and affects the stability of [HBA1 protein binds to Iron] |
CTD |
PMID:16901899 |
|
NCBI chr10:15,589,364...15,590,207
Ensembl chr10:15,589,364...15,590,220
|
|
G |
Hbb |
hemoglobin subunit beta |
multiple interactions affects abundance |
ISO |
[HBB-B1 gene mutant form results in increased abundance of Iron] which results in decreased expression of TFR2 mRNA; [HBB-B1 gene mutant form results in increased abundance of Iron] which results in increased expression of SLC40A1 mRNA HBB-B1 protein affects the abundance of Iron |
CTD |
PMID:17018382 |
|
NCBI chr 1:168,971,269...168,972,680
Ensembl chr 1:168,971,274...168,972,725
|
|
G |
Hdac8 |
histone deacetylase 8 |
multiple interactions |
ISO |
Iron binds to and results in increased activity of HDAC8 protein |
CTD |
PMID:16681389 |
|
NCBI chr X:72,163,777...72,370,058
Ensembl chr X:72,163,777...72,370,044
|
|
G |
Heph |
hephaestin |
affects metabolic processing multiple interactions |
ISO EXP |
HEPH protein affects the metabolism of Iron [Zinc results in decreased expression of HEPH protein] which results in decreased uptake of Iron |
CTD |
PMID:16614402 PMID:17194590 |
|
NCBI chr X:65,377,313...65,658,479
Ensembl chr X:65,563,122...65,658,516
|
|
G |
Hfe |
homeostatic iron regulator |
increases uptake affects metabolic processing affects abundance multiple interactions decreases uptake affects response to substance increases abundance |
ISO |
HFE gene mutant form results in increased uptake of Iron HFE protein affects the metabolism of Iron HFE protein affects the abundance of Iron [HFE gene mutant form co-treated with TFR2 gene mutant form] results in increased abundance of Iron HFE protein results in decreased uptake of Iron [HFE protein binds to B2M protein binds to SLC11A2 protein] which results in decreased uptake of Iron; [HFE protein binds to TFR2 protein] which affects the susceptibility to Iron; HFE protein inhibits the reaction [TFRC protein results in increased uptake of Iron]; TNF gene SNP promotes the reaction [HFE protein mutant form results in increased uptake of Iron] HFE protein affects the susceptibility to Iron HFE gene mutant form results in increased abundance of Iron; HFE gene polymorphism results in increased abundance of Iron HFE gene polymorphism affects the abundance of Iron; HFE protein affects the abundance of Iron |
CTD |
PMID:10085150 PMID:12393473 PMID:16793930 PMID:16823846 PMID:16841247 PMID:16877869 PMID:16893896 PMID:17047092 PMID:17101320 PMID:17194590 PMID:18317567 PMID:22383097 |
|
NCBI chr17:43,661,276...43,669,327
Ensembl chr17:43,661,222...43,669,985
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions decreases expression increases response to substance decreases metabolic processing |
ISO EXP |
[Deferoxamine results in decreased abundance of Iron] which results in increased expression of HIF1A mRNA; [Hemin results in decreased abundance of Iron] which results in increased expression of HIF1A mRNA; [Quercetin results in decreased abundance of Iron] which results in increased expression of HIF1A protein; Iron inhibits the reaction [galangin results in increased expression of HIF1A protein]; Iron inhibits the reaction [manganese chloride results in increased expression of HIF1A protein]; Iron inhibits the reaction [Nickel results in increased stability of HIF1A protein]; Iron inhibits the reaction [Quercetin results in increased expression of and affects the localization of HIF1A protein]; Iron inhibits the reaction [Quercetin results in increased expression of HIF1A protein] Iron deficiency results in decreased expression of HIF1A mRNA HIF1A protein results in increased susceptibility to Iron HIF1A gene mutant form results in decreased metabolism of Iron |
CTD |
PMID:12393473 PMID:16629162 PMID:16787915 PMID:16877034 PMID:17364964 PMID:17973296 PMID:19263519 PMID:19729006 |
|
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
|
|
G |
Hjv |
hemojuvelin BMP co-receptor |
affects metabolic processing |
ISO |
HJV protein affects the metabolism of Iron |
CTD |
PMID:17194590 |
|
NCBI chr 2:198,655,437...198,659,318
Ensembl chr 2:198,655,437...198,659,317
|
|
G |
Hmgcs2 |
3-hydroxy-3-methylglutaryl-CoA synthase 2 |
decreases expression |
EXP |
Iron deficiency results in decreased expression of HMGCS2 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr 2:200,452,623...200,480,785
Ensembl chr 2:200,452,624...200,479,423
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression increases metabolic processing |
ISO EXP |
[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron; [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species; [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased expression of MMP1 mRNA; [[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein; [Deferoxamine results in decreased abundance of Iron] which results in decreased expression of HMOX1 mRNA; [Ethanol results in increased expression of HMOX1 protein] which results in increased abundance of Iron; [ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of HMOX1 mRNA; [Hemin results in increased abundance of Iron] which results in increased expression of HMOX1 mRNA; [HMOX1 protein results in increased degradation of Heme] which results in increased abundance of Iron; [Particulate Matter results in increased abundance of Iron] which results in increased expression of HMOX1 mRNA; Acetylcysteine inhibits the reaction [[[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein]; Iron promotes the reaction [Raloxifene Hydrochloride results in increased expression of HMOX1 mRNA]; zinc protoporphyrin inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] Iron deficiency results in increased expression of HMOX1 mRNA; Iron results in increased expression of HMOX1 protein [Copper co-treated with Diethylnitrosamine co-treated with Iron] results in increased expression of HMOX1 mRNA; [Iron co-treated with Diethylnitrosamine] results in increased expression of HMOX1 protein; Copper promotes the reaction [[Iron co-treated with Diethylnitrosamine] results in increased expression of HMOX1 protein] HMOX1 protein results in increased metabolism of Iron |
CTD |
PMID:12393473 PMID:15602829 PMID:16439612 PMID:16629162 PMID:19136476 PMID:20302851 PMID:20709802 PMID:20888885 PMID:26419736 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hpgds |
hematopoietic prostaglandin D synthase |
increases expression |
ISO |
Iron deficiency results in increased expression of HPGDS mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 4:95,945,356...95,970,666
Ensembl chr 4:95,946,025...95,970,666
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
multiple interactions affects localization |
EXP |
HRAS protein affects the reaction [Iron results in increased phosphorylation of AKT1 protein]; HRAS protein affects the reaction [Iron results in increased phosphorylation of MAPK1 protein]; HRAS protein affects the reaction [Iron results in increased phosphorylation of MAPK3 protein]; HRAS protein affects the reaction [Iron results in increased phosphorylation of NFKBIA protein]; Iron promotes the reaction [MAP3K7 protein binds to HRAS protein binds to PIK3R1 protein] Iron affects the localization of HRAS protein |
CTD |
PMID:17172471 |
|
NCBI chr 1:214,178,404...214,181,841
Ensembl chr 1:214,178,407...214,181,686
|
|
G |
Hsbp1l1 |
heat shock factor binding protein 1-like 1 |
decreases expression |
ISO |
Iron deficiency results in decreased expression of HSBP1L1 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr18:76,748,067...76,754,642
Ensembl chr18:76,748,067...76,753,902
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
multiple interactions |
EXP |
[Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of HSPA1A mRNA |
CTD |
PMID:22198552 |
|
NCBI chr20:4,875,834...4,881,751
Ensembl chr20:4,877,324...4,879,779
|
|
G |
Hspa1l |
heat shock protein family A (Hsp70) member 1 like |
multiple interactions |
ISO |
[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of HSPA1L mRNA; [ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of HSPA1L mRNA; [Hemin results in increased abundance of Iron] which results in increased expression of HSPA1L mRNA |
CTD |
PMID:12393473 |
|
NCBI chr20:4,879,998...4,965,191
Ensembl chr20:4,959,294...4,964,963
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
multiple interactions |
EXP |
[Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of HSPA8 mRNA |
CTD |
PMID:22198552 |
|
NCBI chr 8:44,989,401...44,993,261
Ensembl chr 8:44,990,014...44,993,179
|
|
G |
Hspa9 |
heat shock protein family A (Hsp70) member 9 |
multiple interactions |
ISO |
[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of HSPA9 mRNA; [ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of HSPA9 mRNA; [Hemin results in increased abundance of Iron] which results in increased expression of HSPA9 mRNA |
CTD |
PMID:12393473 |
|
NCBI chr18:27,731,072...27,749,235
Ensembl chr18:27,731,072...27,749,235
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
multiple interactions |
EXP |
[Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of HSPB1 mRNA |
CTD |
PMID:22198552 |
|
NCBI chr12:23,839,390...23,841,051
Ensembl chr12:23,839,399...23,841,049
|
|
G |
Hsph1 |
heat shock protein family H (Hsp110) member 1 |
multiple interactions |
EXP ISO |
[Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of HSPH1 mRNA [Deferoxamine results in decreased abundance of Iron] which results in decreased expression of HSPH1 mRNA; [Hemin results in increased abundance of Iron] which results in increased expression of HSPH1 mRNA |
CTD |
PMID:12393473 PMID:22198552 |
|
NCBI chr12:6,322,685...6,341,898
Ensembl chr12:6,322,668...6,341,902
|
|
G |
Htt |
huntingtin |
decreases uptake |
ISO |
HTT protein mutant form results in decreased uptake of Iron |
CTD |
PMID:20547568 |
|
NCBI chr14:81,105,139...81,254,637
Ensembl chr14:81,105,139...81,254,637
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
[Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of ICAM1 protein] |
CTD |
PMID:12633744 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Idi1 |
isopentenyl-diphosphate delta isomerase 1 |
decreases expression |
EXP |
Iron deficiency results in decreased expression of IDI1 mRNA |
CTD |
PMID:19821111 |
|
NCBI chr17:57,976,266...57,984,036
Ensembl chr17:57,976,268...57,984,036
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
Iron affects the reaction [[IL12A protein binds to IL12B protein] which results in increased secretion of IFNG protein]; Iron affects the reaction [IL18 protein results in increased secretion of IFNG protein] |
CTD |
PMID:15799959 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Ift172 |
intraflagellar transport 172 |
increases expression |
EXP |
Iron deficiency results in increased expression of SLB mRNA |
CTD |
PMID:16629162 |
|
NCBI chr 6:26,390,686...26,485,459
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions |
EXP |
IGF1 protein inhibits the reaction [Carbon Tetrachloride results in increased abundance of Iron] |
CTD |
PMID:15745444 |
|
NCBI chr 7:28,412,123...28,491,815
Ensembl chr 7:28,412,198...28,486,609
|
|
G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
increases expression |
EXP |
Iron deficiency results in increased expression of IGFBP3 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr14:87,457,647...87,465,374
Ensembl chr14:87,457,647...87,465,374
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions |
EXP |
deferiprone inhibits the reaction [Iron results in increased activity of [CHUK protein binds to IKBKB protein]]; Filipin inhibits the reaction [Iron results in increased activity of [CHUK protein binds to IKBKB protein]]; Iron results in increased activity of [CHUK protein binds to IKBKB protein]; N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid inhibits the reaction [Iron results in increased activity of [CHUK protein binds to IKBKB protein]] |
CTD |
PMID:17172471 |
|
NCBI chr16:74,177,233...74,230,809
Ensembl chr16:74,177,215...74,230,815
|
|
G |
Il12a |
interleukin 12A |
multiple interactions |
ISO |
Iron affects the reaction [[IL12A protein binds to IL12B protein] which results in increased secretion of IFNG protein] |
CTD |
PMID:15799959 |
|
NCBI chr 2:165,076,945...165,083,996
Ensembl chr 2:165,076,607...165,084,318
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
Iron affects the reaction [[IL12A protein binds to IL12B protein] which results in increased secretion of IFNG protein] |
CTD |
PMID:15799959 |
|
NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
ISO |
Iron affects the reaction [IL18 protein results in increased secretion of IFNG protein] |
CTD |
PMID:15799959 |
|
NCBI chr 8:55,009,666...55,016,286
Ensembl chr 8:54,993,859...55,016,299
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
EXP |
[Iron co-treated with Diethylnitrosamine co-treated with Copper] results in increased expression of IL1A mRNA; [Iron co-treated with Diethylnitrosamine] results in increased expression of IL1A mRNA |
CTD |
PMID:20302851 |
|
NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP ISO |
[Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of IL1B mRNA; [Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of IL1B protein; lipopolysaccharide A promotes the reaction [Iron results in increased secretion of IL1B protein] [Particulate Matter results in increased abundance of Iron] which results in increased secretion of IL1B protein |
CTD |
PMID:16958088 PMID:22198552 PMID:32007923 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases secretion |
EXP ISO |
[Iron co-treated with Diethylnitrosamine co-treated with Copper] results in decreased expression of IL6 mRNA; [Iron co-treated with Diethylnitrosamine] results in decreased expression of IL6 mRNA; [Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of IL6 mRNA Iron results in increased secretion of IL6 protein [IL6 protein results in increased expression of HAMP protein] which results in decreased secretion of Iron |
CTD |
PMID:16460831 PMID:20302851 PMID:22198552 PMID:26416317 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Iqcd |
IQ motif containing D |
increases expression |
ISO |
Iron deficiency results in increased expression of IQCD mRNA |
CTD |
PMID:20368581 |
|
NCBI chr12:41,490,451...41,507,416
Ensembl chr12:41,490,801...41,497,610
|
|
G |
Ireb2 |
iron responsive element binding protein 2 |
affects metabolic processing multiple interactions increases activity |
ISO EXP |
IREB2 protein affects the metabolism of Iron Clofibrate inhibits the reaction [Iron deficiency results in increased activity of IREB2 protein] |
CTD |
PMID:11969379 PMID:17194590 |
|
NCBI chr 8:59,450,974...59,503,634
Ensembl chr 8:59,420,123...59,501,118
|
|
G |
Irf8 |
interferon regulatory factor 8 |
decreases expression |
ISO |
Iron deficiency results in decreased expression of IRF8 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr19:54,314,859...54,336,643
Ensembl chr19:54,314,865...54,336,640
|
|
G |
Itga6 |
integrin subunit alpha 6 |
increases expression |
EXP |
Iron deficiency results in increased expression of ITGA6 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr 3:58,442,904...58,515,124
Ensembl chr 3:58,443,101...58,515,124
|
|
G |
Itgam |
integrin subunit alpha M |
increases expression multiple interactions |
ISO |
Iron deficiency results in increased expression of ITGAM mRNA; Iron deficiency results in increased expression of ITGAM protein Vitamin D promotes the reaction [Iron deficiency results in increased expression of ITGAM protein] |
CTD |
PMID:20368581 |
|
NCBI chr 1:199,495,312...199,545,738
Ensembl chr 1:199,495,298...199,623,960
|
|
G |
Itgb2 |
integrin subunit beta 2 |
increases expression |
ISO |
Iron deficiency results in increased expression of ITGB2 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr20:11,777,773...11,815,647
Ensembl chr20:11,777,783...11,815,647
|
|
G |
Itln1 |
intelectin 1 |
multiple interactions |
ISO |
ITLN1 protein binds to and results in increased uptake of Iron |
CTD |
PMID:16936804 |
|
NCBI chr13:89,919,570...89,929,774
Ensembl chr13:89,919,667...89,929,770
|
|
G |
Jazf1 |
JAZF zinc finger 1 |
increases expression |
ISO |
Iron deficiency results in increased expression of JAZF1 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 4:82,834,181...83,141,430
Ensembl chr 4:82,836,260...83,137,527
|
|
G |
Jchain |
joining chain of multimeric IgA and IgM |
increases expression |
EXP |
Iron deficiency results in increased expression of JCHAIN mRNA |
CTD |
PMID:16629162 |
|
NCBI chr14:21,176,841...21,183,731
Ensembl chr14:21,177,237...21,183,542
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO |
[Deferoxamine results in decreased abundance of Iron] which results in increased expression of JUN mRNA; [Hemin results in decreased abundance of Iron] which results in increased expression of JUN mRNA Iron deficiency results in increased expression of JUN mRNA |
CTD |
PMID:12393473 PMID:20368581 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Kcne3 |
potassium voltage-gated channel subfamily E regulatory subunit 3 |
increases expression |
EXP |
Iron deficiency results in increased expression of KCNE3 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr 1:165,189,934...165,196,949
Ensembl chr 1:165,189,985...165,196,948
|
|
G |
Kdm3a |
lysine demethylase 3A |
multiple interactions |
ISO |
[[Iron co-treated with Ketoglutaric Acids] results in increased activity of KDM3A protein] which results in decreased methylation of H3-4 protein |
CTD |
PMID:16603237 |
|
NCBI chr 4:99,503,160...99,547,315
Ensembl chr 4:99,503,176...99,546,905
|
|
G |
Kit |
KIT proto-oncogene receptor tyrosine kinase |
decreases expression |
ISO |
Iron deficiency results in decreased expression of KIT mRNA |
CTD |
PMID:20368581 |
|
NCBI chr14:35,072,131...35,149,638
Ensembl chr14:35,072,108...35,149,610
|
|
G |
Klhdc7b |
kelch domain containing 7B |
increases expression |
ISO |
Iron deficiency results in increased expression of KLHDC7B mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 7:130,357,589...130,359,529
Ensembl chr 7:130,357,643...130,359,448
|
|
G |
Lamc2 |
laminin subunit gamma 2 |
increases expression |
EXP |
Iron deficiency results in increased expression of LAMC2 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr13:70,566,643...70,632,126
Ensembl chr13:70,566,643...70,626,252
|
|
G |
Lamp5 |
lysosomal-associated membrane protein family, member 5 |
decreases expression |
ISO |
Iron deficiency results in decreased expression of LAMP5 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 3:129,012,677...129,031,522
Ensembl chr 3:129,018,592...129,031,521
|
|
G |
Lcn2 |
lipocalin 2 |
increases expression affects metabolic processing |
ISO |
Iron results in increased expression of LCN2 mRNA; Iron results in increased expression of LCN2 protein LCN2 protein affects the metabolism of Iron |
CTD |
PMID:17194590 PMID:17350462 |
|
NCBI chr 3:11,414,189...11,417,534
Ensembl chr 3:11,414,186...11,417,546
|
|
G |
Lig3 |
DNA ligase 3 |
decreases activity |
ISO |
Iron results in decreased activity of LIG3 protein |
CTD |
PMID:20622253 |
|
NCBI chr10:70,134,734...70,158,051
Ensembl chr10:70,134,729...70,158,055
|
|
G |
LOC100360841 |
ribosomal protein L37-like |
decreases expression |
ISO |
Iron results in decreased expression of RPL37 mRNA |
CTD |
PMID:27329587 |
|
NCBI chr 9:69,790,829...69,791,199
Ensembl chr 9:69,790,831...69,791,196
|
|
G |
Lox |
lysyl oxidase |
multiple interactions |
ISO |
[Deferoxamine results in decreased abundance of Iron] which results in increased expression of LOX mRNA; [Hemin results in decreased abundance of Iron] which results in increased expression of LOX mRNA |
CTD |
PMID:12393473 |
|
NCBI chr18:47,500,320...47,577,819
Ensembl chr18:47,500,330...47,577,819
|
|
G |
Lpar1 |
lysophosphatidic acid receptor 1 |
decreases expression |
EXP |
Iron deficiency results in decreased expression of LPAR1 mRNA |
CTD |
PMID:19821111 |
|
NCBI chr 5:75,557,038...75,678,067
Ensembl chr 5:75,557,042...75,676,584
|
|
G |
Lrrc25 |
leucine rich repeat containing 25 |
increases expression |
ISO |
Iron deficiency results in increased expression of LRRC25 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr16:20,556,973...20,563,773
Ensembl chr16:20,558,222...20,562,399
|
|
G |
Lta |
lymphotoxin alpha |
multiple interactions |
EXP |
[Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of LTA mRNA |
CTD |
PMID:22198552 |
|
NCBI chr20:4,851,889...4,854,677
Ensembl chr20:4,852,496...4,854,677
|
|
G |
Ly75 |
lymphocyte antigen 75 |
decreases expression |
ISO |
Iron deficiency results in decreased expression of LY75 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 3:46,369,749...46,457,182
Ensembl chr 3:46,365,165...46,457,201
|
|
G |
Lypla1 |
lysophospholipase 1 |
decreases expression |
EXP |
Iron deficiency results in decreased expression of LYPLA1 mRNA |
CTD |
PMID:19821111 |
|
NCBI chr 5:14,559,333...14,588,447
Ensembl chr 5:14,559,334...14,588,422
|
|
G |
Maoa |
monoamine oxidase A |
decreases expression |
EXP |
Iron deficiency results in decreased expression of MAOA mRNA |
CTD |
PMID:16629162 |
|
NCBI chr X:6,554,698...6,620,722
Ensembl chr X:6,554,698...6,620,722
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions |
ISO |
Iron affects the reaction [Deferoxamine results in increased expression of MAP1LC3B protein]; Iron affects the reaction [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone results in increased expression of MAP1LC3B protein] |
CTD |
PMID:25301941 |
|
NCBI chr19:53,635,449...53,643,970
Ensembl chr19:53,629,779...53,646,058
|
|
G |
Map2k6 |
mitogen-activated protein kinase kinase 6 |
multiple interactions increases phosphorylation |
EXP |
Filipin inhibits the reaction [Iron promotes the reaction [MAP3K7 protein results in increased phosphorylation of MAP2K6 protein]]; Filipin inhibits the reaction [Iron results in increased phosphorylation of MAP2K6 protein]; Iron promotes the reaction [MAP3K7 protein results in increased phosphorylation of MAP2K6 protein] |
CTD |
PMID:17172471 |
|
NCBI chr10:98,707,160...98,823,054
Ensembl chr10:98,706,960...98,823,287
|
|
G |
Map3k14 |
mitogen-activated protein kinase kinase kinase 14 |
multiple interactions |
EXP |
MAP3K14 protein affects the reaction [Iron results in increased phosphorylation of NFKBIA protein]; MAP3K14 protein affects the reaction [Iron results in increased secretion of TNF protein] |
CTD |
PMID:17172471 |
|
NCBI chr10:91,303,428...91,353,601
Ensembl chr10:91,303,428...91,353,601
|
|
G |
Map3k7 |
mitogen activated protein kinase kinase kinase 7 |
multiple interactions increases activity affects localization |
EXP |
Filipin inhibits the reaction [Iron promotes the reaction [MAP3K7 protein results in increased phosphorylation of MAP2K6 protein]]; Filipin inhibits the reaction [Iron results in increased activity of MAP3K7 protein]; Iron promotes the reaction [MAP3K7 protein binds to HRAS protein binds to PIK3R1 protein]; Iron promotes the reaction [MAP3K7 protein results in increased phosphorylation of MAP2K6 protein]; MAP3K7 protein affects the reaction [Iron results in increased phosphorylation of AKT1 protein]; MAP3K7 protein affects the reaction [Iron results in increased phosphorylation of NFKBIA protein]; MAP3K7 protein affects the reaction [Iron results in increased secretion of TNF protein] Iron affects the localization of MAP3K7 protein |
CTD |
PMID:17172471 |
|
NCBI chr 5:47,183,142...47,244,424
Ensembl chr 5:47,186,558...47,244,416
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
Iron promotes the reaction [Arsenic results in increased phosphorylation of and results in increased activity of MAPK1 protein] [ferrous chloride results in increased abundance of Iron] which results in increased phosphorylation of MAPK1 protein Iron results in increased phosphorylation of MAPK1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Iron results in increased phosphorylation of MAPK1 protein]; [Vanadium co-treated with Iron] results in increased phosphorylation of MAPK1 protein; deferiprone inhibits the reaction [Iron results in increased phosphorylation of MAPK1 protein]; Filipin inhibits the reaction [Iron results in increased phosphorylation of MAPK1 protein]; HRAS protein affects the reaction [Iron results in increased phosphorylation of MAPK1 protein]; Iron promotes the reaction [Asbestos, Amosite results in increased phosphorylation of MAPK1 protein]; PIK3R1 protein affects the reaction [Iron results in increased phosphorylation of MAPK1 protein]; SB 203580 promotes the reaction [Iron results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Iron results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:11306436 PMID:16728372 PMID:17172471 PMID:23100159 PMID:30914277 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
EXP ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Iron results in increased phosphorylation of MAPK3 protein]; [Aluminum co-treated with Iron] results in increased phosphorylation of MAPK3 protein; [Vanadium co-treated with Iron] results in increased phosphorylation of MAPK3 protein; deferiprone inhibits the reaction [Iron results in increased phosphorylation of MAPK3 protein]; Filipin inhibits the reaction [Iron results in increased phosphorylation of MAPK3 protein]; HRAS protein affects the reaction [Iron results in increased phosphorylation of MAPK3 protein]; Iron promotes the reaction [Asbestos, Amosite results in increased phosphorylation of MAPK3 protein]; PIK3R1 protein affects the reaction [Iron results in increased phosphorylation of MAPK3 protein]; SB 203580 promotes the reaction [Iron results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Iron results in increased phosphorylation of MAPK3 protein] [ferrous chloride results in increased abundance of Iron] which results in increased phosphorylation of MAPK3 protein [Iron co-treated with Arsenic] results in increased phosphorylation of and results in increased activity of MAPK3 protein |
CTD |
PMID:11306436 PMID:16728372 PMID:17172471 PMID:23100159 PMID:30914277 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Marcks |
myristoylated alanine rich protein kinase C substrate |
increases expression |
EXP |
Iron deficiency results in increased expression of MARCKS mRNA |
CTD |
PMID:16629162 |
|
NCBI chr20:42,966,140...42,971,838
Ensembl chr20:42,966,140...42,971,838
|
|
G |
Mcemp1 |
mast cell-expressed membrane protein 1 |
increases expression |
ISO |
Iron deficiency results in increased expression of MCEMP1 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr12:2,211,970...2,217,005
Ensembl chr12:2,213,471...2,217,433
|
|
G |
Mcoln1 |
mucolipin TRP cation channel 1 |
multiple interactions increases expression |
ISO |
[Ethanol co-treated with Iron] results in increased expression of MCOLN1 mRNA; [Ethanol co-treated with Iron] results in increased expression of MCOLN1 protein; Quercetin inhibits the reaction [[Ethanol co-treated with Iron] results in increased expression of MCOLN1 mRNA]; Quercetin inhibits the reaction [[Ethanol co-treated with Iron] results in increased expression of MCOLN1 protein]; Quercetin inhibits the reaction [Iron results in increased expression of MCOLN1 mRNA]; Quercetin inhibits the reaction [Iron results in increased expression of MCOLN1 protein] Iron results in increased expression of MCOLN1 mRNA; Iron results in increased expression of MCOLN1 protein |
CTD |
PMID:24569067 |
|
NCBI chr12:2,054,629...2,068,682
Ensembl chr12:2,054,680...2,068,682
|
|
G |
Mctp1 |
multiple C2 and transmembrane domain containing 1 |
increases expression |
ISO |
Iron deficiency results in increased expression of MCTP1 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 2:3,400,883...4,089,949
Ensembl chr 2:3,400,977...4,088,989
|
|
G |
Me1 |
malic enzyme 1 |
increases expression |
ISO |
Iron deficiency results in increased expression of ME1 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 8:94,256,830...94,368,834
Ensembl chr 8:94,256,839...94,368,834
|
|
G |
Mif |
macrophage migration inhibitory factor |
multiple interactions |
EXP |
[Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of MIF mRNA |
CTD |
PMID:22198552 |
|
NCBI chr20:13,715,219...13,732,980
Ensembl chr20:13,732,198...13,732,859
|
|
G |
Miox |
myo-inositol oxygenase |
affects binding |
ISO |
[MIOX protein binds to Iron] which binds to Inositol |
CTD |
PMID:17012379 |
|
NCBI chr 7:130,308,707...130,311,205
Ensembl chr 7:130,308,532...130,313,727
|
|
G |
Mir196b |
microRNA 196b |
multiple interactions |
ISO |
[Air Pollutants, Occupational results in increased abundance of Iron] which results in increased expression of MIR196B mRNA |
CTD |
PMID:27506416 |
|
NCBI chr 4:82,199,056...82,199,140
Ensembl chr 4:82,199,056...82,199,140
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
multiple interactions |
ISO |
[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased expression of MMP1 mRNA; [[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein; Acetylcysteine inhibits the reaction [[[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein] |
CTD |
PMID:19136476 |
|
NCBI chr 8:5,703,206...5,723,593
Ensembl chr 8:5,703,206...5,723,591
|
|
G |
Mpo |
myeloperoxidase |
increases activity multiple interactions |
EXP |
Iron results in increased activity of MPO protein [Hexachlorocyclohexane co-treated with Iron] results in increased activity of MPO protein |
CTD |
PMID:11141352 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Ms4a6a |
membrane spanning 4-domains A6A |
decreases expression |
ISO |
Iron deficiency results in decreased expression of MS4A6A mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 1:227,919,284...227,932,637
Ensembl chr 1:227,919,301...227,932,603
|
|
G |
Ms4a7 |
membrane spanning 4-domains A7 |
increases expression |
EXP |
Iron deficiency results in increased expression of MS4A7 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr 1:227,490,777...227,506,819
Ensembl chr 1:227,490,777...227,506,822
|
|
G |
Mt1 |
metallothionein 1 |
multiple interactions increases expression |
EXP ISO |
[Zinc co-treated with Iron] results in increased expression of and affects the localization of MT1A protein; Iron results in increased expression of and affects the localization of MT1A protein Iron deficiency results in increased expression of MT1A; Iron deficiency results in increased expression of MT1A mRNA Iron deficiency results in increased expression of MT1 mRNA ATP7A gene mutant form promotes the reaction [Iron deficiency results in increased expression of MT1 mRNA] |
CTD |
PMID:16629162 PMID:17241390 PMID:21852364 PMID:23776592 PMID:24089420 |
|
NCBI chr19:11,301,991...11,303,007
Ensembl chr17:78,793,336...78,793,724
|
|
G |
Mt2A |
metallothionein 2A |
multiple interactions affects abundance increases expression |
ISO EXP |
[Deferoxamine results in decreased abundance of Iron] which results in increased expression of MT2A mRNA; [ferric ammonium citrate results in decreased abundance of Iron] which results in increased expression of MT2A mRNA; [Hemin results in decreased abundance of Iron] which results in increased expression of MT2A mRNA MT2A gene SNP affects the abundance of Iron Iron deficiency results in increased expression of MT2 mRNA [Zinc co-treated with Iron] results in increased expression of and affects the localization of MT2A protein; Iron results in increased expression of and affects the localization of MT2A protein Iron deficiency results in increased expression of MT2A mRNA |
CTD |
PMID:12393473 PMID:16629162 PMID:17241390 PMID:21328412 PMID:24089420 |
|
NCBI chr19:11,307,966...11,308,740
Ensembl chr19:11,307,967...11,308,740
|
|
G |
Mvd |
mevalonate diphosphate decarboxylase |
increases expression |
EXP |
Iron deficiency results in increased expression of MVD mRNA |
CTD |
PMID:19821111 |
|
NCBI chr19:55,258,910...55,268,933
Ensembl chr19:55,258,905...55,268,951
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
ISO |
[Deferoxamine results in decreased abundance of Iron] which results in decreased expression of MYC mRNA; [Hemin results in increased abundance of Iron] which results in increased expression of MYC mRNA |
CTD |
PMID:12393473 |
|
NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
|
|
G |
Ndrg1 |
N-myc downstream regulated 1 |
multiple interactions |
ISO |
[di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone binds to Iron] which results in increased expression of NDRG1 protein; NDRG1 protein results in decreased susceptibility to [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone binds to Iron] |
CTD |
PMID:24532803 |
|
NCBI chr 7:107,734,326...107,775,701
Ensembl chr 7:107,734,323...107,775,714
|
|
G |
Ndufs1 |
NADH:ubiquinone oxidoreductase core subunit S1 |
affects expression |
ISO |
Iron affects the expression of NDUFS1 protein |
CTD |
PMID:11313346 |
|
NCBI chr 9:69,919,863...69,953,182
Ensembl chr 9:69,919,867...69,953,182
|
|
G |
Nedd9 |
neural precursor cell expressed, developmentally down-regulated 9 |
increases expression |
EXP |
Iron deficiency results in increased expression of NEDD9 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr17:22,984,792...23,179,701
Ensembl chr17:22,984,844...23,179,701
|
|
G |
Neil1 |
nei-like DNA glycosylase 1 |
multiple interactions |
ISO |
Curcumin inhibits the reaction [Iron binds to and results in decreased activity of NEIL1 protein]; Edetic Acid inhibits the reaction [Iron binds to and results in decreased activity of NEIL1 protein]; Iron binds to and affects the folding of and results in decreased activity of NEIL1 protein; Iron binds to and inhibits the reaction [NEIL1 protein binds to FEN1 protein]; Iron binds to and inhibits the reaction [NEIL1 protein binds to POLB protein] |
CTD |
PMID:20622253 |
|
NCBI chr 8:61,817,258...61,824,023
Ensembl chr 8:61,817,258...61,823,102
|
|
G |
Neil2 |
nei-like DNA glycosylase 2 |
multiple interactions |
ISO |
Iron binds to and results in decreased activity of NEIL2 protein |
CTD |
PMID:20622253 |
|
NCBI chr15:46,371,780...46,382,730
Ensembl chr15:46,372,485...46,381,967
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
multiple interactions increases activity |
ISO EXP |
NFE2L2 protein promotes the reaction [SLC40A1 protein results in increased export of Iron] [Particulate Matter results in increased abundance of Iron] which affects the localization of NFE2L2 protein; [Particulate Matter results in increased abundance of Iron] which results in increased expression of NFE2L2 mRNA [Iron co-treated with Diethylnitrosamine co-treated with Copper] results in increased expression of NFE2L2 mRNA Iron results in increased activity of NFE2L2 promoter |
CTD |
PMID:20302851 PMID:21303654 PMID:21643505 PMID:26419736 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nfil3 |
nuclear factor, interleukin 3 regulated |
increases expression |
ISO |
Iron deficiency results in increased expression of NFIL3 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr17:12,261,102...12,276,316
Ensembl chr17:12,261,102...12,276,315
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions increases phosphorylation |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Iron results in increased phosphorylation of NFKBIA protein]; [Copper co-treated with Diethylnitrosamine co-treated with Iron] results in decreased expression of NFKBIA mRNA; [Iron co-treated with Diethylnitrosamine] results in decreased expression of NFKBIA mRNA; HRAS protein affects the reaction [Iron results in increased phosphorylation of NFKBIA protein]; MAP3K14 protein affects the reaction [Iron results in increased phosphorylation of NFKBIA protein]; MAP3K7 protein affects the reaction [Iron results in increased phosphorylation of NFKBIA protein]; PIK3R1 protein affects the reaction [Iron results in increased phosphorylation of NFKBIA protein]; SB 203580 promotes the reaction [Iron results in increased phosphorylation of NFKBIA protein]; U 0126 inhibits the reaction [Iron results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:17172471 PMID:20302851 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Ngb |
neuroglobin |
decreases uptake |
ISO |
NGB protein results in decreased uptake of Iron |
CTD |
PMID:19154338 |
|
NCBI chr 6:111,126,259...111,131,699
Ensembl chr 6:111,126,261...111,132,320
|
|
G |
Nlrc4 |
NLR family, CARD domain containing 4 |
increases expression |
ISO |
Iron deficiency results in increased expression of NLRC4 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 6:22,167,874...22,194,755
Ensembl chr 6:22,167,919...22,194,250
|
|
G |
Nmt2 |
N-myristoyltransferase 2 |
multiple interactions |
EXP |
[Tungsten co-treated with Nickel co-treated with Iron] results in increased expression of NMT2 mRNA |
CTD |
PMID:24619124 |
|
NCBI chr17:78,919,235...78,966,013
Ensembl chr17:78,921,793...78,962,476
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP ISO |
[Aluminum co-treated with Iron] results in increased expression of NOS2 protein; [Iron co-treated with Diethylnitrosamine co-treated with Copper] results in decreased expression of NOS2 mRNA; [Iron co-treated with Diethylnitrosamine] results in decreased expression of NOS2 mRNA; [Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of NOS2 mRNA Iron inhibits the reaction [Asbestos, Crocidolite results in increased expression of NOS2 mRNA]; Iron inhibits the reaction [Asbestos, Crocidolite results in increased expression of NOS2 protein] |
CTD |
PMID:11461780 PMID:16728372 PMID:20302851 PMID:22198552 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Npc1 |
NPC intracellular cholesterol transporter 1 |
decreases abundance |
ISO |
NPC1 gene mutant form results in decreased abundance of Iron |
CTD |
PMID:24901380 |
|
NCBI chr18:3,616,878...3,662,656
Ensembl chr18:3,616,878...3,662,683
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases reduction multiple interactions |
ISO |
NQO1 protein results in increased reduction of Iron [Particulate Matter results in increased abundance of Iron] which results in increased expression of NQO1 mRNA |
CTD |
PMID:17178108 PMID:26419736 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Ocln |
occludin |
multiple interactions |
EXP |
Iron inhibits the reaction [Lead results in decreased expression of OCLN mRNA]; Iron inhibits the reaction [Lead results in decreased expression of OCLN protein] |
CTD |
PMID:17234227 |
|
NCBI chr 2:30,527,327...30,577,218
Ensembl chr 2:30,527,715...30,577,218
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
multiple interactions increases activity |
ISO |
Iron affects the reaction [3-chloroperbenzoic acid results in increased activity of ODC1 protein]; Iron deficiency inhibits the reaction [Benzoyl Peroxide results in increased activity of ODC1 protein]; Iron promotes the reaction [Benzoyl Peroxide results in increased activity of ODC1 protein]; Iron promotes the reaction [cumene hydroperoxide results in increased activity of ODC1 protein]; Iron promotes the reaction [Hydrogen Peroxide results in increased activity of ODC1 protein]; Iron promotes the reaction [mezerein results in increased activity of ODC1 protein]; Iron promotes the reaction [Tetradecanoylphorbol Acetate results in increased activity of ODC1 protein] Iron results in increased activity of ODC1 protein |
CTD |
PMID:7653998 PMID:12065085 PMID:12067571 PMID:12504893 |
|
NCBI chr 6:42,852,529...42,859,142
Ensembl chr 6:42,852,683...42,859,927
|
|
G |
Opn3 |
opsin 3 |
decreases expression |
ISO |
Iron deficiency results in decreased expression of OPN3 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr13:93,716,481...93,746,994
Ensembl chr13:93,716,481...93,746,994
|
|
G |
Osbpl11 |
oxysterol binding protein-like 11 |
increases expression |
ISO |
Iron deficiency results in increased expression of OSBPL11 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr11:70,770,509...70,855,425
Ensembl chr11:70,770,507...70,833,577
|
|
G |
P2rx7 |
purinergic receptor P2X 7 |
increases expression |
ISO |
Iron deficiency results in increased expression of P2RX7 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr12:39,353,613...39,396,042
Ensembl chr12:39,353,613...39,396,042
|
|
G |
P4ha1 |
prolyl 4-hydroxylase subunit alpha 1 |
increases expression |
EXP |
Iron deficiency results in increased expression of P4HA1 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr20:28,920,616...28,972,576
Ensembl chr20:28,920,616...28,971,966
|
|
G |
P4htm |
prolyl 4-hydroxylase, transmembrane |
multiple interactions |
ISO |
Iron inhibits the reaction [manganese chloride results in decreased activity of P4HTM protein] |
CTD |
PMID:19263519 |
|
NCBI chr 8:117,364,895...117,383,275
Ensembl chr 8:117,365,101...117,382,715
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
[Acetaminophen co-treated with [ferric nitrate results in increased abundance of Iron]] results in increased cleavage of PARP1 protein; [Arachidonic Acid co-treated with Iron] results in increased expression of PARP1 protein modified form; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of PARP1 protein modified form]; Rifampin inhibits the reaction [[Acetaminophen co-treated with [ferric nitrate results in increased abundance of Iron]] results in increased cleavage of PARP1 protein] |
CTD |
PMID:30626086 PMID:31678598 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Pcgf5 |
polycomb group ring finger 5 |
increases expression |
ISO |
Iron deficiency results in increased expression of PCGF5 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 1:254,974,688...255,090,925
Ensembl chr 1:254,974,789...255,086,207
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
decreases expression |
EXP |
Iron deficiency results in decreased expression of PCK1 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr 3:171,213,936...171,219,885
Ensembl chr 3:171,213,936...171,219,871
|
|
G |
Pcna |
proliferating cell nuclear antigen |
increases expression |
EXP |
Iron deficiency results in increased expression of PCNA mRNA |
CTD |
PMID:16629162 |
|
NCBI chr 3:124,880,698...124,884,570
Ensembl chr 3:124,880,698...124,884,570
|
|
G |
Pctp |
phosphatidylcholine transfer protein |
decreases expression |
EXP |
Iron deficiency results in decreased expression of PCTP mRNA |
CTD |
PMID:19821111 |
|
NCBI chr10:77,491,445...77,537,268
Ensembl chr10:77,491,454...77,512,032
|
|
G |
Pdgfa |
platelet derived growth factor subunit A |
multiple interactions |
EXP |
Iron promotes the reaction [Asbestos, Amosite results in increased expression of PDGFA mRNA] |
CTD |
PMID:11306436 PMID:12475806 |
|
NCBI chr12:17,734,141...17,756,186
Ensembl chr12:17,734,133...17,755,285
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
increases expression |
EXP |
Iron deficiency results in increased expression of PDK4 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr 4:30,546,772...30,556,774
Ensembl chr 4:30,546,664...30,556,814
|
|
G |
Pfkfb4 |
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 |
multiple interactions |
ISO |
[cobaltous chloride results in decreased abundance of Iron] which results in increased expression of PFKFB4 mRNA; [Deferoxamine results in decreased abundance of Iron] which results in increased expression of PFKFB4 mRNA |
CTD |
PMID:16025159 |
|
NCBI chr 8:117,733,347...117,776,525
Ensembl chr 8:117,737,117...117,775,386
|
|
G |
Phospho1 |
phosphoethanolamine/phosphocholine phosphatase 1 |
decreases expression |
EXP |
Iron deficiency results in decreased expression of PHOSPHO1 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr10:83,635,557...83,643,862
Ensembl chr10:83,636,518...83,643,859
|
|
G |
Pik3c2b |
phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 beta |
increases expression |
EXP |
Iron deficiency results in increased expression of PIK3C2B mRNA |
CTD |
PMID:16629162 |
|
NCBI chr13:49,848,939...49,909,404
Ensembl chr13:49,850,189...49,911,202
|
|
G |
Pik3r1 |
phosphoinositide-3-kinase regulatory subunit 1 |
multiple interactions |
EXP |
Iron promotes the reaction [MAP3K7 protein binds to HRAS protein binds to PIK3R1 protein]; PIK3R1 protein affects the reaction [Iron results in increased phosphorylation of AKT1 protein]; PIK3R1 protein affects the reaction [Iron results in increased phosphorylation of MAPK1 protein]; PIK3R1 protein affects the reaction [Iron results in increased phosphorylation of MAPK3 protein]; PIK3R1 protein affects the reaction [Iron results in increased phosphorylation of NFKBIA protein]; PIK3R1 protein affects the reaction [Iron results in increased secretion of TNF protein] |
CTD |
PMID:17172471 |
|
NCBI chr 2:31,742,326...31,826,882
Ensembl chr 2:31,745,088...31,826,867
|
|
G |
Pim1 |
Pim-1 proto-oncogene, serine/threonine kinase |
increases expression |
ISO |
Iron deficiency results in increased expression of PIM1 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr20:8,165,423...8,169,557
Ensembl chr20:8,165,307...8,169,555
|
|
G |
Pip5k1b |
phosphatidylinositol-4-phosphate 5-kinase type 1 beta |
increases expression |
ISO |
Iron deficiency results in increased expression of PIP5K1B mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 1:242,168,462...242,441,247
Ensembl chr 1:242,168,462...242,441,247
|
|
G |
Pla2g1b |
phospholipase A2 group IB |
increases expression |
EXP |
Iron deficiency results in increased expression of PLA2G1B mRNA |
CTD |
PMID:19821111 |
|
NCBI chr12:46,879,346...46,890,234
Ensembl chr12:46,879,343...46,889,082
|
|
G |
Pla2g4a |
phospholipase A2 group IVA |
decreases expression |
EXP |
Iron deficiency results in decreased expression of PLA2G4A mRNA |
CTD |
PMID:19821111 |
|
NCBI chr13:67,062,252...67,206,688
Ensembl chr13:66,988,937...67,206,693
|
|
G |
Plaa |
phospholipase A2, activating protein |
decreases expression |
EXP |
Iron deficiency results in decreased expression of PLAA mRNA |
CTD |
PMID:19821111 |
|
NCBI chr 5:113,548,913...113,578,928
Ensembl chr 5:113,548,913...113,578,928
|
|
G |
Pld4 |
phospholipase D family, member 4 |
decreases expression |
ISO |
Iron deficiency results in decreased expression of PLD4 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 6:137,323,713...137,331,231
Ensembl chr 6:137,323,713...137,331,231
|
|
G |
Plpp1 |
phospholipid phosphatase 1 |
increases expression |
ISO |
Iron deficiency results in increased expression of PLPP1 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 2:44,664,076...44,726,820
Ensembl chr 2:44,664,124...44,726,689
|
|
G |
Plscr1 |
phospholipid scramblase 1 |
decreases expression |
EXP |
Iron deficiency results in decreased expression of PLSCR1 mRNA |
CTD |
PMID:19821111 |
|
NCBI chr 8:99,625,523...99,645,882
Ensembl chr 8:99,625,545...99,725,217
|
|
G |
Pmp22 |
peripheral myelin protein 22 |
increases expression multiple interactions |
ISO EXP |
Iron deficiency results in increased expression of PMP22 mRNA [Deferoxamine results in decreased abundance of Iron] which results in decreased expression of PMP22 mRNA; [ferric ammonium citrate results in increased abundance of Iron] which results in increased expression of PMP22 mRNA; [Hemin results in decreased abundance of Iron] which results in increased expression of PMP22 mRNA |
CTD |
PMID:12393473 PMID:16629162 PMID:20368581 |
|
NCBI chr10:49,538,588...49,568,583
Ensembl chr10:49,538,588...49,568,583
|
|
G |
Pmvk |
phosphomevalonate kinase |
increases expression |
EXP |
Iron deficiency results in increased expression of PMVK mRNA |
CTD |
PMID:19821111 |
|
NCBI chr 2:188,784,329...188,793,890
Ensembl chr 2:188,784,222...188,793,895
|
|
G |
Pnlip |
pancreatic lipase |
increases expression |
EXP |
Iron deficiency results in increased expression of PNLIP mRNA |
CTD |
PMID:19821111 |
|
NCBI chr 1:279,798,187...279,811,372
Ensembl chr 1:279,798,187...279,811,372
|
|
G |
Pnliprp1 |
pancreatic lipase-related protein 1 |
increases expression |
EXP |
Iron deficiency results in increased expression of PNLIPRP1 mRNA |
CTD |
PMID:19821111 |
|
NCBI chr 1:279,867,034...279,882,663
Ensembl chr 1:279,867,034...279,882,663
|
|
G |
Pnliprp2 |
pancreatic lipase related protein 2 |
decreases expression |
EXP |
Iron deficiency results in decreased expression of PNLIPRP2 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr 1:279,896,973...279,927,600
Ensembl chr 1:279,896,973...279,927,600
|
|
G |
Poglut2 |
protein O-glucosyltransferase 2 |
increases expression |
ISO |
Iron deficiency results in increased expression of POGLUT2 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 9:50,872,492...50,884,596
Ensembl chr 9:50,872,492...50,884,596
|
|
G |
Polb |
DNA polymerase beta |
multiple interactions |
ISO |
Iron binds to and inhibits the reaction [NEIL1 protein binds to POLB protein] |
CTD |
PMID:20622253 |
|
NCBI chr16:74,237,001...74,260,272
Ensembl chr16:74,237,001...74,260,271
|
|
G |
Polr3e |
RNA polymerase III subunit E |
multiple interactions |
EXP |
[Tungsten co-treated with Nickel co-treated with Iron] results in increased expression of POLR3E mRNA |
CTD |
PMID:24619124 |
|
NCBI chr 1:190,852,954...190,881,539
Ensembl chr 1:190,852,985...190,881,108
|
|
G |
Pon1 |
paraoxonase 1 |
multiple interactions |
ISO EXP |
[Iron co-treated with Ascorbic Acid] results in decreased activity of PON1 protein; [Iron co-treated with Ascorbic Acid] results in decreased expression of PON1 protein; Butylated Hydroxytoluene inhibits the reaction [[Iron co-treated with Ascorbic Acid] results in decreased expression of PON1 protein] |
CTD |
PMID:16052486 |
|
NCBI chr 4:30,249,749...30,276,297
Ensembl chr 4:30,249,742...30,276,372
|
|
G |
Por |
cytochrome p450 oxidoreductase |
multiple interactions |
ISO |
[[Iron co-treated with POR protein] results in increased metabolism of Diquat] which results in increased abundance of Hydroxyl Radical; [[Iron co-treated with POR protein] results in increased metabolism of Paraquat] which results in increased abundance of Hydroxyl Radical; [Iron co-treated with POR protein] results in increased metabolism of Diquat; [Iron co-treated with POR protein] results in increased metabolism of Paraquat |
CTD |
PMID:21215309 |
|
NCBI chr12:23,998,411...24,017,063
Ensembl chr12:23,998,411...24,046,814
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression |
ISO |
Iron deficiency results in increased expression of PPARG mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Ppp1r16b |
protein phosphatase 1, regulatory subunit 16B |
increases expression |
ISO |
Iron deficiency results in increased expression of PPP1R16B mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 3:155,160,474...155,267,002
Ensembl chr 3:155,160,481...155,262,941
|
|
G |
Ppp1r1b |
protein phosphatase 1, regulatory (inhibitor) subunit 1B |
increases expression |
EXP |
Iron deficiency results in increased expression of PPP1R1B mRNA |
CTD |
PMID:16629162 |
|
NCBI chr10:86,303,727...86,312,770
Ensembl chr10:86,303,727...86,312,762
|
|
G |
Prg3 |
proteoglycan 3, pro eosinophil major basic protein 2 |
decreases expression |
ISO |
Iron deficiency results in decreased expression of PRG3 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 3:72,395,194...72,401,254
Ensembl chr 3:72,395,218...72,401,318
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
decreases expression |
EXP |
Iron deficiency results in decreased expression of PRKAA1 mRNA |
CTD |
PMID:19821111 |
|
NCBI chr 2:54,857,688...54,893,404
Ensembl chr 2:54,857,688...54,893,404
|
|
G |
Prnp |
prion protein |
multiple interactions decreases abundance |
ISO |
[Hydrogen Peroxide co-treated with Iron] results in increased cleavage of PRNP protein; Edetic Acid inhibits the reaction [[Hydrogen Peroxide co-treated with Iron] results in increased cleavage of PRNP protein]; Iron, Dietary inhibits the reaction [PRNP gene mutant form results in decreased abundance of Iron] |
CTD |
PMID:16595185 PMID:23478311 |
|
NCBI chr 3:124,515,917...124,531,320
Ensembl chr 3:124,515,978...124,531,316
|
|
G |
Prtn3 |
proteinase 3 |
decreases expression |
ISO |
Iron deficiency results in decreased expression of PRTN3 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 7:12,643,712...12,646,951
Ensembl chr 7:12,643,516...12,646,960
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
[Copper co-treated with Diethylnitrosamine co-treated with Iron] results in increased expression of PTGS2 protein |
CTD |
PMID:20302851 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Ptx3 |
pentraxin 3 |
increases expression |
ISO |
Iron deficiency results in increased expression of PTX3 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 2:158,097,843...158,103,653
Ensembl chr 2:158,097,843...158,103,653
|
|
G |
Rab30 |
RAB30, member RAS oncogene family |
decreases expression |
EXP |
Iron deficiency results in decreased expression of RAB30 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr 1:157,573,344...157,667,973
Ensembl chr 1:157,573,324...157,660,008
|
|
G |
Rasd1 |
ras related dexamethasone induced 1 |
multiple interactions |
EXP |
Nitric Oxide promotes the reaction [[RASD1 protein binds to ACBD3 protein binds to SLC11A2 protein] which results in increased uptake of Iron] |
CTD |
PMID:16908409 |
|
NCBI chr10:46,330,361...46,339,326
Ensembl chr10:46,330,368...46,332,172
|
|
G |
Rbp7 |
retinol binding protein 7 |
increases expression |
EXP |
Iron deficiency results in increased expression of RBP7 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr 5:166,278,214...166,282,832
Ensembl chr 5:166,278,187...166,282,831
|
|
G |
Relb |
RELB proto-oncogene, NF-kB subunit |
increases expression |
ISO |
Iron deficiency results in increased expression of RELB mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 1:80,517,081...80,545,019
Ensembl chr 1:80,517,411...80,544,825
|
|
G |
Retn |
resistin |
increases expression |
ISO |
Iron deficiency results in increased expression of RETN mRNA |
CTD |
PMID:20368581 |
|
NCBI chr12:2,201,909...2,203,649
Ensembl chr12:2,201,891...2,204,249
|
|
G |
Rgs1 |
regulator of G-protein signaling 1 |
increases expression |
ISO |
Iron deficiency results in increased expression of RGS1 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr13:61,066,196...61,070,772
Ensembl chr13:61,066,153...61,070,599
|
|
G |
Rgs2 |
regulator of G-protein signaling 2 |
increases expression |
ISO |
Iron deficiency results in increased expression of RGS2 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr13:60,846,458...60,849,061
Ensembl chr13:60,846,308...60,849,094
|
|
G |
Rhob |
ras homolog family member B |
increases expression |
EXP |
Iron deficiency results in increased expression of RHOB mRNA |
CTD |
PMID:16629162 |
|
NCBI chr 6:33,689,127...33,691,301
Ensembl chr 6:33,689,127...33,691,301
|
|
G |
Rnase4 |
ribonuclease A family member 4 |
increases expression |
ISO |
Iron deficiency results in increased expression of RNASE4 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr15:28,018,040...28,035,395
Ensembl chr15:28,018,040...28,035,389 Ensembl chr15:28,018,040...28,035,389
|
|
G |
Ropn1l |
rhophilin associated tail protein 1-like |
decreases expression |
ISO |
Iron deficiency results in decreased expression of ROPN1L mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 2:84,520,421...84,531,192
Ensembl chr 2:84,520,421...84,531,342
|
|
G |
Rrm2 |
ribonucleotide reductase regulatory subunit M2 |
multiple interactions |
ISO |
[Iron co-treated with Oxygen] binds to RRM2 protein |
CTD |
PMID:16829694 |
|
NCBI chr 6:43,884,627...43,890,818
Ensembl chr 6:43,884,678...43,889,515
|
|
G |
RT1-Bb |
RT1 class II, locus Bb |
increases expression |
EXP |
Iron deficiency results in increased expression of RT1-BB mRNA |
CTD |
PMID:16629162 |
|
NCBI chr20:4,043,726...4,049,367
Ensembl chr20:4,039,413...4,049,711
|
|
G |
RT1-Db1 |
RT1 class II, locus Db1 |
increases expression |
EXP |
Iron deficiency results in increased expression of RT1-DB1 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr20:4,087,621...4,097,190
Ensembl chr20:4,087,618...4,097,190
|
|
G |
S100a9 |
S100 calcium binding protein A9 |
decreases expression |
EXP |
Iron deficiency results in decreased expression of S100A9 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr 2:190,097,436...190,100,209
Ensembl chr 2:190,097,554...190,100,276
|
|
G |
Scd2 |
stearoyl-Coenzyme A desaturase 2 |
increases expression decreases expression |
EXP |
Iron deficiency results in increased expression of SCD2 mRNA Iron deficiency results in decreased expression of SCD2 mRNA |
CTD |
PMID:16629162 PMID:19821111 |
|
NCBI chr 1:264,059,374...264,072,433
Ensembl chr 1:264,059,374...264,072,433
|
|
G |
Scp2 |
sterol carrier protein 2 |
decreases expression |
EXP |
Iron deficiency results in decreased expression of SCP2 mRNA |
CTD |
PMID:19821111 |
|
NCBI chr 5:127,647,934...127,735,703
Ensembl chr 5:127,620,274...127,735,739
|
|
G |
Sele |
selectin E |
multiple interactions |
ISO |
[Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of SELE mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of SELE protein] |
CTD |
PMID:12633744 |
|
NCBI chr13:82,355,234...82,365,323
Ensembl chr13:82,355,471...82,365,341
|
|
G |
Serpinb8 |
serpin family B member 8 |
increases expression |
ISO |
Iron deficiency results in increased expression of SERPINB8 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr13:27,876,662...27,914,038
Ensembl chr13:27,889,345...27,914,006
|
|
G |
Sesn3 |
sestrin 3 |
decreases expression |
ISO |
Iron deficiency results in decreased expression of SESN3 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 8:12,823,060...12,878,749
Ensembl chr 8:12,823,155...12,872,705
|
|
G |
Ska1 |
spindle and kinetochore associated complex subunit 1 |
increases expression |
ISO |
Iron deficiency results in increased expression of SKA1 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr18:70,174,316...70,184,368
Ensembl chr18:70,173,944...70,184,337
|
|
G |
Slc11a1 |
solute carrier family 11 member 1 |
multiple interactions |
ISO |
[CP gene mutant form results in increased abundance of Iron] which results in increased expression of SLC11A1 mRNA |
CTD |
PMID:16988052 |
|
NCBI chr 9:81,655,590...81,666,697
Ensembl chr 9:81,655,629...81,666,706
|
|
G |
Slc11a2 |
solute carrier family 11 member 2 |
multiple interactions increases uptake affects abundance increases expression increases transport decreases uptake affects metabolic processing decreases expression decreases transport |
ISO EXP |
[Deferoxamine results in decreased abundance of Iron] which results in increased expression of SLC11A2 mRNA; [HFE protein binds to B2M protein binds to SLC11A2 protein] which results in decreased uptake of Iron; cupric chloride inhibits the reaction [SLC11A2 protein results in increased uptake of Iron]; Dronabinol inhibits the reaction [SLC11A2 protein results in increased uptake of Iron]; ebselen inhibits the reaction [SLC11A2 protein results in increased uptake of Iron]; prolinedithiocarbamate inhibits the reaction [SLC11A2 protein results in increased uptake of Iron] SLC11A2 gene SNP affects the abundance of Iron Iron deficiency results in increased expression of SLC11A2 mRNA; Iron deficiency results in increased expression of SLC11A2 protein; Iron results in increased expression of SLC11A2 mRNA; Iron results in increased expression of SLC11A2 protein [Doxorubicin results in increased expression of SLC11A2 protein] which results in increased uptake of Iron; Iron inhibits the reaction [SLC11A2 protein results in increased uptake of manganese chloride]; Iron inhibits the reaction [SLC11A2 protein results in increased uptake of Manganese]; Manganese promotes the reaction [SLC11A2 protein results in increased transport of Iron]; Metals promotes the reaction [SLC11A2 protein results in increased transport of Iron]; Nitric Oxide promotes the reaction [[RASD1 protein binds to ACBD3 protein binds to SLC11A2 protein] which results in increased uptake of Iron]; SLC11A2 protein affects the reaction [Manganese results in increased transport of Iron] Iron deficiency results in increased expression of SLC11A2 mRNA; Iron results in increased expression of SLC11A2 mRNA; Iron results in increased expression of SLC11A2 protein SLC11A2 gene mutant form results in decreased uptake of Iron; SLC11A2 protein mutant form results in decreased uptake of Iron SLC11A2 protein affects the metabolism of Iron Iron results in decreased expression of SLC11A2 protein SLC11A2 gene mutant form results in decreased transport of Iron SLC11A2 protein alternative form results in increased uptake of Iron; SLC11A2 protein results in increased uptake of Iron [Ethanol co-treated with Iron] results in increased expression of SLC11A2 mRNA; [Ethanol co-treated with Iron] results in increased expression of SLC11A2 protein; [SLC11A2 protein mutant form results in decreased phosphorylation of SLC11A2 protein] which results in decreased uptake of Iron; [Staurosporine results in decreased phosphorylation of SLC11A2 protein] which results in decreased uptake of Iron; Iron inhibits the reaction [Diethylnitrosamine results in decreased expression of SLC11A2 protein]; Quercetin inhibits the reaction [[Ethanol co-treated with Iron] results in increased expression of SLC11A2 mRNA]; Quercetin inhibits the reaction [[Ethanol co-treated with Iron] results in increased expression of SLC11A2 protein]; Quercetin inhibits the reaction [Iron results in increased expression of SLC11A2 mRNA]; Quercetin inhibits the reaction [Iron results in increased expression of SLC11A2 protein] |
CTD |
PMID:11439223 PMID:12220667 PMID:12388109 PMID:12393473 PMID:15157939 PMID:15908475 PMID:16629162 PMID:16648237 PMID:16841247 PMID:16908409 PMID:16984886 PMID:17060373 PMID:17116712 PMID:17116743 PMID:17194590 PMID:18648087 PMID:18815723 PMID:18849539 PMID:19061943 PMID:19821111 PMID:21540277 PMID:22666436 PMID:23776592 PMID:23814049 PMID:24089420 PMID:24569067 PMID:25483413 PMID:27681840 |
|
NCBI chr 7:142,025,812...142,062,892
Ensembl chr 7:142,025,815...142,063,212
|
|
G |
Slc12a2 |
solute carrier family 12 member 2 |
increases expression |
EXP |
Iron deficiency results in increased expression of SLC12A2 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr18:52,917,124...52,985,281
Ensembl chr18:52,917,124...52,985,261
|
|
G |
Slc23a2 |
solute carrier family 23 member 2 |
increases expression |
EXP |
Iron deficiency results in increased expression of SLC23A2 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr 3:124,632,491...124,842,225
Ensembl chr 3:124,632,492...124,724,252
|
|
G |
Slc26a11 |
solute carrier family 26 member 11 |
increases expression |
ISO |
Iron deficiency results in increased expression of SLC26A11 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr10:108,479,105...108,504,188
Ensembl chr10:108,480,368...108,503,706
|
|
G |
Slc2a5 |
solute carrier family 2 member 5 |
decreases expression |
ISO EXP |
Iron deficiency results in decreased expression of SLC2A5 mRNA |
CTD |
PMID:16629162 PMID:20368581 |
|
NCBI chr 5:167,142,182...167,174,203
Ensembl chr 5:167,141,875...167,174,310
|
|
G |
Slc34a2 |
solute carrier family 34 member 2 |
decreases expression |
EXP |
Iron deficiency results in decreased expression of SLC34A2 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr14:60,257,211...60,276,516
Ensembl chr14:60,256,712...60,276,794
|
|
G |
Slc39a14 |
solute carrier family 39 member 14 |
multiple interactions increases import increases expression increases uptake |
ISO |
4,7-diphenylphenanthroline sulfonate inhibits the reaction [SLC39A14 protein results in increased uptake of Iron]; [Ethanol co-treated with Iron] results in increased expression of SLC39A14 mRNA; [Ethanol co-treated with Iron] results in increased expression of SLC39A14 protein; Quercetin inhibits the reaction [[Ethanol co-treated with Iron] results in increased expression of SLC39A14 mRNA]; Quercetin inhibits the reaction [[Ethanol co-treated with Iron] results in increased expression of SLC39A14 protein]; Quercetin inhibits the reaction [Iron results in increased expression of SLC39A14 mRNA]; Quercetin inhibits the reaction [Iron results in increased expression of SLC39A14 protein] SLC39A14 protein results in increased import of Iron Iron results in increased expression of SLC39A14 mRNA; Iron results in increased expression of SLC39A14 protein |
CTD |
PMID:16950869 PMID:22898811 PMID:24569067 |
|
NCBI chr15:51,982,872...52,029,841
Ensembl chr15:51,982,982...52,029,816
|
|
G |
Slc39a8 |
solute carrier family 39 member 8 |
increases import multiple interactions |
ISO EXP |
SLC39A8 protein results in increased import of Iron Cobalt inhibits the reaction [SLC39A8 protein results in increased import of Iron]; Iron inhibits the reaction [SLC39A8 protein results in increased import of Zinc]; Iron results in increased expression of and affects the localization of SLC39A8 protein; Manganese inhibits the reaction [SLC39A8 protein results in increased import of Iron]; Zinc inhibits the reaction [SLC39A8 protein results in increased import of Iron] Protons affects the reaction [SLC39A8 protein results in increased import of Iron] |
CTD |
PMID:22898811 |
|
NCBI chr 2:241,028,851...241,092,584
Ensembl chr 2:241,029,693...241,092,582
|
|
G |
Slc40a1 |
solute carrier family 40 member 1 |
decreases expression multiple interactions increases expression increases export decreases export affects metabolic processing |
ISO EXP |
Iron results in decreased expression of SLC40A1 protein [CP protein results in increased oxidation of Iron] which results in increased stability of SLC40A1 protein; Iron affects the reaction [HAMP protein results in increased uptake of SLC40A1 protein]; Iron inhibits the reaction [SLC40A1 protein results in increased export of Manganese] Iron deficiency results in increased expression of SLC40A1 mRNA; Iron results in increased expression of SLC40A1 mRNA SLC40A1 protein mutant form results in increased export of Iron; SLC40A1 protein results in increased export of Iron SLC40A1 protein mutant form results in decreased export of Iron [HBB-B1 gene mutant form results in increased abundance of Iron] which results in increased expression of SLC40A1 mRNA; [HBB-B2 gene mutant form results in increased abundance of Iron] which results in increased expression of SLC40A1 mRNA; Iron inhibits the reaction [Diethylnitrosamine results in decreased expression of SLC40A1 mRNA]; Iron inhibits the reaction [Diethylnitrosamine results in decreased expression of SLC40A1 protein]; NFE2L2 protein promotes the reaction [SLC40A1 protein results in increased export of Iron]; SLC40A1 protein inhibits the reaction [ferrous sulfate results in increased uptake of Iron] SLC40A1 protein affects the metabolism of Iron |
CTD |
PMID:16457665 PMID:16565419 PMID:16648237 PMID:17018382 PMID:17194590 PMID:18648087 PMID:19061943 PMID:19821111 PMID:19913091 PMID:20655381 PMID:21303654 PMID:21540277 PMID:22178646 PMID:22659129 PMID:23776592 |
|
NCBI chr 9:52,819,451...52,830,461
Ensembl chr 9:52,894,365...52,912,293
|
|
G |
Slc6a1 |
solute carrier family 6 member 1 |
multiple interactions increases expression decreases expression |
EXP |
[Iron deficiency co-treated with manganese chloride] results in decreased expression of SLC6A1 mRNA; [Iron deficiency co-treated with manganese chloride] results in decreased expression of SLC6A1 protein; [Iron deficiency co-treated with manganese chloride] results in increased expression of SLC6A1 mRNA Iron deficiency results in increased expression of SLC6A1 mRNA Iron deficiency results in decreased expression of SLC6A1 protein |
CTD |
PMID:18771689 |
|
NCBI chr 4:146,258,842...146,292,176
Ensembl chr 4:146,276,862...146,292,213
|
|
G |
Slc6a3 |
solute carrier family 6 member 3 |
multiple interactions |
EXP |
[manganese chloride co-treated with Iron deficiency] results in decreased expression of SLC6A3 protein |
CTD |
PMID:22479410 |
|
NCBI chr 1:32,323,011...32,363,983
Ensembl chr 1:32,321,580...32,363,983
|
|
G |
Slpi |
secretory leukocyte peptidase inhibitor |
decreases expression |
ISO |
Iron deficiency results in decreased expression of SLPI mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 3:160,799,979...160,802,228
Ensembl chr 3:160,799,981...160,802,433
|
|
G |
Smim3 |
small integral membrane protein 3 |
increases expression |
EXP |
Iron deficiency results in increased expression of SMIM3 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr18:55,744,809...55,797,186
Ensembl chr18:55,744,810...55,771,730
|
|
G |
Snapc1 |
small nuclear RNA activating complex, polypeptide 1 |
increases expression |
EXP |
Iron deficiency results in increased expression of SNAPC1 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr 6:96,871,675...96,893,422
Ensembl chr 6:96,871,625...96,893,444
|
|
G |
Snca |
synuclein alpha |
multiple interactions affects localization increases response to substance |
ISO |
Cytarabine promotes the reaction [SNCA protein mutant form results in increased susceptibility to Iron]; Hydroxyurea promotes the reaction [SNCA protein mutant form results in increased susceptibility to Iron]; SNCA protein mutant form results in increased susceptibility to [Paraquat co-treated with Iron] EUK-189 results in decreased susceptibility to [Iron co-treated with Paraquat co-treated with SNCA gene mutant form] Iron affects the localization of SNCA protein |
CTD |
PMID:12401952 PMID:14535945 PMID:21039522 PMID:27324791 |
|
NCBI chr 4:90,782,412...90,883,236
Ensembl chr 4:90,782,374...90,882,285
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions affects abundance |
ISO EXP |
SOD1 protein inhibits the reaction [Asbestos, Crocidolite results in increased uptake of Iron] [Zinc co-treated with Iron co-treated with Calcium] inhibits the reaction [lead acetate results in decreased expression of SOD1 protein] SOD1 protein affects the abundance of Iron [Corn Oil co-treated with Iron] results in decreased activity of SOD1 protein; Iron promotes the reaction [Corn Oil results in decreased activity of SOD1 protein] |
CTD |
PMID:16272461 PMID:17194920 PMID:19482077 PMID:22534743 |
|
NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
|
|
G |
Sod2 |
superoxide dismutase 2 |
affects abundance multiple interactions |
ISO EXP |
SOD2 protein polymorphism affects the abundance of Iron [Zinc co-treated with Iron co-treated with Calcium] inhibits the reaction [lead acetate results in decreased expression of SOD2 protein] Deferoxamine inhibits the reaction [SOD2 protein affects the reaction [Ethanol results in increased abundance of Iron]]; SOD2 protein affects the reaction [Ethanol results in increased abundance of Iron] Iron results in decreased expression of and results in decreased activity of SOD2 protein |
CTD |
PMID:18760346 PMID:19063909 PMID:22534743 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Sord |
sorbitol dehydrogenase |
affects abundance |
EXP |
SORD protein affects the abundance of Iron |
CTD |
PMID:18549825 |
|
NCBI chr 3:114,176,127...114,207,368
Ensembl chr 3:114,176,309...114,207,366
|
|
G |
Sort1 |
sortilin 1 |
increases expression |
ISO |
Iron deficiency results in increased expression of SORT1 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 2:211,078,092...211,156,312
Ensembl chr 2:211,078,334...211,156,312
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
increases expression |
EXP |
Iron deficiency results in increased expression of SOX9 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr10:101,288,528...101,294,030
Ensembl chr10:101,288,489...101,293,379
|
|
G |
Sp1 |
Sp1 transcription factor |
multiple interactions |
ISO |
[Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased activity of SP1 protein] |
CTD |
PMID:12633744 |
|
NCBI chr 7:144,014,173...144,044,635
Ensembl chr 7:144,014,173...144,044,629
|
|
G |
Sp6 |
Sp6 transcription factor |
increases expression |
EXP |
Iron deficiency results in increased expression of SP6 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr10:84,950,751...84,961,368
Ensembl chr10:84,955,864...84,960,045
|
|
G |
Spr |
sepiapterin reductase |
increases expression |
EXP |
Iron deficiency results in increased expression of SPR mRNA |
CTD |
PMID:16629162 |
|
NCBI chr 4:116,912,343...116,916,073
Ensembl chr 4:116,912,351...116,916,236
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
ISO |
[Iron co-treated with Deferoxamine] results in increased expression of SQSTM1 protein; Iron affects the reaction [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone results in increased expression of SQSTM1 protein] |
CTD |
PMID:25301941 |
|
NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
ISO |
Iron promotes the reaction [Arsenic results in increased phosphorylation of and results in increased activity of SRC protein] |
CTD |
PMID:23100159 |
|
NCBI chr 3:153,547,807...153,595,643
Ensembl chr 3:153,580,861...153,595,642
|
|
G |
Steap2 |
STEAP2 metalloreductase |
increases reduction increases uptake |
ISO |
STEAP2 protein results in increased reduction of Iron STEAP2 protein results in increased uptake of Iron |
CTD |
PMID:16609065 |
|
NCBI chr 4:25,506,604...25,527,088
Ensembl chr 4:25,507,463...25,527,087
|
|
G |
Steap3 |
STEAP3 metalloreductase |
affects metabolic processing increases reduction increases uptake |
ISO |
STEAP3 protein affects the metabolism of Iron STEAP3 protein results in increased reduction of Iron STEAP3 protein results in increased uptake of Iron |
CTD |
PMID:16609065 PMID:17194590 |
|
NCBI chr13:36,257,220...36,274,144
Ensembl chr13:36,257,112...36,290,531
|
|
G |
Steap4 |
STEAP4 metalloreductase |
increases uptake increases reduction |
ISO |
STEAP4 protein results in increased uptake of Iron STEAP4 protein results in increased reduction of Iron |
CTD |
PMID:16609065 |
|
NCBI chr 4:23,112,682...23,135,354
Ensembl chr 4:23,090,029...23,135,354
|
|
G |
Stk11 |
serine/threonine kinase 11 |
multiple interactions |
ISO |
STK11 protein affects the reaction [resveratrol results in decreased susceptibility to [Arachidonic Acid co-treated with Iron]] |
CTD |
PMID:19620254 |
|
NCBI chr 7:12,440,751...12,457,513
Ensembl chr 7:12,440,751...12,457,513
|
|
G |
Sulf2 |
sulfatase 2 |
increases expression |
ISO |
Iron deficiency results in increased expression of SULF2 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 3:162,791,349...162,872,984
Ensembl chr 3:162,791,355...162,872,831
|
|
G |
Tasl |
TLR adaptor interacting with endolysosomal SLC15A4 |
decreases expression |
ISO |
Iron deficiency results in decreased expression of TASL mRNA |
CTD |
PMID:20368581 |
|
NCBI chr X:54,390,733...54,409,466
Ensembl chr X:54,390,733...54,409,466
|
|
G |
Tert |
telomerase reverse transcriptase |
increases activity |
EXP |
Iron results in increased activity of TERT protein |
CTD |
PMID:17189828 |
|
NCBI chr 1:32,250,876...32,275,330
Ensembl chr 1:32,251,714...32,272,476
|
|
G |
Tes |
testin LIM domain protein |
increases expression |
ISO |
Iron deficiency results in increased expression of TES mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 4:44,321,883...44,360,407
Ensembl chr 4:44,321,883...44,360,405
|
|
G |
Tf |
transferrin |
multiple interactions affects metabolic processing affects binding increases expression increases uptake |
ISO EXP |
[Aluminum binds to TF protein] which results in decreased uptake of Iron; [Iron binds to TF protein] which results in decreased uptake of Iron; [TF protein binds to Aluminum] affects the activity of [TF protein binds to Iron]; [TF protein binds to Aluminum] which results in increased uptake of Iron; ammonium ferric sulfate promotes the reaction [TF protein results in increased uptake of Iron]; cobaltous chloride inhibits the reaction [TF protein results in increased uptake of Iron]; cuprous chloride inhibits the reaction [TF protein results in increased uptake of Iron]; ferric ammonium citrate inhibits the reaction [TF protein results in increased uptake of Iron]; ferric chloride promotes the reaction [TF protein results in increased uptake of Iron]; ferrous sulfate promotes the reaction [TF protein results in increased uptake of Iron]; gallium nitrate promotes the reaction [TF protein results in increased uptake of Iron]; TF protein binds to [Aluminum co-treated with Iron]; TF protein binds to and affects the transport of Iron; zinc chloride inhibits the reaction [TF protein results in increased uptake of Iron] TRF protein affects the metabolism of Iron Iron deficiency results in increased expression of TF protein [Iron deficiency co-treated with Manganese] results in increased expression of TF protein; [Melatonin results in increased expression of TF protein] which affects the abundance of Iron; [S-Adenosylmethionine results in increased expression of TF protein] which affects the abundance of Iron; Copper deficiency results in decreased expression of [Iron binds to TF protein] [Iron binds to TF protein] which binds to TFRC protein; [TF protein binds to Iron] which binds to TFRC protein; CP protein binds to [TF protein binds to Iron]; Iron binds to TF protein; TF protein binds to Iron |
CTD |
PMID:2039817 PMID:2308257 PMID:8782865 PMID:11193083 PMID:11335103 PMID:15214510 PMID:16564538 PMID:16793765 PMID:16819174 PMID:16988841 PMID:17060373 PMID:17194590 PMID:17266333 PMID:17327678 PMID:18571630 PMID:19859668 PMID:20164366 PMID:21049900 PMID:22873711 |
|
NCBI chr 8:111,694,570...111,721,275
Ensembl chr 8:111,673,547...111,721,333
|
|
G |
Tff1 |
trefoil factor 1 |
increases expression |
EXP |
Iron deficiency results in increased expression of TFF1 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr20:9,892,124...9,895,984
Ensembl chr20:9,892,124...9,895,984
|
|
G |
Tfr2 |
transferrin receptor 2 |
multiple interactions decreases expression affects metabolic processing increases uptake affects response to substance |
ISO EXP |
[HFE protein binds to TFR2 protein] which affects the susceptibility to Iron Iron deficiency results in decreased expression of TFR2 protein TFR2 protein affects the metabolism of Iron TFR2 protein mutant form results in increased uptake of Iron TFR2 protein affects the susceptibility to Iron [HBB-B1 gene mutant form results in increased abundance of Iron] which results in decreased expression of TFR2 mRNA; [HBB-B2 gene mutant form results in increased abundance of Iron] which results in decreased expression of TFR2 mRNA; [HFE gene mutant form co-treated with TFR2 gene mutant form] results in increased abundance of Iron; Iron inhibits the reaction [Diethylnitrosamine results in decreased expression of TFR2 protein] |
CTD |
PMID:16893896 PMID:16935854 PMID:17018382 PMID:17194590 PMID:17241880 PMID:19061943 PMID:20164366 PMID:22383097 PMID:22457245 |
|
NCBI chr12:22,177,382...22,194,330
Ensembl chr12:22,177,382...22,194,299
|
|
G |
Tfrc |
transferrin receptor |
multiple interactions increases expression decreases expression increases uptake affects expression affects metabolic processing affects binding |
ISO EXP |
[Deferoxamine results in decreased abundance of Iron] which results in increased expression of TFRC mRNA; [ferric ammonium citrate results in decreased abundance of Iron] which results in increased expression of TFRC mRNA; [fluvastatin results in decreased expression of TFRC protein] which results in decreased uptake of Iron; [GGTI 298 results in decreased expression of TFRC protein] which results in decreased uptake of Iron; [Hemin results in decreased abundance of Iron] which results in increased expression of TFRC mRNA; HFE protein inhibits the reaction [TFRC protein results in increased uptake of Iron] Iron deficiency results in increased expression of TFRC mRNA; Iron results in increased expression of TFRC mRNA Iron results in decreased expression of TFRC mRNA Iron deficiency results in increased expression of TFRC mRNA; Iron deficiency results in increased expression of TFRC protein [Iron co-treated with Diethylnitrosamine co-treated with Copper] results in decreased expression of TFRC mRNA; [Iron co-treated with Diethylnitrosamine] results in decreased expression of TFRC mRNA; [Iron co-treated with Diethylnitrosamine] results in decreased expression of TFRC protein; Clofibrate inhibits the reaction [Iron deficiency results in increased expression of TFRC mRNA] Iron affects the expression of TFRC mRNA; Iron affects the expression of TFRC protein TFRC protein affects the metabolism of Iron [CP gene mutant form results in increased abundance of Iron] which results in decreased expression of TFRC mRNA; [Iron co-treated with Ethanol] results in increased expression of TFRC mRNA; [Zinc deficiency results in increased abundance of Iron] which results in increased expression of TFRC mRNA; [Zinc deficiency results in increased abundance of Iron] which results in increased expression of TFRC protein; Iron inhibits the reaction [Diethylnitrosamine results in increased expression of TFRC protein]; Quercetin inhibits the reaction [[Iron co-treated with Ethanol] results in increased expression of TFRC mRNA]; Quercetin inhibits the reaction [Iron results in increased expression of TFRC mRNA] Iron results in increased expression of TFRC protein [Iron binds to TF protein] which binds to TFRC protein; [TF protein binds to Iron] which binds to TFRC protein |
CTD |
PMID:10085150 PMID:11068183 PMID:11969379 PMID:12393473 PMID:16428268 PMID:16564538 PMID:16629162 PMID:16988052 PMID:16988136 PMID:17060373 PMID:17091493 PMID:17101452 PMID:17194590 PMID:18073202 PMID:19061943 PMID:19859668 PMID:20302851 PMID:22457245 PMID:23776592 PMID:24569067 PMID:24964743 |
|
NCBI chr11:71,397,423...71,419,263
Ensembl chr11:71,397,383...71,419,223
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
Iron promotes the reaction [Asbestos, Amosite results in increased expression of TGFB1 mRNA] |
CTD |
PMID:11306436 PMID:12475806 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Tgif1 |
TGFB-induced factor homeobox 1 |
increases expression |
EXP |
Iron deficiency results in increased expression of TGIF1 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr 9:119,181,079...119,190,698
Ensembl chr 9:119,181,083...119,190,698
|
|
G |
Tmem154 |
transmembrane protein 154 |
increases expression |
ISO |
Iron deficiency results in increased expression of TMEM154 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 2:183,674,361...183,714,232
Ensembl chr 2:183,674,522...183,711,812
|
|
G |
Tmem252 |
transmembrane protein 252 |
increases expression |
EXP |
Iron deficiency results in increased expression of TMEM252 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr 1:242,572,558...242,577,817
Ensembl chr 1:242,572,533...242,577,817
|
|
G |
Tmem45b |
transmembrane protein 45b |
decreases expression |
EXP |
Iron deficiency results in decreased expression of TMEM45B mRNA |
CTD |
PMID:16629162 |
|
NCBI chr 8:32,563,872...32,609,212
Ensembl chr 8:32,563,874...32,609,212
|
|
G |
Tmem86a |
transmembrane protein 86A |
increases expression |
EXP |
Iron deficiency results in increased expression of TMEM86A mRNA |
CTD |
PMID:16629162 |
|
NCBI chr 1:103,173,032...103,177,382
Ensembl chr 1:103,172,987...103,177,417
|
|
G |
Tmprss6 |
transmembrane serine protease 6 |
affects abundance |
ISO |
TMPRSS6 gene SNP affects the abundance of Iron |
CTD |
PMID:19820698 PMID:19820699 |
|
NCBI chr 7:119,659,323...119,689,953
Ensembl chr 7:119,659,324...119,689,938
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases uptake increases expression increases secretion decreases abundance |
ISO EXP |
[Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased activity of SP1 protein]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of SELE mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of SELE protein]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; TNF gene SNP promotes the reaction [HFE protein mutant form results in increased uptake of Iron] TNF protein results in increased uptake of Iron Iron results in increased expression of TNF mRNA Iron results in increased secretion of TNF protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Iron results in increased secretion of TNF protein]; [Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of TNF protein; lipopolysaccharide A promotes the reaction [Iron results in increased secretion of TNF protein]; MAP3K14 protein affects the reaction [Iron results in increased secretion of TNF protein]; MAP3K7 protein affects the reaction [Iron results in increased secretion of TNF protein]; PIK3R1 protein affects the reaction [Iron results in increased secretion of TNF protein]; TNF protein affects the transport of and results in decreased abundance of Iron; U 0126 inhibits the reaction [Iron results in increased secretion of TNF protein] TNF protein results in decreased abundance of Iron |
CTD |
PMID:10865941 PMID:12633744 PMID:16566752 PMID:16793930 PMID:16890145 PMID:16958088 PMID:17172471 PMID:19900513 PMID:22198552 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
increases expression |
ISO |
Iron deficiency results in increased expression of TNFSF10 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 2:113,008,008...113,026,899
Ensembl chr 2:113,007,549...113,026,899
|
|
G |
Tppp3 |
tubulin polymerization-promoting protein family member 3 |
increases expression |
EXP |
Iron deficiency results in increased expression of TPPP3 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr19:37,424,323...37,428,075
Ensembl chr19:37,424,324...37,427,989
|
|
G |
Treml2 |
triggering receptor expressed on myeloid cells-like 2 |
increases expression |
ISO |
Iron deficiency results in increased expression of TREML2 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 9:14,659,967...14,668,313
Ensembl chr 9:14,660,738...14,668,297
|
|
G |
Trim27 |
tripartite motif-containing 27 |
increases expression |
EXP |
Iron deficiency results in increased expression of TRIM27 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr17:45,613,863...45,626,212
Ensembl chr17:45,613,864...45,626,212
|
|
G |
Trpc6 |
transient receptor potential cation channel, subfamily C, member 6 |
increases uptake |
ISO |
TRPC6 protein results in increased uptake of Iron |
CTD |
PMID:14640978 |
|
NCBI chr 8:6,811,543...6,917,534
Ensembl chr 8:6,811,543...6,917,535
|
|
G |
Tshz1 |
teashirt zinc finger homeobox 1 |
increases expression |
EXP |
Iron deficiency results in increased expression of TSHZ1 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr18:80,860,995...80,907,744
Ensembl chr18:80,862,372...80,865,584
|
|
G |
Tshz3 |
teashirt zinc finger homeobox 3 |
increases expression |
ISO |
Iron deficiency results in increased expression of TSHZ3 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 1:92,703,180...92,775,020
Ensembl chr 1:92,703,080...92,774,975
|
|
G |
Txn2 |
thioredoxin 2 |
multiple interactions |
ISO |
[3-aminopyridine-2-carboxaldehyde thiosemicarbazone binds to Iron] which results in increased oxidation of TXN2 protein |
CTD |
PMID:21195754 |
|
NCBI chr 7:119,144,350...119,158,173
Ensembl chr 7:119,144,351...119,158,201
|
|
G |
Ube2e1 |
ubiquitin-conjugating enzyme E2E 1 |
decreases expression |
ISO |
Iron deficiency results in decreased expression of UBE2E1 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr15:8,124,869...8,178,252
Ensembl chr15:8,125,526...8,177,781
|
|
G |
Ugt1a6 |
UDP glucuronosyltransferase family 1 member A6 |
multiple interactions |
EXP |
[Nickel co-treated with Iron co-treated with Tungsten] results in decreased expression of UGT1A6 mRNA |
CTD |
PMID:22198552 |
|
NCBI chr 9:95,241,609...95,302,822
Ensembl chr 9:95,161,157...95,302,822
|
|
G |
Ugt2b15 |
UDP glucuronosyltransferase family 2 member B15 |
decreases expression |
EXP |
Iron deficiency results in decreased expression of UGT2B15 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr14:22,375,428...22,486,291
Ensembl chr14:22,375,955...22,534,720
|
|
G |
Ugt2b17 |
UDP glucuronosyltransferase family 2 member B17 |
decreases expression |
EXP |
Iron deficiency results in decreased expression of UGT2B17 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr14:22,724,399...22,736,148
Ensembl chr14:22,724,070...22,825,444
|
|
G |
Urod |
uroporphyrinogen decarboxylase |
decreases activity multiple interactions |
ISO EXP |
Iron results in decreased activity of UROD protein Iron inhibits the reaction [Ethinyl Estradiol results in increased activity of UROD protein] |
CTD |
PMID:3945969 PMID:12030801 |
|
NCBI chr 5:135,855,429...135,859,515
Ensembl chr 5:135,855,433...135,859,643
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
[Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; [Deferoxamine affects the abundance of Iron] inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] |
CTD |
PMID:12633744 |
|
NCBI chr 2:219,071,193...219,090,931
Ensembl chr 2:219,071,193...219,097,619
|
|
G |
Vdr |
vitamin D receptor |
increases expression |
ISO |
Iron deficiency results in increased expression of VDR mRNA |
CTD |
PMID:20368581 |
|
NCBI chr 7:139,344,452...139,394,138
Ensembl chr 7:139,342,063...139,394,166
|
|
G |
Vsig10l |
V-set and immunoglobulin domain containing 10 like |
decreases expression |
EXP |
Iron deficiency results in decreased expression of VSIG10L mRNA |
CTD |
PMID:16629162 |
|
NCBI chr 1:98,458,691...98,467,444
Ensembl chr 1:98,459,834...98,467,262
|
|
G |
Wipi1 |
WD repeat domain, phosphoinositide interacting 1 |
increases expression |
ISO |
Iron deficiency results in increased expression of WIPI1 mRNA |
CTD |
PMID:20368581 |
|
NCBI chr10:97,859,730...97,896,949
Ensembl chr10:97,859,727...97,896,525
|
|
G |
Zfp503 |
zinc finger protein 503 |
increases expression |
EXP |
Iron deficiency results in increased expression of ZFP503 mRNA |
CTD |
PMID:16629162 |
|
NCBI chr15:2,374,582...2,378,370
Ensembl chr15:2,374,582...2,378,370
|
|
|
G |
Abcf1 |
ATP binding cassette subfamily F member 1 |
increases expression |
ISO |
ferrous sulfate results in increased expression of ABCF1 mRNA |
CTD |
PMID:19428942 |
|
NCBI chr20:3,309,914...3,322,828
Ensembl chr20:3,309,899...3,322,825
|
|
G |
Aco1 |
aconitase 1 |
multiple interactions |
ISO |
[nickel chloride results in increased activity of ACO1 protein] inhibits the reaction [ferrous sulfate results in increased expression of FTL protein] |
CTD |
PMID:16039939 |
|
NCBI chr 5:56,425,076...56,481,218
Ensembl chr 5:56,425,024...56,481,218
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP |
[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of ACTA2 protein |
CTD |
PMID:7593635 |
|
NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ferrous sulfate results in increased phosphorylation of AKT1 protein]; deferiprone inhibits the reaction [ferrous sulfate results in increased phosphorylation of AKT1 protein]; Filipin inhibits the reaction [ferrous sulfate results in increased phosphorylation of AKT1 protein]; HRAS protein affects the reaction [ferrous sulfate results in increased phosphorylation of AKT1 protein]; MAP3K7 protein affects the reaction [ferrous sulfate results in increased phosphorylation of AKT1 protein]; PIK3R1 protein affects the reaction [ferrous sulfate results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:17172471 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Atp2a1 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1 |
multiple interactions |
EXP |
[ferrous sulfate co-treated with Edetic Acid] results in decreased activity of ATP2A1 protein; Butylated Hydroxytoluene inhibits the reaction [[ferrous sulfate co-treated with Edetic Acid] results in decreased activity of ATP2A1 protein]; dicarbine inhibits the reaction [[ferrous sulfate co-treated with Edetic Acid] results in decreased activity of ATP2A1 protein] |
CTD |
PMID:12870653 |
|
NCBI chr 1:197,855,912...197,875,038
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
EXP |
ferrous sulfate results in increased expression of BAX protein 2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased expression of BAX protein] |
CTD |
PMID:28583816 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
EXP |
ferrous sulfate results in decreased expression of BCL2 protein 2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in decreased expression of BCL2 protein] |
CTD |
PMID:28583816 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bcl2a1 |
BCL2-related protein A1 |
increases expression |
ISO |
ferrous sulfate results in increased expression of BCL2A1 mRNA |
CTD |
PMID:21540303 |
|
NCBI chr 8:96,551,424...96,559,527
Ensembl chr 8:96,551,245...96,559,483
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions |
EXP ISO |
ferrous sulfate results in increased cleavage of CASP3 protein [Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of CASP3 protein; [Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CASP3 mRNA; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of CASP3 protein]; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CASP3 mRNA] 2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased cleavage of CASP3 protein] |
CTD |
PMID:17879260 PMID:28583816 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of CASP7 protein; [Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CASP7 mRNA; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of CASP7 protein]; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CASP7 mRNA] |
CTD |
PMID:17879260 |
|
NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of [NFKB1 protein binds to RELA protein]]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased degradation of Hyaluronic Acid]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CD44 mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CD44 protein]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of IL1B mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of IL1B protein]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of MMP13 mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of MMP13 protein]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of NOS2 mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of NOS2 protein]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR2 mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR2 protein]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR4 mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR4 protein]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TNF mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TNF protein] |
CTD |
PMID:23692848 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Cav1 |
caveolin 1 |
affects localization |
EXP |
ferrous sulfate affects the localization of CAV1 protein |
CTD |
PMID:17172471 |
|
NCBI chr 4:44,597,123...44,630,206
Ensembl chr 4:44,597,123...44,630,200
|
|
G |
Ccl17 |
C-C motif chemokine ligand 17 |
decreases expression |
ISO |
ferrous sulfate results in decreased expression of CCL17 mRNA |
CTD |
PMID:19428942 |
|
NCBI chr19:10,619,220...10,620,671
Ensembl chr19:10,619,220...10,620,671
|
|
G |
Ccl19 |
C-C motif chemokine ligand 19 |
decreases expression |
ISO |
ferrous sulfate results in decreased expression of CCL19 mRNA |
CTD |
PMID:19428942 |
|
NCBI chr 5:58,181,025...58,182,969
Ensembl chr 5:58,181,026...58,183,017
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
increases expression |
ISO |
ferrous sulfate results in increased expression of CCL20 mRNA |
CTD |
PMID:19428942 PMID:21540303 |
|
NCBI chr 9:88,918,359...88,921,017
Ensembl chr 9:88,918,433...88,921,001
|
|
G |
Ccl21 |
C-C motif chemokine ligand 21 |
decreases expression |
ISO |
ferrous sulfate results in decreased expression of CCL21 mRNA |
CTD |
PMID:19428942 |
|
NCBI chr 5:58,197,678...58,198,782
Ensembl chr 5:58,197,680...58,198,782
|
|
G |
Ccl24 |
C-C motif chemokine ligand 24 |
decreases expression |
ISO |
ferrous sulfate results in decreased expression of CCL24 mRNA |
CTD |
PMID:19428942 |
|
NCBI chr12:24,131,529...24,152,626
Ensembl chr12:24,148,567...24,152,625
|
|
G |
Ccr6 |
C-C motif chemokine receptor 6 |
decreases expression |
ISO |
ferrous sulfate results in decreased expression of CCR6 mRNA |
CTD |
PMID:19428942 |
|
NCBI chr 1:53,063,380...53,087,519
Ensembl chr 1:53,065,025...53,087,474
|
|
G |
Ccr7 |
C-C motif chemokine receptor 7 |
decreases expression |
ISO |
ferrous sulfate results in decreased expression of CCR7 mRNA |
CTD |
PMID:19428942 |
|
NCBI chr10:87,057,335...87,067,444
Ensembl chr10:87,057,136...87,067,456
|
|
G |
Ccr8 |
C-C motif chemokine receptor 8 |
decreases expression |
ISO |
ferrous sulfate results in decreased expression of CCR8 mRNA |
CTD |
PMID:19428942 |
|
NCBI chr 8:128,779,552...128,782,531
Ensembl chr 8:128,781,395...128,782,456
|
|
G |
Cd44 |
CD44 molecule (Indian blood group) |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CD44 mRNA; [Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CD44 protein; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CD44 mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CD44 protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CD44 mRNA]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of CD44 protein] |
CTD |
PMID:23692848 |
|
NCBI chr 3:92,695,083...92,783,820
Ensembl chr 3:92,696,313...92,783,658
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
ferrous sulfate results in increased expression of CDKN1A mRNA |
CTD |
PMID:21540303 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
increases expression |
ISO |
ferrous sulfate results in increased expression of CEBPB mRNA |
CTD |
PMID:19428942 |
|
NCBI chr 3:164,424,502...164,425,933
Ensembl chr 3:164,424,515...164,425,910
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
EXP |
deferiprone inhibits the reaction [ferrous sulfate results in increased activity of [CHUK protein binds to IKBKB protein]]; ferrous sulfate results in increased activity of [CHUK protein binds to IKBKB protein]; Filipin inhibits the reaction [ferrous sulfate results in increased activity of [CHUK protein binds to IKBKB protein]]; N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid inhibits the reaction [ferrous sulfate results in increased activity of [CHUK protein binds to IKBKB protein]] |
CTD |
PMID:17172471 |
|
NCBI chr 1:263,848,829...263,884,354
Ensembl chr 1:263,848,884...263,885,169
|
|
G |
Crp |
C-reactive protein |
decreases expression |
ISO |
ferrous sulfate results in decreased expression of CRP mRNA; ferrous sulfate results in decreased expression of CRP protein |
CTD |
PMID:17119383 PMID:19428942 |
|
NCBI chr13:91,080,448...91,081,358
Ensembl chr13:91,054,974...91,093,713
|
|
G |
Csf2 |
colony stimulating factor 2 |
increases expression |
ISO |
ferrous sulfate results in increased expression of CSF2 mRNA |
CTD |
PMID:21540303 |
|
NCBI chr10:39,602,089...39,604,070
Ensembl chr10:39,602,089...39,604,070
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
increases expression |
ISO |
ferrous sulfate results in increased expression of CXCL10 mRNA |
CTD |
PMID:19428942 |
|
NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930
|
|
G |
Cxcl11 |
C-X-C motif chemokine ligand 11 |
increases expression |
ISO |
ferrous sulfate results in increased expression of CXCL11 mRNA |
CTD |
PMID:19428942 |
|
NCBI chr14:17,195,395...17,198,170
Ensembl chr14:17,195,014...17,198,291
|
|
G |
Cxcl13 |
C-X-C motif chemokine ligand 13 |
decreases expression |
ISO |
ferrous sulfate results in decreased expression of CXCL13 mRNA |
CTD |
PMID:19428942 |
|
NCBI chr14:15,253,146...15,258,221
Ensembl chr14:15,253,125...15,258,207
|
|
G |
Cxcl14 |
C-X-C motif chemokine ligand 14 |
decreases expression |
ISO |
ferrous sulfate results in decreased expression of CXCL14 mRNA |
CTD |
PMID:19428942 |
|
NCBI chr17:9,109,731...9,117,754
Ensembl chr17:9,109,731...9,117,750
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
increases expression |
EXP |
ferrous sulfate results in increased expression of CXCL2 mRNA |
CTD |
PMID:11708899 |
|
NCBI chr14:18,731,346...18,733,391
Ensembl chr14:18,731,378...18,733,391
|
|
G |
Cxcr2 |
C-X-C motif chemokine receptor 2 |
decreases expression |
ISO |
ferrous sulfate results in decreased expression of CXCR2 mRNA |
CTD |
PMID:19428942 |
|
NCBI chr 9:81,427,275...81,435,065
Ensembl chr 9:81,427,730...81,434,102
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]; ferrous sulfate inhibits the reaction [picolinic acid inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]] |
CTD |
PMID:10799651 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Dnajb1 |
DnaJ heat shock protein family (Hsp40) member B1 |
decreases response to substance |
ISO |
DNAJB1 protein results in decreased susceptibility to ferrous sulfate |
CTD |
PMID:11359866 |
|
NCBI chr19:24,747,178...24,750,919
Ensembl chr19:24,747,178...24,750,919
|
|
G |
Egln1 |
egl-9 family hypoxia-inducible factor 1 |
increases activity |
ISO |
ferrous sulfate results in increased activity of EGLN1 protein |
CTD |
PMID:16649251 |
|
NCBI chr19:57,660,194...57,701,158
Ensembl chr19:57,662,278...57,699,113
|
|
G |
Egr1 |
early growth response 1 |
decreases expression |
ISO |
ferrous sulfate results in decreased expression of EGR1 mRNA |
CTD |
PMID:21540303 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
multiple interactions |
ISO |
ferrous sulfate inhibits the reaction [galangin results in increased expression of EPAS1 protein]; ferrous sulfate inhibits the reaction [Quercetin results in increased expression of EPAS1 protein] |
CTD |
PMID:17973296 |
|
NCBI chr 6:10,306,508...10,385,239
Ensembl chr 6:10,306,405...10,387,265
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions |
ISO |
ferrous sulfate inhibits the reaction [Quercetin promotes the reaction [ERBB2 protein binds to HSP90AA1 protein]]; ferrous sulfate inhibits the reaction [Quercetin results in decreased expression of and results in increased ubiquitination of ERBB2 protein] |
CTD |
PMID:18655187 |
|
NCBI chr10:86,367,596...86,391,728
Ensembl chr10:86,367,596...86,391,728
|
|
G |
F10 |
coagulation factor X |
decreases activity |
ISO |
ferrous sulfate results in decreased activity of F10 protein |
CTD |
PMID:6421970 |
|
NCBI chr16:81,803,169...81,822,476
Ensembl chr16:81,803,110...81,822,716
|
|
G |
F2 |
coagulation factor II |
decreases activity |
ISO |
ferrous sulfate results in decreased activity of F2 protein |
CTD |
PMID:6421970 |
|
NCBI chr 3:80,529,468...80,542,993
Ensembl chr 3:80,529,428...80,543,031
|
|
G |
Ftl1 |
ferritin light chain 1 |
multiple interactions increases expression |
ISO EXP |
[nickel chloride results in increased activity of ACO1 protein] inhibits the reaction [ferrous sulfate results in increased expression of FTL protein] ferrous sulfate results in increased expression of FTL1 protein |
CTD |
PMID:16039939 PMID:28993186 |
|
NCBI chr 1:101,448,190...101,450,034
Ensembl chr 1:101,448,346...101,449,829
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions decreases expression |
ISO |
ferrous sulfate promotes the reaction [SNCA protein results in decreased expression of GCLC protein] ferrous sulfate results in decreased expression of GCLC protein |
CTD |
PMID:27424009 |
|
NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
decreases response to substance |
ISO |
GDNF protein results in decreased susceptibility to ferrous sulfate |
CTD |
PMID:17935603 |
|
NCBI chr 2:56,884,181...56,912,964
Ensembl chr 2:56,887,987...56,910,238
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
increases expression multiple interactions |
EXP |
ferrous sulfate results in increased expression of GPX1 protein 2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased expression of GPX1 protein] |
CTD |
PMID:28583816 |
|
NCBI chr 8:117,117,430...117,118,528
Ensembl chr 8:117,117,430...117,118,522
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
increases phosphorylation |
EXP |
ferrous sulfate results in increased phosphorylation of GSK3B protein |
CTD |
PMID:19608791 |
|
NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
|
|
G |
H2ax |
H2A.X variant histone |
increases expression multiple interactions |
EXP |
ferrous sulfate results in increased expression of H2AX protein 2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased expression of H2AX protein] |
CTD |
PMID:28583816 |
|
NCBI chr 8:48,665,652...48,666,981
Ensembl chr 8:48,665,652...48,666,981
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
ISO |
ferrous sulfate inhibits the reaction [Chromium results in increased expression of HIF1A protein]; ferrous sulfate inhibits the reaction [Cobalt results in increased expression of HIF1A protein]; ferrous sulfate inhibits the reaction [galangin results in increased expression of HIF1A protein]; ferrous sulfate inhibits the reaction [Nickel results in increased expression of HIF1A protein]; ferrous sulfate inhibits the reaction [Quercetin results in increased expression of HIF1A protein] |
CTD |
PMID:16386771 PMID:17973296 |
|
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO EXP |
ferrous sulfate inhibits the reaction [2,2'-Dipyridyl analog inhibits the reaction [Cadmium Chloride results in increased expression of HMOX1 mRNA]]; ferrous sulfate inhibits the reaction [2,2'-Dipyridyl analog inhibits the reaction [Cadmium Chloride results in increased expression of HMOX1 protein]]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [Cadmium Chloride results in increased activity of HMOX1 protein]]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [Cadmium Chloride results in increased expression of HMOX1 mRNA]]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [phenethyl isothiocyanate results in increased expression of HMOX1 mRNA]]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [phenethyl isothiocyanate results in increased expression of HMOX1 protein]]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [sulforafan results in increased expression of HMOX1 mRNA]] 2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased expression of HMOX1 protein] |
CTD |
PMID:20934533 PMID:26945724 PMID:28583816 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
affects localization multiple interactions |
EXP |
ferrous sulfate affects the localization of HRAS protein ferrous sulfate promotes the reaction [MAP3K7 protein binds to HRAS protein binds to PIK3R1 protein]; HRAS protein affects the reaction [ferrous sulfate results in increased phosphorylation of AKT1 protein]; HRAS protein affects the reaction [ferrous sulfate results in increased phosphorylation of MAPK1 protein]; HRAS protein affects the reaction [ferrous sulfate results in increased phosphorylation of MAPK3 protein]; HRAS protein affects the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:17172471 |
|
NCBI chr 1:214,178,404...214,181,841
Ensembl chr 1:214,178,407...214,181,686
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
multiple interactions |
ISO |
ferrous sulfate inhibits the reaction [Quercetin promotes the reaction [ERBB2 protein binds to HSP90AA1 protein]] |
CTD |
PMID:18655187 |
|
NCBI chr 6:135,107,262...135,112,793
Ensembl chr 6:135,107,271...135,112,775
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions |
EXP |
deferiprone inhibits the reaction [ferrous sulfate results in increased activity of [CHUK protein binds to IKBKB protein]]; ferrous sulfate results in increased activity of [CHUK protein binds to IKBKB protein]; Filipin inhibits the reaction [ferrous sulfate results in increased activity of [CHUK protein binds to IKBKB protein]]; N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid inhibits the reaction [ferrous sulfate results in increased activity of [CHUK protein binds to IKBKB protein]] |
CTD |
PMID:17172471 |
|
NCBI chr16:74,177,233...74,230,809
Ensembl chr16:74,177,215...74,230,815
|
|
G |
Il10rb |
interleukin 10 receptor subunit beta |
decreases expression |
ISO |
ferrous sulfate results in decreased expression of IL10RB mRNA |
CTD |
PMID:19428942 |
|
NCBI chr11:31,560,301...31,582,457
Ensembl chr11:31,560,530...31,582,457
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression |
ISO EXP |
[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of IL1B mRNA; [Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of IL1B protein; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of IL1B mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of IL1B protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of IL1B mRNA]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of IL1B protein] 2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased expression of IL1B protein] |
CTD |
PMID:23692848 PMID:28583816 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il1rn |
interleukin 1 receptor antagonist |
increases expression |
ISO |
ferrous sulfate results in increased expression of IL1RN mRNA |
CTD |
PMID:19428942 |
|
NCBI chr 3:1,449,778...1,468,624
Ensembl chr 3:1,452,644...1,468,614
|
|
G |
Il36rn |
interleukin 36 receptor antagonist |
decreases expression |
ISO |
ferrous sulfate results in decreased expression of IL36RN mRNA |
CTD |
PMID:19428942 |
|
NCBI chr 3:1,385,256...1,392,275
Ensembl chr 3:1,385,654...1,392,275
|
|
G |
Il4 |
interleukin 4 |
increases expression |
ISO |
ferrous sulfate results in increased expression of IL4 protein |
CTD |
PMID:15963385 |
|
NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
|
|
G |
Il6 |
interleukin 6 |
decreases expression |
ISO |
ferrous sulfate results in decreased expression of IL6 protein |
CTD |
PMID:17119383 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
ferrous sulfate results in increased expression of JUN mRNA |
CTD |
PMID:21540303 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Klk1 |
kallikrein 1 |
decreases activity |
ISO |
ferrous sulfate results in decreased activity of KLK1 protein |
CTD |
PMID:6421970 |
|
NCBI chr 1:100,131,562...100,135,556
Ensembl chr 1:100,059,967...100,203,329 Ensembl chr 1:100,059,967...100,203,329 Ensembl chr 1:100,059,967...100,203,329
|
|
G |
Lep |
leptin |
increases expression |
ISO |
ferrous sulfate results in increased expression of LEP mRNA |
CTD |
PMID:21540303 |
|
NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
|
|
G |
Lta |
lymphotoxin alpha |
increases expression decreases expression |
ISO |
ferrous sulfate results in increased expression of LTA mRNA ferrous sulfate results in decreased expression of LTA mRNA |
CTD |
PMID:19428942 PMID:21540303 |
|
NCBI chr20:4,851,889...4,854,677
Ensembl chr20:4,852,496...4,854,677
|
|
G |
Map2k6 |
mitogen-activated protein kinase kinase 6 |
multiple interactions increases phosphorylation |
EXP |
ferrous sulfate promotes the reaction [MAP3K7 protein results in increased phosphorylation of MAP2K6 protein]; Filipin inhibits the reaction [ferrous sulfate promotes the reaction [MAP3K7 protein results in increased phosphorylation of MAP2K6 protein]]; Filipin inhibits the reaction [ferrous sulfate results in increased phosphorylation of MAP2K6 protein] |
CTD |
PMID:17172471 |
|
NCBI chr10:98,707,160...98,823,054
Ensembl chr10:98,706,960...98,823,287
|
|
G |
Map3k14 |
mitogen-activated protein kinase kinase kinase 14 |
multiple interactions |
EXP |
MAP3K14 protein affects the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein]; MAP3K14 protein affects the reaction [ferrous sulfate results in increased secretion of TNF protein] |
CTD |
PMID:17172471 |
|
NCBI chr10:91,303,428...91,353,601
Ensembl chr10:91,303,428...91,353,601
|
|
G |
Map3k7 |
mitogen activated protein kinase kinase kinase 7 |
affects localization increases activity multiple interactions |
EXP |
ferrous sulfate affects the localization of MAP3K7 protein ferrous sulfate results in increased activity of MAP3K7 protein ferrous sulfate promotes the reaction [MAP3K7 protein binds to HRAS protein binds to PIK3R1 protein]; ferrous sulfate promotes the reaction [MAP3K7 protein results in increased phosphorylation of MAP2K6 protein]; Filipin inhibits the reaction [ferrous sulfate promotes the reaction [MAP3K7 protein results in increased phosphorylation of MAP2K6 protein]]; Filipin inhibits the reaction [ferrous sulfate results in increased activity of MAP3K7 protein]; MAP3K7 protein affects the reaction [ferrous sulfate results in increased phosphorylation of AKT1 protein]; MAP3K7 protein affects the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein]; MAP3K7 protein affects the reaction [ferrous sulfate results in increased secretion of TNF protein] |
CTD |
PMID:17172471 |
|
NCBI chr 5:47,183,142...47,244,424
Ensembl chr 5:47,186,558...47,244,416
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ferrous sulfate results in increased phosphorylation of MAPK1 protein]; Deferiprone inhibits the reaction [ferrous sulfate results in increased phosphorylation of MAPK1 protein]; Filipin inhibits the reaction [ferrous sulfate results in increased phosphorylation of MAPK1 protein]; HRAS protein affects the reaction [ferrous sulfate results in increased phosphorylation of MAPK1 protein]; PIK3R1 protein affects the reaction [ferrous sulfate results in increased phosphorylation of MAPK1 protein]; SB 203580 promotes the reaction [ferrous sulfate results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [ferrous sulfate results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:17172471 PMID:19608791 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ferrous sulfate results in increased phosphorylation of MAPK3 protein]; deferiprone inhibits the reaction [ferrous sulfate results in increased phosphorylation of MAPK3 protein]; Filipin inhibits the reaction [ferrous sulfate results in increased phosphorylation of MAPK3 protein]; HRAS protein affects the reaction [ferrous sulfate results in increased phosphorylation of MAPK3 protein]; PIK3R1 protein affects the reaction [ferrous sulfate results in increased phosphorylation of MAPK3 protein]; SB 203580 promotes the reaction [ferrous sulfate results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [ferrous sulfate results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:17172471 PMID:19608791 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mir146a |
microRNA 146a |
multiple interactions |
ISO |
[ferrous sulfate co-treated with aluminum sulfate] results in increased expression of MIR146A mRNA; Curcumin inhibits the reaction [[ferrous sulfate co-treated with aluminum sulfate] results in increased expression of MIR146A mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [[ferrous sulfate co-treated with aluminum sulfate] results in increased expression of MIR146A mRNA]; Resveratrol analog inhibits the reaction [[ferrous sulfate co-treated with aluminum sulfate] results in increased expression of MIR146A mRNA] |
CTD |
PMID:22099153 |
|
NCBI chr10:28,962,476...28,962,570
Ensembl chr10:28,962,476...28,962,570
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
multiple interactions increases expression |
ISO EXP |
[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of MMP13 mRNA; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of MMP13 mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of MMP13 protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of MMP13 mRNA]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of MMP13 protein] Diltiazem promotes the reaction [ferrous sulfate results in increased expression of MMP13 protein]; Nimodipine promotes the reaction [ferrous sulfate results in increased expression of MMP13 protein]; Verapamil promotes the reaction [ferrous sulfate results in increased expression of MMP13 protein] |
CTD |
PMID:23692848 PMID:27095094 |
|
NCBI chr 8:5,522,739...5,533,018
Ensembl chr 8:5,522,739...5,533,018
|
|
G |
Mt1 |
metallothionein 1 |
increases expression multiple interactions |
EXP |
ferrous sulfate results in increased expression of MT1A mRNA [Zinc Sulfate co-treated with ferrous sulfate] results in increased expression of and affects the localization of MT1A protein; ferrous sulfate results in increased expression of and affects the localization of MT1A protein |
CTD |
PMID:17241390 PMID:19679144 |
|
NCBI chr19:11,301,991...11,303,007
Ensembl chr17:78,793,336...78,793,724
|
|
G |
Mt2A |
metallothionein 2A |
multiple interactions |
EXP |
[Zinc Sulfate co-treated with ferrous sulfate] results in increased expression of and affects the localization of MT2A protein; ferrous sulfate results in increased expression of and affects the localization of MT2A protein |
CTD |
PMID:17241390 |
|
NCBI chr19:11,307,966...11,308,740
Ensembl chr19:11,307,967...11,308,740
|
|
G |
Myb |
MYB proto-oncogene, transcription factor |
multiple interactions |
EXP |
[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of MYB protein |
CTD |
PMID:7593635 |
|
NCBI chr 1:16,658,178...16,690,135
Ensembl chr 1:16,659,442...16,687,817
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
multiple interactions increases expression |
ISO EXP |
ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [Ethacrynic Acid affects the localization of NFE2L2 protein]]; ferrous sulfate inhibits the reaction [Deferoxamine inhibits the reaction [phenethyl isothiocyanate results in increased expression of and affects the localization of NFE2L2 protein]] ferrous sulfate results in increased expression of NFE2L2 mRNA 2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased expression of NFE2L2 mRNA]; 2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased expression of NFE2L2 protein]; Acetylcysteine inhibits the reaction [ferrous sulfate affects the localization of NFE2L2 protein]; ferrous sulfate results in increased expression of and affects the localization of NFE2L2 protein |
CTD |
PMID:26945724 PMID:28583816 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of [NFKB1 protein binds to RELA protein]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of [NFKB1 protein binds to RELA protein]]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of [NFKB1 protein binds to RELA protein]] [Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of NFKB1 protein; [ferrous sulfate co-treated with aluminum sulfate] results in increased expression of and results in increased activity of [RELA protein binds to NFKB1 protein]; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of NFKB1 protein] |
CTD |
PMID:17879260 PMID:22099153 PMID:23692848 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions increases phosphorylation |
EXP ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein]; 2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein]; Acetylcysteine inhibits the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein]; HRAS protein affects the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein]; MAP3K14 protein affects the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein]; MAP3K7 protein affects the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein]; PIK3R1 protein affects the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein]; SB 203580 promotes the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein]; U 0126 inhibits the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein] [Ascorbic Acid co-treated with ferrous sulfate] results in decreased expression of NFKBIA protein; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in decreased expression of NFKBIA protein] |
CTD |
PMID:17172471 PMID:17879260 PMID:28583816 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of NOS2 mRNA; [Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of NOS2 protein; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of NOS2 mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of NOS2 protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of NOS2 mRNA]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of NOS2 protein] |
CTD |
PMID:23692848 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression multiple interactions |
EXP |
ferrous sulfate results in increased expression of NQO1 protein 2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased expression of NQO1 protein] |
CTD |
PMID:28583816 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Pik3r1 |
phosphoinositide-3-kinase regulatory subunit 1 |
multiple interactions |
EXP |
ferrous sulfate promotes the reaction [MAP3K7 protein binds to HRAS protein binds to PIK3R1 protein]; PIK3R1 protein affects the reaction [ferrous sulfate results in increased phosphorylation of AKT1 protein]; PIK3R1 protein affects the reaction [ferrous sulfate results in increased phosphorylation of MAPK1 protein]; PIK3R1 protein affects the reaction [ferrous sulfate results in increased phosphorylation of MAPK3 protein]; PIK3R1 protein affects the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein]; PIK3R1 protein affects the reaction [ferrous sulfate results in increased secretion of TNF protein] |
CTD |
PMID:17172471 |
|
NCBI chr 2:31,742,326...31,826,882
Ensembl chr 2:31,745,088...31,826,867
|
|
G |
Pmepa1 |
prostate transmembrane protein, androgen induced 1 |
increases expression |
ISO |
ferrous sulfate results in increased expression of PMEPA1 mRNA |
CTD |
PMID:21540303 |
|
NCBI chr 3:171,295,630...171,342,662
Ensembl chr 3:171,294,856...171,342,646
|
|
G |
Pon1 |
paraoxonase 1 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with ferrous sulfate] inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; [Ascorbic Acid co-treated with ferrous sulfate] inhibits the reaction [PON1 protein results in increased hydrolysis of phenylacetic acid]; [Ascorbic Acid co-treated with ferrous sulfate] results in decreased activity of PON1 protein |
CTD |
PMID:12871208 PMID:15375178 |
|
NCBI chr 4:30,249,749...30,276,297
Ensembl chr 4:30,249,742...30,276,372
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression multiple interactions |
EXP |
ferrous sulfate results in increased expression of PTGS2 protein 2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased expression of PTGS2 protein] |
CTD |
PMID:28583816 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions affects localization |
ISO EXP |
[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of [NFKB1 protein binds to RELA protein]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of [NFKB1 protein binds to RELA protein]]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of [NFKB1 protein binds to RELA protein]] ferrous sulfate affects the localization of RELA protein 2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate affects the localization of RELA protein]; Acetylcysteine inhibits the reaction [ferrous sulfate affects the localization of RELA protein] [Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of RELA protein; [ferrous sulfate co-treated with aluminum sulfate] results in increased expression of and results in increased activity of [RELA protein binds to NFKB1 protein]; [Hyaluronic Acid co-treated with Chondroitin Sulfates] inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased activity of RELA protein] |
CTD |
PMID:17879260 PMID:22099153 PMID:23692848 PMID:28583816 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Selplg |
selectin P ligand |
increases expression |
ISO |
ferrous sulfate results in increased expression of SELPLG mRNA |
CTD |
PMID:21540303 |
|
NCBI chr12:48,577,905...48,579,196
Ensembl chr12:48,577,905...48,579,196
|
|
G |
Slc11a2 |
solute carrier family 11 member 2 |
decreases expression |
ISO |
ferrous sulfate results in decreased expression of SLC11A2 mRNA |
CTD |
PMID:10966897 |
|
NCBI chr 7:142,025,812...142,062,892
Ensembl chr 7:142,025,815...142,063,212
|
|
G |
Slc40a1 |
solute carrier family 40 member 1 |
multiple interactions |
ISO |
SLC40A1 protein inhibits the reaction [ferrous sulfate results in increased abundance of Reactive Oxygen Species]; SLC40A1 protein inhibits the reaction [ferrous sulfate results in increased uptake of Iron] |
CTD |
PMID:19913091 |
|
NCBI chr 9:52,819,451...52,830,461
Ensembl chr 9:52,894,365...52,912,293
|
|
G |
Snca |
synuclein alpha |
multiple interactions |
ISO |
ferrous sulfate inhibits the reaction [SNCA protein results in decreased abundance of Glutathione]; ferrous sulfate inhibits the reaction [SNCA protein results in decreased expression of SOD1 protein]; ferrous sulfate promotes the reaction [SNCA protein results in decreased activity of SOD1 protein]; ferrous sulfate promotes the reaction [SNCA protein results in decreased expression of GCLC protein]; ferrous sulfate promotes the reaction [SNCA protein results in increased abundance of Reactive Oxygen Species] |
CTD |
PMID:27424009 |
|
NCBI chr 4:90,782,412...90,883,236
Ensembl chr 4:90,782,374...90,882,285
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions decreases activity |
ISO |
ferrous sulfate inhibits the reaction [SNCA protein results in decreased expression of SOD1 protein]; ferrous sulfate promotes the reaction [SNCA protein results in decreased activity of SOD1 protein] ferrous sulfate results in decreased activity of SOD1 protein |
CTD |
PMID:27424009 |
|
NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
|
|
G |
Sod2 |
superoxide dismutase 2 |
increases activity decreases expression |
ISO |
ferrous sulfate results in increased activity of SOD2 protein ferrous sulfate results in decreased expression of SOD2 protein |
CTD |
PMID:27424009 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
decreases expression |
ISO |
ferrous sulfate results in decreased expression of SPP1 mRNA |
CTD |
PMID:19428942 |
|
NCBI chr14:6,673,686...6,679,965
Ensembl chr14:6,673,686...6,679,901
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
increases phosphorylation |
EXP |
ferrous sulfate results in increased phosphorylation of STAT1 protein |
CTD |
PMID:17607690 |
|
NCBI chr 9:54,287,540...54,327,958
Ensembl chr 9:54,287,541...54,484,533
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
[ferrous sulfate co-treated with Copper Sulfate] promotes the reaction [Hydrogen Peroxide affects the localization of STAT3 protein] |
CTD |
PMID:10364193 |
|
NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
|
|
G |
Tas1r3 |
taste 1 receptor member 3 |
affects response to substance |
ISO |
TAS1R3 protein affects the susceptibility to ferrous sulfate |
CTD |
PMID:19244541 |
|
NCBI chr 5:173,307,325...173,312,950
Ensembl chr 5:173,308,870...173,312,023
|
|
G |
Tf |
transferrin |
multiple interactions increases expression |
ISO EXP |
ferrous sulfate promotes the reaction [TF protein results in increased uptake of Iron] ferrous sulfate results in increased expression of TF protein |
CTD |
PMID:11335103 PMID:28993186 |
|
NCBI chr 8:111,694,570...111,721,275
Ensembl chr 8:111,673,547...111,721,333
|
|
G |
Tfrc |
transferrin receptor |
decreases expression |
ISO EXP |
ferrous sulfate results in decreased expression of TFRC mRNA ferrous sulfate results in decreased expression of TFRC protein |
CTD |
PMID:10966897 PMID:16039939 PMID:28993186 |
|
NCBI chr11:71,397,423...71,419,263
Ensembl chr11:71,397,383...71,419,223
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions increases expression |
EXP |
Diltiazem inhibits the reaction [ferrous sulfate results in increased expression of TIMP1 protein]; Nimodipine inhibits the reaction [ferrous sulfate results in increased expression of TIMP1 protein]; Verapamil inhibits the reaction [ferrous sulfate results in increased expression of TIMP1 protein] |
CTD |
PMID:27095094 |
|
NCBI chr X:1,364,771...1,369,451
Ensembl chr X:1,364,786...1,369,384
|
|
G |
Tlr2 |
toll-like receptor 2 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR2 mRNA; [Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR2 protein; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR2 mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR2 protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR2 mRNA]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR2 protein] |
CTD |
PMID:23692848 |
|
NCBI chr 2:182,840,171...182,846,061
Ensembl chr 2:182,840,727...182,846,061
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR4 mRNA; [Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR4 protein; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR4 mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR4 protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR4 mRNA]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TLR4 protein] |
CTD |
PMID:23692848 |
|
NCBI chr 5:82,587,424...82,601,056
Ensembl chr 5:82,587,420...82,601,052
|
|
G |
Tnf |
tumor necrosis factor |
increases expression multiple interactions increases secretion |
ISO EXP |
ferrous sulfate results in increased expression of TNF mRNA; ferrous sulfate results in increased expression of TNF protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ferrous sulfate results in increased secretion of TNF protein]; 2-tert-butylhydroquinone inhibits the reaction [ferrous sulfate results in increased expression of TNF protein]; Dimethyl Sulfoxide inhibits the reaction [ferrous sulfate promotes the reaction [Hydrogen Peroxide results in increased secretion of TNF protein]]; ferrous sulfate promotes the reaction [Hydrogen Peroxide results in increased secretion of TNF protein]; MAP3K14 protein affects the reaction [ferrous sulfate results in increased secretion of TNF protein]; MAP3K7 protein affects the reaction [ferrous sulfate results in increased secretion of TNF protein]; PIK3R1 protein affects the reaction [ferrous sulfate results in increased secretion of TNF protein]; tetramethylthiourea inhibits the reaction [ferrous sulfate promotes the reaction [Hydrogen Peroxide results in increased secretion of TNF protein]]; U 0126 inhibits the reaction [ferrous sulfate results in increased secretion of TNF protein] [Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TNF mRNA; [Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TNF protein; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TNF mRNA]; CAT protein inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TNF protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TNF mRNA]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Ascorbic Acid co-treated with ferrous sulfate] results in increased expression of TNF protein] ferrous sulfate inhibits the reaction [Deferoxamine results in decreased activity of TNF protein]; ferrous sulfate inhibits the reaction [Mimosine results in decreased activity of TNF protein] |
CTD |
PMID:7539275 PMID:15550384 PMID:15963385 PMID:17172471 PMID:19428942 PMID:21540303 PMID:23692848 PMID:28583816 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Trpm5 |
transient receptor potential cation channel, subfamily M, member 5 |
affects response to substance |
ISO |
TRPM5 protein affects the susceptibility to ferrous sulfate |
CTD |
PMID:19244541 |
|
NCBI chr 1:216,256,653...216,281,504
Ensembl chr 1:216,257,820...216,274,930
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
increases activity |
ISO |
ferrous sulfate results in increased activity of TRPV1 protein |
CTD |
PMID:17567713 |
|
NCBI chr10:59,799,123...59,824,208
Ensembl chr10:59,799,123...59,824,679
|
|
G |
Xcr1 |
X-C motif chemokine receptor 1 |
decreases expression |
ISO |
ferrous sulfate results in decreased expression of XCR1 mRNA |
CTD |
PMID:19428942 |
|
NCBI chr 8:132,911,474...132,919,110
Ensembl chr 8:132,911,486...132,919,110
|
|
|
G |
Aco1 |
aconitase 1 |
multiple interactions |
ISO |
ferric sulfate inhibits the reaction [Nickel results in increased activity of ACO1 protein] |
CTD |
PMID:16877034 |
|
NCBI chr 5:56,425,076...56,481,218
Ensembl chr 5:56,425,024...56,481,218
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
multiple interactions increases activity |
EXP |
Capsaicin inhibits the reaction [ferric sulfate results in increased activity of GOT1 protein]; Curcumin inhibits the reaction [ferric sulfate results in increased activity of GOT1 protein] |
CTD |
PMID:16956363 |
|
NCBI chr 1:263,246,248...263,269,762
Ensembl chr 1:263,246,248...263,269,762
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions increases activity |
EXP |
Capsaicin inhibits the reaction [ferric sulfate results in increased activity of GPT protein]; Curcumin inhibits the reaction [ferric sulfate results in increased activity of GPT protein] |
CTD |
PMID:16956363 |
|
NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
ISO |
ferric sulfate inhibits the reaction [Nickel results in increased stability of HIF1A protein] |
CTD |
PMID:16877034 |
|
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
|
|
|
G |
Alb |
albumin |
increases secretion multiple interactions increases expression |
ISO |
ferric citrate results in increased secretion of ALB protein Alcohols inhibits the reaction [ferric citrate results in increased expression of ALB mRNA]; Alcohols inhibits the reaction [ferric citrate results in increased secretion of ALB protein]; ferric citrate inhibits the reaction [Alcohols results in increased expression of ALB mRNA]; ferric citrate inhibits the reaction [Alcohols results in increased secretion of ALB protein] |
CTD |
PMID:24025710 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Aldob |
aldolase, fructose-bisphosphate B |
increases expression multiple interactions |
ISO |
ferric citrate results in increased expression of ALDOB mRNA Alcohols inhibits the reaction [ferric citrate results in increased expression of ALDOB mRNA]; ferric citrate inhibits the reaction [Alcohols results in increased expression of ALDOB mRNA] |
CTD |
PMID:24025710 |
|
NCBI chr 5:64,805,772...64,818,813
Ensembl chr 5:64,805,773...64,818,824
|
|
G |
Aqp4 |
aquaporin 4 |
decreases expression |
ISO |
ferric citrate results in decreased expression of AQP4 mRNA |
CTD |
PMID:29959986 |
|
NCBI chr18:6,766,009...6,782,757
Ensembl chr18:6,765,945...6,782,996
|
|
G |
Ca9 |
carbonic anhydrase 9 |
decreases expression |
ISO |
ferric citrate results in decreased expression of CA9 mRNA |
CTD |
PMID:29959986 |
|
NCBI chr 5:59,008,277...59,015,535
Ensembl chr 5:59,008,933...59,015,528
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression |
ISO |
ferric citrate results in decreased expression of CCL2 mRNA |
CTD |
PMID:29959986 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Cftr |
CF transmembrane conductance regulator |
decreases expression |
ISO |
ferric citrate results in decreased expression of CFTR mRNA |
CTD |
PMID:29959986 |
|
NCBI chr 4:42,693,263...42,860,679
Ensembl chr 4:42,692,836...42,860,676
|
|
G |
Crp |
C-reactive protein |
increases expression |
ISO |
ferric citrate results in increased expression of CRP mRNA |
CTD |
PMID:29959986 |
|
NCBI chr13:91,080,448...91,081,358
Ensembl chr13:91,054,974...91,093,713
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions increases expression |
ISO |
Alcohols inhibits the reaction [ferric citrate results in increased expression of CYP2E1 mRNA]; ferric citrate inhibits the reaction [Alcohols results in increased expression of CYP2E1 mRNA] |
CTD |
PMID:24025710 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
increases expression multiple interactions |
ISO |
ferric citrate results in increased expression of CYP3A4 mRNA; ferric citrate results in increased expression of CYP3A4 protein Alcohols inhibits the reaction [ferric citrate results in increased expression of CYP3A4 mRNA]; Alcohols promotes the reaction [ferric citrate results in increased expression of CYP3A4 protein]; ferric citrate inhibits the reaction [Alcohols results in increased expression of CYP3A4 mRNA]; ferric citrate promotes the reaction [Alcohols results in increased expression of CYP3A4 protein] |
CTD |
PMID:24025710 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
[trigonelline co-treated with ferric citrate] results in increased expression of DDIT3 mRNA |
CTD |
PMID:29959986 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Edn1 |
endothelin 1 |
decreases expression |
ISO |
ferric citrate results in decreased expression of EDN1 mRNA |
CTD |
PMID:29959986 |
|
NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
|
|
G |
Epo |
erythropoietin |
increases expression |
ISO |
ferric citrate results in increased expression of EPO mRNA |
CTD |
PMID:29959986 |
|
NCBI chr12:22,274,828...22,278,268
Ensembl chr12:22,274,828...22,278,266
|
|
G |
F10 |
coagulation factor X |
decreases activity |
ISO |
ferric citrate results in decreased activity of F10 protein |
CTD |
PMID:6421970 |
|
NCBI chr16:81,803,169...81,822,476
Ensembl chr16:81,803,110...81,822,716
|
|
G |
F2 |
coagulation factor II |
decreases activity |
ISO |
ferric citrate results in decreased activity of F2 protein |
CTD |
PMID:6421970 |
|
NCBI chr 3:80,529,468...80,542,993
Ensembl chr 3:80,529,428...80,543,031
|
|
G |
Fth1 |
ferritin heavy chain 1 |
increases expression multiple interactions |
ISO |
ferric citrate results in increased expression of FTH1 mRNA [trigonelline co-treated with ferric citrate] results in increased expression of FTH1 mRNA |
CTD |
PMID:29959986 |
|
NCBI chr 1:226,030,940...226,033,228
Ensembl chr 1:226,030,938...226,033,228
|
|
G |
Ftl1 |
ferritin light chain 1 |
multiple interactions |
ISO |
[trigonelline co-treated with ferric citrate] results in increased expression of FTL mRNA |
CTD |
PMID:29959986 |
|
NCBI chr 1:101,448,190...101,450,034
Ensembl chr 1:101,448,346...101,449,829
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression |
ISO |
ferric citrate results in increased expression of GCLM mRNA |
CTD |
PMID:29959986 |
|
NCBI chr 2:225,827,504...225,847,876
Ensembl chr 2:225,827,504...225,847,874
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
ISO |
ferric citrate inhibits the reaction [Deferoxamine results in increased expression of HIF1A protein] ferric citrate inhibits the reaction [Deferoxamine results in increased expression of HIF1A protein]; ferric citrate inhibits the reaction [Quercetin results in increased expression of HIF1A mRNA]; ferric citrate inhibits the reaction [Quercetin results in increased expression of HIF1A protein] |
CTD |
PMID:16527254 PMID:17015263 PMID:17364964 |
|
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
ferric citrate results in increased expression of HMOX1 mRNA |
CTD |
PMID:29959986 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Il1a |
interleukin 1 alpha |
decreases expression |
ISO |
ferric citrate results in decreased expression of IL1A mRNA |
CTD |
PMID:29959986 |
|
NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
ISO |
[trigonelline co-treated with ferric citrate] results in decreased expression of KEAP1 mRNA |
CTD |
PMID:29959986 |
|
NCBI chr 8:22,250,518...22,259,868
Ensembl chr 8:22,250,518...22,259,779
|
|
G |
Klk1 |
kallikrein 1 |
decreases activity |
ISO |
ferric citrate results in decreased activity of KLK1 protein |
CTD |
PMID:6421970 |
|
NCBI chr 1:100,131,562...100,135,556
Ensembl chr 1:100,059,967...100,203,329 Ensembl chr 1:100,059,967...100,203,329 Ensembl chr 1:100,059,967...100,203,329
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
affects localization multiple interactions |
ISO |
ferric citrate affects the localization of NFE2L2 protein trigonelline inhibits the reaction [ferric citrate affects the localization of NFE2L2 protein] |
CTD |
PMID:29959986 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression multiple interactions |
ISO |
ferric citrate results in increased expression of NQO1 mRNA; ferric citrate results in increased expression of NQO1 protein trigonelline inhibits the reaction [ferric citrate results in increased expression of NQO1 protein] |
CTD |
PMID:29959986 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
ferric citrate inhibits the reaction [Deferoxamine results in increased expression of PTGS2 protein] |
CTD |
PMID:16527254 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Serpine1 |
serpin family E member 1 |
decreases expression |
ISO |
ferric citrate results in decreased expression of SERPINE1 mRNA |
CTD |
PMID:29959986 |
|
NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
|
|
G |
Sqstm1 |
sequestosome 1 |
increases expression |
ISO |
ferric citrate results in increased expression of SQSTM1 mRNA |
CTD |
PMID:29959986 |
|
NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
|
|
G |
Tf |
transferrin |
increases expression |
ISO |
ferric citrate results in increased expression of TF mRNA |
CTD |
PMID:24025710 |
|
NCBI chr 8:111,694,570...111,721,275
Ensembl chr 8:111,673,547...111,721,333
|
|
G |
Tfrc |
transferrin receptor |
increases expression multiple interactions |
ISO |
ferric citrate results in increased expression of TFRC protein ferric citrate inhibits the reaction [Quercetin results in increased expression of TFRC protein] |
CTD |
PMID:17364964 PMID:29959986 |
|
NCBI chr11:71,397,423...71,419,263
Ensembl chr11:71,397,383...71,419,223
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression |
ISO |
ferric citrate results in decreased expression of TNF mRNA |
CTD |
PMID:29959986 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
increases expression |
ISO |
ferric citrate results in increased expression of TXNRD1 mRNA |
CTD |
PMID:29959986 |
|
NCBI chr 7:26,946,124...26,984,400
Ensembl chr 7:26,946,125...26,984,400
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
ISO |
ferric nitrilotriacetate inhibits the reaction [Asbestos, Crocidolite results in increased expression of ABCB1 protein]; ferric nitrilotriacetate inhibits the reaction [Razoxane results in increased expression of ABCB1 protein] |
CTD |
PMID:18385176 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of ABCC1 mRNA |
CTD |
PMID:18617210 |
|
NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of ABCC2 mRNA |
CTD |
PMID:18617210 |
|
NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of ABCC4 mRNA |
CTD |
PMID:18617210 |
|
NCBI chr15:103,695,415...103,927,980
Ensembl chr15:103,696,557...103,927,592
|
|
G |
Anxa2 |
annexin A2 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of ANXA2 mRNA |
CTD |
PMID:10854235 |
|
NCBI chr 8:75,687,134...75,723,589
Ensembl chr 8:75,687,100...75,723,594
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of BAX mRNA |
CTD |
PMID:23208426 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of BBC3 mRNA |
CTD |
PMID:23208426 |
|
NCBI chr 1:78,261,491...78,267,802
|
|
G |
Bik |
BCL2-interacting killer |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of BIK mRNA |
CTD |
PMID:23208426 |
|
NCBI chr 7:124,390,924...124,410,449
Ensembl chr 7:124,391,432...124,410,447
|
|
G |
Cald1 |
caldesmon 1 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of CALD1 mRNA |
CTD |
PMID:10854235 |
|
NCBI chr 4:62,103,948...62,291,375
Ensembl chr 4:62,220,736...62,291,489
|
|
G |
Canx |
calnexin |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of CANX protein |
CTD |
PMID:16908007 |
|
NCBI chr10:35,800,942...35,833,939
Ensembl chr10:35,800,942...35,833,861
|
|
G |
Casp12 |
caspase 12 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of CASP12 mRNA |
CTD |
PMID:23208426 |
|
NCBI chr 8:2,658,892...2,686,160
Ensembl chr 8:2,659,865...2,686,160
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased cleavage of and results in decreased expression of CASP3 protein; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased expression of CASP3 mRNA; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased cleavage of and results in decreased expression of CASP3 protein]; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased expression of CASP3 mRNA] |
CTD |
PMID:21907755 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
EXP |
[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased cleavage of and results in decreased expression of CASP8 protein; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased expression of CASP8 mRNA; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased cleavage of and results in decreased expression of CASP8 protein]; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased expression of CASP8 mRNA] |
CTD |
PMID:21907755 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP |
[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased cleavage of and results in decreased expression of CASP9 protein; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased expression of CASP9 mRNA; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased cleavage of and results in decreased expression of CASP9 protein]; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased expression of CASP9 mRNA] |
CTD |
PMID:21907755 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cat |
catalase |
multiple interactions decreases activity |
EXP |
[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in decreased activity of CAT protein; chrysin inhibits the reaction [ferric nitrilotriacetate results in decreased activity of CAT protein]; geraniol inhibits the reaction [ferric nitrilotriacetate results in decreased activity of CAT protein]; Hesperidin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in decreased activity of CAT protein]; Quercetin inhibits the reaction [ferric nitrilotriacetate results in decreased activity of CAT protein] |
CTD |
PMID:9667754 PMID:15198074 PMID:18684806 PMID:21907755 PMID:23194824 PMID:30098279 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of CCND1 mRNA; ferric nitrilotriacetate results in increased expression of CCND1 protein |
CTD |
PMID:18055543 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Cd44 |
CD44 molecule (Indian blood group) |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of CD44 mRNA; ferric nitrilotriacetate results in increased expression of CD44 protein |
CTD |
PMID:18055543 |
|
NCBI chr 3:92,695,083...92,783,820
Ensembl chr 3:92,696,313...92,783,658
|
|
G |
Cd47 |
Cd47 molecule |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of CD47 mRNA |
CTD |
PMID:9119739 |
|
NCBI chr11:53,511,485...53,575,754
Ensembl chr11:53,514,595...53,575,175
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of CDKN1A mRNA |
CTD |
PMID:23208426 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
decreases expression |
EXP |
ferric nitrilotriacetate results in decreased expression of CHRM1 mRNA |
CTD |
PMID:19490752 |
|
NCBI chr 1:224,869,087...224,885,101
Ensembl chr 1:224,882,439...224,884,205
|
|
G |
Chrm2 |
cholinergic receptor, muscarinic 2 |
decreases expression |
EXP |
ferric nitrilotriacetate results in decreased expression of CHRM2 mRNA |
CTD |
PMID:19490752 |
|
NCBI chr 4:64,089,028...64,091,090
Ensembl chr 4:64,088,900...64,091,090
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression multiple interactions |
EXP |
ferric nitrilotriacetate results in increased expression of COL1A1 protein ethylisopropylamiloride inhibits the reaction [ferric nitrilotriacetate results in increased expression of COL1A1 protein] |
CTD |
PMID:11159895 |
|
NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
|
|
G |
Cygb |
cytoglobin |
multiple interactions |
EXP |
CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TGFB1 mRNA]; CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TIMP1 mRNA]; CYGB protein results in decreased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid] |
CTD |
PMID:16581302 |
|
NCBI chr10:105,618,325...105,628,091
Ensembl chr10:105,618,326...105,628,091
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO |
[[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT18 protein; [[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT8 protein; [Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein; allyl sulfide inhibits the reaction [CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]]; CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]; Ditiocarb inhibits the reaction [CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]] |
CTD |
PMID:12086689 PMID:17034788 PMID:21352821 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of FOS mRNA |
CTD |
PMID:10381381 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of FOSL1 mRNA; ferric nitrilotriacetate results in increased expression of FOSL1 protein |
CTD |
PMID:18055543 |
|
NCBI chr 1:220,826,560...220,835,066
Ensembl chr 1:220,826,560...220,835,066
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
decreases activity |
EXP |
ferric nitrilotriacetate results in decreased activity of G6PD protein |
CTD |
PMID:9667754 |
|
NCBI chr X:156,274,800...156,293,935
Ensembl chr X:156,274,800...156,293,926
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of GCLC mRNA |
CTD |
PMID:18617210 |
|
NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
|
|
G |
Gsr |
glutathione-disulfide reductase |
decreases activity multiple interactions |
EXP |
ferric nitrilotriacetate results in decreased activity of GSR protein [Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in decreased activity of GSR protein; Hesperidin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in decreased activity of GSR protein]; Quercetin inhibits the reaction [ferric nitrilotriacetate results in decreased activity of GSR protein] |
CTD |
PMID:9667754 PMID:15198074 PMID:30098279 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Gtse1 |
G-2 and S-phase expressed 1 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of GTSE1 mRNA |
CTD |
PMID:23208426 |
|
NCBI chr 7:126,736,416...126,753,221
Ensembl chr 7:126,736,732...126,753,220
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased secretion of HAVCR1 protein; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of HAVCR1 mRNA; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of HAVCR1 protein; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of HAVCR1 mRNA]; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of HAVCR1 protein]; Hesperidin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased secretion of HAVCR1 protein] |
CTD |
PMID:21907755 PMID:30098279 |
|
NCBI chr10:31,813,819...31,860,934
Ensembl chr10:31,813,814...31,848,379
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
ISO |
ferric nitrilotriacetate inhibits the reaction [Asbestos, Crocidolite results in increased activity of HIF1A protein]; ferric nitrilotriacetate inhibits the reaction [Razoxane results in increased activity of HIF1A protein] |
CTD |
PMID:18385176 |
|
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
EXP ISO |
ferric nitrilotriacetate results in increased expression of HMOX1 mRNA |
CTD |
PMID:18617210 PMID:19490752 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of HSP90AA1 mRNA |
CTD |
PMID:10854235 |
|
NCBI chr 6:135,107,262...135,112,793
Ensembl chr 6:135,107,271...135,112,775
|
|
G |
Il24 |
interleukin 24 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of IL24 mRNA |
CTD |
PMID:23208426 |
|
NCBI chr13:47,618,451...47,623,849
Ensembl chr13:47,618,452...47,623,849
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
ISO EXP |
ferric nitrilotriacetate results in increased expression of IL6 protein ferric nitrilotriacetate results in increased expression of IL6 mRNA [Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of IL6 protein; chrysin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of IL6 protein] |
CTD |
PMID:15781289 PMID:19490752 PMID:23194824 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of JUN mRNA; ferric nitrilotriacetate results in increased expression of JUN protein |
CTD |
PMID:18055543 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Krt18 |
keratin 18 |
multiple interactions |
ISO |
[[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT18 protein |
CTD |
PMID:17034788 |
|
NCBI chr 7:143,629,455...143,633,131
Ensembl chr 7:143,629,455...143,633,131
|
|
G |
Krt8 |
keratin 8 |
multiple interactions |
ISO |
[[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT8 protein |
CTD |
PMID:17034788 |
|
NCBI chr 7:143,596,511...143,603,745
Ensembl chr 7:143,596,511...143,603,803
|
|
G |
Mcm3 |
minichromosome maintenance complex component 3 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of MCM3 mRNA |
CTD |
PMID:23208426 |
|
NCBI chr 9:26,914,057...26,932,201
Ensembl chr 9:26,914,057...26,932,201
|
|
G |
Mt1 |
metallothionein 1 |
multiple interactions |
ISO |
[ferric nitrilotriacetate co-treated with Hydrogen Peroxide] inhibits the reaction [MT1 protein binds to Cadmium]; [ferric nitrilotriacetate co-treated with Hydrogen Peroxide] inhibits the reaction [MT1 protein binds to Zinc]; ferric nitrilotriacetate results in increased oxidation of [MT1 protein binds to Zinc] |
CTD |
PMID:22001350 |
|
NCBI chr19:11,301,991...11,303,007
Ensembl chr17:78,793,336...78,793,724
|
|
G |
Mt2A |
metallothionein 2A |
multiple interactions |
ISO |
[ferric nitrilotriacetate co-treated with Hydrogen Peroxide] inhibits the reaction [MT2 protein binds to Cadmium] |
CTD |
PMID:22001350 |
|
NCBI chr19:11,307,966...11,308,740
Ensembl chr19:11,307,967...11,308,740
|
|
G |
Mt3 |
metallothionein 3 |
decreases response to substance |
ISO |
MT3 protein results in decreased susceptibility to ferric nitrilotriacetate |
CTD |
PMID:12383939 |
|
NCBI chr19:11,324,708...11,326,112
Ensembl chr19:11,324,698...11,326,139
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of MYC mRNA; ferric nitrilotriacetate results in increased expression of MYC protein |
CTD |
PMID:18055543 |
|
NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
affects localization |
ISO |
ferric nitrilotriacetate affects the localization of NFE2L2 protein |
CTD |
PMID:18617210 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
EXP |
[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of NFKB1 mRNA; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of NFKB1 mRNA] |
CTD |
PMID:21907755 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases expression |
ISO EXP |
ferric nitrilotriacetate inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA]; ferric nitrilotriacetate inhibits the reaction [Doxorubicin results in increased expression of NOS2 protein]; ferric nitrilotriacetate inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] ferric nitrilotriacetate results in increased expression of NOS2 protein [Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of NOS2 protein; chrysin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of NOS2 protein]; chrysin inhibits the reaction [ferric nitrilotriacetate results in increased expression of NOS2 protein]; ferric nitrilotriacetate promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 mRNA]; ferric nitrilotriacetate promotes the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA] |
CTD |
PMID:11461780 PMID:11746204 PMID:12490132 PMID:23194824 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of NQO1 mRNA; ferric nitrilotriacetate results in increased expression of NQO1 protein |
CTD |
PMID:18617210 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
multiple interactions increases activity |
EXP |
[ferric nitrilotriacetate results in increased abundance of Hydroxyl Radical] which results in increased activity of ODC1 protein; Active Hexose Correlated Compound inhibits the reaction [[ferric nitrilotriacetate results in increased abundance of Hydroxyl Radical] which results in increased activity of ODC1 protein]; Vitamin E inhibits the reaction [ferric nitrilotriacetate results in increased activity of ODC1 protein] |
CTD |
PMID:9667754 PMID:14623030 PMID:15949125 |
|
NCBI chr 6:42,852,529...42,859,142
Ensembl chr 6:42,852,683...42,859,927
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of PCK1 mRNA |
CTD |
PMID:16960379 |
|
NCBI chr 3:171,213,936...171,219,885
Ensembl chr 3:171,213,936...171,219,871
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of PCNA protein; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of PCNA mRNA; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of PCNA protein; chrysin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of PCNA protein]; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of PCNA mRNA]; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of PCNA protein] |
CTD |
PMID:21907755 PMID:23194824 |
|
NCBI chr 3:124,880,698...124,884,570
Ensembl chr 3:124,880,698...124,884,570
|
|
G |
Phlda3 |
pleckstrin homology-like domain, family A, member 3 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of PHLDA3 mRNA |
CTD |
PMID:23208426 |
|
NCBI chr13:52,588,917...52,592,002
Ensembl chr13:52,588,917...52,592,001
|
|
G |
Plau |
plasminogen activator, urokinase |
multiple interactions increases expression increases activity |
ISO |
Deferoxamine inhibits the reaction [ferric nitrilotriacetate results in increased activity of PLAU mRNA]; Deferoxamine inhibits the reaction [ferric nitrilotriacetate results in increased expression of PLAU mRNA] |
CTD |
PMID:17571974 |
|
NCBI chr15:3,644,296...3,650,765
Ensembl chr15:3,644,769...3,650,819
|
|
G |
Plk2 |
polo-like kinase 2 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of PLK2 mRNA |
CTD |
PMID:23208426 |
|
NCBI chr 2:41,911,143...41,916,901
Ensembl chr 2:41,911,131...41,916,901
|
|
G |
Pola1 |
DNA polymerase alpha 1, catalytic subunit |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of POLA1 mRNA |
CTD |
PMID:10854235 |
|
NCBI chr X:62,382,604...62,698,830
Ensembl chr X:62,382,608...62,698,830
|
|
G |
Ppia |
peptidylprolyl isomerase A |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of PPIA protein |
CTD |
PMID:16908007 |
|
NCBI chr14:86,673,775...86,677,443
Ensembl chr14:86,673,775...86,677,443
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression |
EXP |
[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of PTGS2 protein; chrysin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of PTGS2 protein]; chrysin inhibits the reaction [ferric nitrilotriacetate results in increased expression of PTGS2 protein]; Hesperidin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of PTGS2 protein] |
CTD |
PMID:23194824 PMID:30098279 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Ptprb |
protein tyrosine phosphatase, receptor type, B |
decreases expression |
EXP |
ferric nitrilotriacetate results in decreased expression of PTPRB mRNA |
CTD |
PMID:10854235 |
|
NCBI chr 7:59,326,484...59,431,114
Ensembl chr 7:59,326,518...59,425,718
|
|
G |
Ptprz1 |
protein tyrosine phosphatase, receptor type Z1 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of PTPRZ1 mRNA; ferric nitrilotriacetate results in increased expression of PTPRZ1 protein |
CTD |
PMID:18055543 |
|
NCBI chr 4:49,941,046...50,140,764
Ensembl chr 4:49,941,304...50,140,762
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased localization of RELA protein; chrysin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased localization of RELA protein] |